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6ABSTRACT
DNA mismatch repair (MMR) is a system of evolutionary conserved DNA surveillance 
proteins that maintain the integrity o f the genome by correcting errors of DNA 
replication and by regulating DNA excision and recombinational repair processes. Loss 
of human MMR is associated with microsatellite instability (MI), a mutator phenotype, 
and hereditary as well as sporadic cancers. Cells deficient in MMR display resistance 
to the cytotoxic effects of an expanding list o f DNA-damaging agents such as DNA 
methylating, platinating and antimetabolite drugs, many of which are routinely used in 
the treatment o f cancer. MMR deficiency has also been linked to defects in G2 cell 
cycle arrest in response to DNA damage.
To explore the role that MMR has in cellular responses to DNA damage in isogenic 
strains o f S. cerevisiae, individual disruptions in the MMR genes MSH2, MSH3, MSH6, 
MLH1, MLH2 and PMS1 were tested for cytotoxic and cell cycle responses to various 
DNA damaging agents. A significant 2.6 - 5.6-fold increase (P<0.05) in clonogenic 
resistance to a 24 hour exposure of ImM cisplatin was seen in all mutants except for 
pm sl, compared to wild type. All mutants, but not mlh2, displayed a 10-30-fold 
increased forward mutation frequency, indicative o f loss o f MMR function. These 
results indicate that specific components o f MMR, but not necessarily MMR per se, are 
involved in conferring sensitivity to cisplatin. Re-introducing ScMLHl back into the 
mlhl mutant using a high copy yeast expression vector restored cisplatin sensitivity to 
levels greater than wild type.
Strains null for the recombinational repair gene RAD52 and the 
recombination/nucleotide excision repair gene RADI were hypersensitive to cisplatin. 
m lhl, msh2 and mlh2 strains in rad52 and radl backgrounds were as sensitive as single 
rad52 and radl strains indicating that the presence of these recombination/excision 
repair proteins is required for the MMR-deficient-induced resistance phenotype. Wild
7type cells grown to confluence and hence under growth inhibitory conditions were more 
resistant to killing by cisplatin than logarithmically growing cells, whereas no 
difference was seen in the msh2 mutants. This suggests a requirement for DNA 
replication for the MMR-dependent cytotoxic response. A model in which MMR acts 
to inhibit recombinational bypass o f cisplatin-induced DNA adducts is described.
Cell cycle analysis o f these strains indicated that mlhl and msh2 disruption lead to an 
early release from G2-M arrest in response to a 1 hour, 4mM exposure to cisplatin. 
MMR mutants exposed to lOOgy ionising irradiation, after a transiently quicker entry 
into G2-M, did not display any significant difference in arrest pattern or cytotoxicity 
compared with wild type. These results suggest that MMR in budding yeast functions 
in a cisplatin-specific DNA damage response pathway that leads to a prolonged G2 cell 
cycle arrest response. A model is described in which MMR induces S. cerevisiae cell 
cycle checkpoint arrest in response to persistent cisplatin-induced DNA lesions and/or 
replication inhibition.
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INTRODUCTION
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1. INTRODUCTION
The maintenance o f genetic stability is fundamental for cell and organism. Biosynthetic 
errors of DNA replication, physically- or chemically-induced damage to DNA and 
unrepaired intermediates of DNA metabolism continually threaten the integrity o f the 
genome and are the major causes of mutagenesis and cancer (Loeb, 1991; Freidberg et 
al, 1995). Maintaining genetic fidelity depends on the ability to monitor, repair and 
signal appropriate responses to these perturbations.
DNA mismatch repair (MMR) is a complex evolutionary-conserved DNA surveillance 
system that not only rectifies errors of DNA replication (Modrich, 1991), but also has 
activities in recombinational (Rayssigiuer et al, 1989; Datta et al, 1995; Saparbaev et 
al, 1996) and nucleotide excision repair pathways (Mellon and Champe, 1996; 
Kirkpatrick and Petes, 1997).
Loss of MMR function has been associated with microsatellite instability and a mutator 
phenotype (Shibata et al, 1994; Umar et al, 1994; Bhattacharya et al, 1994). Germline 
mutations in MMR genes have been linked to hereditary non-polyposis colorectal 
cancer or Lynch syndrome (Leach et al, 1993; Fischel et al, 1993; Bronner et al, 1994; 
Nicolaides et al, 1994; Papadopoulos et al, 1994; Tannergard et al, 1995; Fischel and 
Kolodner, 1995; Lui et al, 1995) and loss of MMR is also a common finding in many 
types of sporadic human cancers (Parsons et al, 1993; Umar et al, 1994; Risinger et al, 
1995; Hatta et al, 1998).
In addition, MMR deficiency has been associated with tolerance to DNA methylating 
agents (Goldmacher et al, 1986; Griffin et al, 1994; Karran and Bignami 1994), 
resistance to an expanding list of DNA damaging agents (Anthoney et al, 1996;
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Drummond et al, 1996; Brown et al, 1997) and defects in DNA damage-induced cell 
cycle arrest (Koi et al, 1994; Hawn et al, 1995; Carethers et al, 1996; Davis et al, 1998). 
This thesis explores the current literature and presents data using isogenic strains o f S. 
cerevisiae to investigate the role o f MMR in cellular responses to DNA damage.
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1.1. The Maintenance of Genomic Stability
1.1.1. The E.coli MutHLS mismatch repair pathway
The first to be identified and best understood function of MMR is its role in the 
correction of DNA biosynthetic errors. By relying on normal Watson-Crick base 
pairing, the MMR system can distinguish mismatched bases (with efficiencies: G-T > 
G-G = A-C > C-C) (Holmes et al, 1990) and other abnormal structures such as small 
looped sequences that distort the DNA helix (Modrich, 1997). These are estimated to 
arise approximately one in every 105 - 106 bases synthesised during proof-read DNA 
polymerase I and Ill-activated DNA replication (Darnell et al, 1990). The fully 
characterised MutHLS MMR system in Escherichia coli has revealed the mechanisms 
of bacterial strand discrimination, strand incision and repair.
DNA in E.coli is postreplicationally methylated by the Dam methylase. This 
modification asymmetry is used to direct MMR towards the transiently unmethylated 
adenine o f newly synthesised palindromic d(GATC) sequences. It is in these sequences 
that the newly synthesised, transiently unmethylated daughter strand is discriminated. 
Incision o f the unmodified strand at a hemimethylated d(GATC) site results in a nick 
and this is what directs repair (Kolodner and Alani, 1994).
All components o f the MutHLS system o f E.coli have been characterised (Lahue et al, 
1989; Modrich 1991; Grilley et al, 1993; Fischel and Kolodner 1995). After the MutS 
protein binds to mismatched DNA, MutL then forms a heterodimer which then recruits 
the MutH endonuclease to cleave at the d(GATC) site (Hall and Matson, 1999). After 
this, DNA unwinding occurs at the nick by UvrD (helicase II) and proceeds to a point 
beyond the error. The action of one o f several exonucleases - Exol, Exo VII and RecJ - 
excises the strand containing the mismatch and this can occur on either side o f the 
mismatch, reflecting the bidirectionality o f the system. ExoVII and RecJ being 5’ —» 3’
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and Exol being 3’ —> 5’ (Cooper et al, 1993) (See Fig. 1). In the presence of DNA 
polymerase III holoenzyme and single-stranded DNA-binding protein (SSB), repair 
synthesis occurs to fill the gap and DNA ligase seals the final nick (Modrich and Lahue,
1996).
CHi CHj
3 ' I_________ A---------------1--------- 5*5.------------------- v---------------------y
/ MutH, MutL, \MutS, ATP X
CHj C Hj C H j CHj
3« I a ____________ I_______ y  y  , I ■■ ■ ■ . ...—a,-------------------1----------- S'
5 '-----------------------------v-----------------------------  3' 5*------------------------------ *-----------------   3*
exo VII I 
or RecJ 1 helicase II, I exo IATP i
CHj C H j  C H j  C H j
J  S' V  1 ^ -----------  1 5*3*----------«------------------*----------
5-------   y  5'------------------    3’
I DNApoim  holoenzyme, SSB 1
CHj C H j  C H j  C H j
3*----------1-------------------------------------- 1----------  5' 3*-----------1---------------------------------- - r 1- ------   ?!
5............... ♦ -----------------------------  3* 5 '......................................    3
Figure 1 The E. coli methyl-directed MutHLS mismatch repair system
(taken from Grilley et al, 1993)
The requirement for MutH and the use o f Dam methylation to distinguish new from 
template DNA is unique to certain bacteria and certainly not a common mechanism for 
daughter strand discrimination in any eukaryotic cell studied. The Streptococcus 
pneumoniae Hex MMR system is not known to utilise a MutH homologue or 
methylation asymmetry (Modrich, 1991; Fischel and Kolodner 1995; Modrich and 
Lahue 1996). Since DNA methylation does not seem to occur in S. cerevisiae (Proffitt 
et al, 1984), Drosophila or Caenorhabditis elegans (Modrich, 1991; Fischel and
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Kolodner 1995; Freidberg et al, 1995; Modrich and Lahue 1996), the way in which the 
newly synthesised strand is recognised in higher systems is not known.
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1.1.2. Eukaryotic MMR
When Williamson and colleagues (1985) used a unique disomic haploid strain o f the 
budding yeast Saccharomyces cerevisiae containing two copies o f chromosome III to 
identify meiotic hyperrecombination mutants, they found that a series o f pms 1-6 
mutants displayed mitotic mutator phenotypes, making them candidates for MMR- 
deficiency. PMS1 proved to be the first eukaryotic MMR gene identified.
Since then, homologues o f bacterial MMR proteins have been found in yeast, fly, 
nematode, mouse and human cells and a remarkable degree o f homology exists between 
them (Modrich and Lahue, 1996). The larger numbers o f gene products identified in 
eukaryotes indicates the increased complexity and functional diversity evolved in these 
systems. At least six MutS homologues (MSH) have now been found in S. cerevisiae 
(Williamson et al, 1985; Bishop et al, 1987; Kramer et al, 1989; Reenan and Kolodner 
1992; Kolodner 1995). scMSHl-6 show high degrees o f amino acid similarity to 
bacterial MutS and homologues o f these have been identified in murine and human cell 
lines (Bhattacharyya et al, 1994; Shibita et al, 1994; Boyer et al, 1995; Liu et al, 1995; 
Papadopoulos et al, 1995). Three of these proteins, Msh2, Msh3 and Msh6 function in 
a eukaryotic MutHLS-like manner (Strand et al, 1995; Marsischky et al, 1996).
Purified Msh2 from both S. cerevisiae and human cells recognises with high affinity 
single base mispairs and multiple base insertion and deletion loops (Fischel et al, 1994; 
Alani et al, 1995). Msh3 and Msh6 (GTBP/pl60) both copurify separately with Msh2 
(Drummond et al, 1995; Palombo et al, 1995; Marsischky et al, 1996) and it is now 
known, through rates o f single-base substitution verses frameshift mutation studies, that 
the Msh2-Msh6 heterodimer binds specifically to single mismatches and Msh2-Msh3 
binds preferentially to looped insertion/deletions (Strand et al, 1995; Marsischky et al,
1996).
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Homologues of the MutL protein have been identified in humans. Two proteins, 
ScMlhl and ScPmsl (Pms2 in humans) are required for mismatch repair (Prolla et al, 
1994; Modrich and Lahue, 1996). These proteins exist as a heterodimer and interact 
with Msh2 bound to a mispaired base. S. cerevisiae mlhl and pm sl mutants show 
similar strong mutator phenotypes equivalent to that of msh2 mutants (Strand et al, 
1993). Human Pmsl is a third MutL protein identified by virtue of a germ-line 
mutation in PMS1 in a single patient with a family history of colon cancer (Nicolaides 
et al, 1994). It was not known if  this mutation caused Microsatellite instability.
Other components involved in the mismatch repair pathway have been implicated. S. 
cerevisiae strains lacking RAD27/RTH1 (human FEN1/MF-1, EXOIV), a 5’-3’ 
endo/exonuclease, have a mutator phenotype (Johnson et al, 1995) as strong as msh2, 
mlhl or pm sl strains. However, double mutant combinations of rad27 and either msh2, 
mlhl, or pm sl show a three-five fold synergistic effect which suggests that RAD27 
exists as part o f a separate pathway from MSH2, MLH1 and PMSl. Rad27 is a member 
of the Rad6 epistasis group and is involved in repair of other types o f DNA damage. 
rad27 mutants also display cell cycle arrest defects (Reagan et al, 1995).
Human Exol has been identified in a GST-fusion screen as a protein that interacts with 
human Msh2 (Schmutte et al, 1998). Exol S. pombe mutants show a weak mutator 
phenotype (Szankasi and Smith 1995) and has been proposed to function in an MSH2- 
dependent manner (see Fig. 1). Both DNA polymerases II (epsilon) and III (delta) have 
been shown to participate in correcting mismatches in S. cerevisiae and these are the 
only DNA polymerases known to possess an intrinsic 3’ to 5’ exonuclease in S. 
cerevisiae (Morrison and Sugino, 1994). Human Replication protein A (RPA), which is 
also part o f the replication fork machinery, is known to be required for mismatch repair 
(Lin et al, 1998). Proliferating cell nuclear antigen (PCNA) is known to bind to human 
Mlhl in a yeast two-hybrid screen (Umar et al, 1996) and S. cerevisiae null for PCNA 
display a mutator phenotype (Johnson et al, 1996).
Recently, M edl, a novel human methyl-CpG-binding endonuclease, has been shown to 
bind to human Mlhl and transfecting a medl mutant lacking the methyl-CpG-binding 
domain resulted in microsatellite instability (Bellacosa et al, 1999). This may
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represent the putative homologue of bacterial MutH since MED1 has homology to 
bacterial DNA repair enzymes, displays endonuclease activity, binds with varying 
affinity to and hence discriminates between methylated and hemimethylated CpG 
sequences and stabilises Microsatellite sequences. This observation may also suggest 
that cytosine methylation may play a role in human mismatch repair. However, the lack 
of DNA methylation in Drosophila, Caenorhabditis elegans and S. cerevisiae (Modrich 
and Lahue, 1996) would represent a substantial evolutionary skip in the mechanism of 
strand discrimination.
M ispairs  and  one unpaired base
(Mu tSa)
MS H 2  .  MS H6
(MutLa)
M L HI |  h P MS 2 /  
4  s c PMS l
PMS2
[fMLH
Medl  ; PCNA 
■  E x o l
Helicase ?
RPA ?
Pol a  or 6 or e ?
T w o  to four unpaired  base s
j ^ - G T G T  
(?A<pA‘
MS H 2 |  M S H 3
CA
(MutS|l)
»
utL 
»
Medl 5 P C N A  
»  E x o  I
Helicase ?
RPA?
Pol a or 5 or e ?
(M l a)
ML H 1  ■  hPM S2/  
s c P M S l
-7VZ~GTGI—V7\vx— CACA—
Figure 2 Schematic diagram of eukaryotic MMR
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There is recent evidence to show that bacterial MutS and MutL, as well as eukaryotic 
Msh2 and Msh6 proteins act as molecular switches dependent on ATP hydrolysis. It 
has long been known that ATP is required for MutHLS mismatch repair (Welsh et al, 
1987). Haber and Walker (1991) then showed that MutS bound and hydrolysed ATP 
and that a mutant MutS containing a mutation in the ATP phosphate binding loop 
consensus displayed reduced ATPase activity. It was then shown that point mutations 
in the ATP binding helix-tum-helix domain of S. cerevisiae Msh2 did not affect 
mismatch binding o f the Msh2-msh6p complex, but did cause biochemical defects in 
mismatch repair downstream (Alani et al, 1997; Studamire et al, 1998). Additionally, 
crystal structure analysis of MutL has shown that it belongs to an emerging ATPase 
superfamily that includes DNA topoisomerase II and Hsp90 (Ban and Yang, 1998). A 
model has been proposed which suggests that a molecular switch is in operation so that 
when Msh2-Msh6 is in the ADP-bound form it is ON and binds to mismatched 
nucleotides, and OFF in the ATP-bound form and released (Gradia et al, 1997; Fischel 
1998; Ban et al, 1999). In this way, it is proposed that the timing of ATP-ADP 
hydrolysis controls the sequential steps of downstream components o f MMR.
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1.1.3. The role of MMR in homologous recombination
Homologous recombination is a mechanism used for mitotic and meiotic strand 
exchange and DNA-double strand break repair. Various components o f bacterial, yeast 
and mammalian MMR have evolved to function in both of these systems.
1.1.3.1. Mitotic and meiotic recombination
Homologous recombination is usually thought o f as occurring between sequences at 
identical positions on homologous chromosomes (allelic recombination), but it can also 
occur between similar (homeologous) sequences at nonallelic (ectopic) locations. 
These similar sequences are found in large numbers of repeated regions found dispersed 
throughout eukaryotic genomes.
Such homeologous events can generate novel gene conversions and are likely to be 
important mechanisms for the evolution o f multigene families. It is also implied that 
these events represent a source of diversity at immunoglobulin loci (Maizels 1989). 
However, crossing-over between more dispersed repeats can lead to genome 
rearrangements such as deletions, insertions and translocations, events commonly found 
in tumour cells. MMR has been shown to regulate these recombinant events, thus 
adding weight to its role as a genome stabiliser.
It has been known for some time that prokaryotic MMR acts as a potent barrier to 
recombination between divergent (homeologous) sequences (Rayssigiuer et al, 1989). 
More recently, it was demonstrated that the S. cerevisiae MMR genes MSH2, MSH3 
and PMS1 regulated mitotic cross-overs between diverged sequences and that this effect 
was dependent on the degree of sequence divergence (Datta et al, 1995). In contrast, it 
was shown that Msh2 and Msh3 proteins are actually components of the Radl/10
Chapter 1-25
pathway of mitotic recombination (Saparbaev et al, 1996), obscuring the role MMR has 
in regulating recombination events.
A study which looked at the involvement o f the S. cerevisiae MMR protein Mlhl during 
meiosis revealed that this protein was unique among all the other components o f MMR 
in its ability to promote meiotic crossing-over (Hunter and Borts, 1997). This function 
was originally assigned to the MMR-independent, exclusively meiotic proteins Msh4 
and Msh5 (Ross-Macdonald and Roeder, 1994; Hollingsworth et al, 1995). The fact 
that these proteins are not required for mitotic recombination indicates that they act in 
mutually exclusive pathways for mitotic and meiotic recombination.
1.1.3.2. DNA double-strand break repair
Double strand breaks in DNA result from normal enzymatic activities of endonucleases 
and from the genotoxic effects o f agents such as ionising radiation. They pose a 
considerable threat to Genomic integrity and cell survival. If left unrepaired, a single 
double-strand break is sufficient to cause cell death and, if  inefficiently or 
inappropriately repaired, can generate potentially oncogenic chromosomal aberrations 
(Hiom, 1999).
Homologous recombination and non-homologous end-joining (NHER) are two 
mechanisms used to repair double-strand breaks in eukaryotes. NHER requires the 
Ku70 and Ku80 subunits of DNA protein kinase (DNA-PK) to bind to and initiate the 
re-joining of double-stranded DNA ends. This repair pathway is error-prone and the 
preferred pathway for double-strand break repair in mammalian cells. Homologous 
recombination utilises stretches o f homologous donor sequences to repair the double 
strand break. This pathway is less error-prone, is the preferred mechanism in yeast and 
requires specific components of MMR.
Two major pathways of homologous recombination exist in S. cerevisiae -  gene 
conversion and single-strand annealing (SSA). Both have the same first step of
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processing the DNA ends which entails the 5’ to 3’ degradation of DNA strands that 
yields single-stranded 3’ ends that act as donor templates for repair synthesis. Any 
nonhomologous bases contained at the 3’ tail o f this invading strand must be removed 
and this has been shown to be dependent on the nucleotide excision repair endonuclease 
Radi /Rad 10 and the MMR proteins Msh2 and Msh3 (Sugawara et al, 1997). Pmsl and 
Mlhl proteins are not required (Sugawara et al, 1997). Only when 3’ tails are 30 
nucleotides long or longer are Radi, Msh2 and Msh3 proteins necessary as shorter tails 
can be removed at least in part by the 3’ to 5’ proof-reading activity o f DNA 
polymerase 8 (Paques and Haber, 1997). After this initial process is complete the key 
process of Rad51-Rad52-dependent pairing and strand-exchange between homologous 
DNA molecules then proceeds (Shinohara and Ogawa, 1998).
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1.1.4. Nucleotide excision repair and MMR
The present literature concerning the functional and mechanistic overlap between MMR 
and excision repair is contentious. Mismatch repair proteins predominantly repair base 
mismatches and small looped sequences whereas NER primarily removes pyrimidine 
dimers (induced by UV radiation) and other helix distorting adducts. It has been shown 
in S. cerevisiae however that repair of 26-base loops involves both the NER protein 
Radi (human ERCC4) and Msh2 (Kirkpatrick and Petes, 1997). By using elevated 
levels of post meiotic segregation (PMS) events as opposed to gene conversions it was 
demonstrated that homozygous deletions in either RADI or MSH2 caused a three-fold 
increase in PMS. However, double radl/msh2 mutants had the same PMS frequency 
indicating that these proteins function in the same pathway. Radi acts in conjunction 
with RadlO (human ERCC1) to cleave 5’ and Rad2 cuts 3’ to a pyrimidine dimer during 
NER. Rad 14 acts as the DNA damage recognition protein. Both rad2 and radl4  
mutants did not increase PMS frequency indicating that complete NER is not required 
(Kirkpatrick and Petes, 1997).
A mutation of mei-9, the Drosophila melanogaster homologue of scRadl (Sekelsky et 
al, 1995) increases PMS, and thus may be defective in meiotic mismatch repair 
(Carpenter 1982). A surprising observation came from Yang et al, (1996) who showed 
that a mutant scRad3 conferred a mutator phenotype and actually enhanced the 
efficiency o f heteroduplex repair. In two studies looking at base mismatch correction or 
short patch MMR (not dependent on MMR proteins), the human NER complex was 
found to act on G/G and G/A mismatched substrates (Huang et al, 1994), and more 
recently, it was shown that S. pombe NER proteins Rhpl4p (scRadl4), SwilOp 
(scRadlO) and Radl6p (scRadl), which are components o f a short-patch MSH2- and 
PMS1- independent mismatch repair pathway, corrects mainly C/C mismatches (the 
error least recognised by long patch MMR) (Fleck et al, 1999).
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Another link between MMR and NER has been made specifically with respect to 
transcription-coupled NER. The removal o f many types o f DNA damage occurs more 
rapidly in transcriptionally active regions o f DNA. This rapid repair has been shown to 
be due to faster repair o f damage in the transcribed strand than non-transcribed strand 
of active genes. The process is a highly conserved mechanism of excision repair 
occurring in bacteria (Mellon and Hanawalt, 1989), yeast (Sweder and Hanawalt, 1992) 
and humans (Mellon et al, 1987; Leadon and Lawrence, 1991).
It has been demonstrated that mutant E.coli strains (uvrA, uvrB, icvrC and uvrD) 
defective in nucleotide excision repair could not repair cyclobutane pyrimidine dimers 
from expressed or non-expressed strands o f the lactose operon. However, in this study, 
strains lacking either MutS or MutL selectively abolished repair in the transcribed 
strand and rendered the cells moderately sensitive to UV irradiation (Mellon and 
Champe, 1996). Similarly, several MMR-deficient tumour cell lines and HNPCC- 
derived lymphoblastoid cell lines deficient in either Msh2, Mlhl, or Pms2 were also 
found to be deficient in transcription-coupled repair (TCR) of UV damage, thus 
extending the connection between prokaryotic TCR and MMR to humans (Mellon et al,
1996). Another study reported that the hMSH2 gene product, but not hMlhl was 
required for the removal of ionising radiation (ER)-induced oxidative damage, including 
thymine glycols, from the transcribed strand o f an active gene (Leadon and Avrutskaya,
1997). In contrast however, the sensitivity to IR or UV was unaltered.
Several studies dispute the overlapping role o f these two repair pathways. No defects in 
TCR of UV damage have been found in yeast mutants for msh2, mlhl, pm sl or msh3 
(Sweder et al, 1996), which may indicate some functional difference between yeast and 
human MMR proteins in TCR. More studies on yeast exposed to other DNA damaging 
agents are needed before it can be ruled out that MMR plays any role in yeast TCR. In 
an in vitro study that analysed the activities o f human MMR and excision repair upon a 
compound DNA lesion, i.e. one containing a mismatch as well as a UV-induced 
pyrimidine dimer adduct, no difference in repair activity was seen in MMR defective 
cell extracts indicating that MMR has no activity in UV-damage repair (Mu et al,
1997). Similarly, a recent complementary study showed that a human cell line 
defective in both MMR and NER was no different in cytotoxic or sister chromatid
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exchange responses to UV compared to the derived NER-defective cell line (O’Driscoll 
et al, 1999). Therefore, since UV damage is a common genetic lesion, the authors 
dispute the idea that MMR acts as a general sensor of DNA damage.
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1.1.5. Cancers associated with Microsatellite instability 
(MI) and MMR-deficiency
1.1.5.1. HNPCC and related disorders
It is widely considered that genetic instability is an integral component of human 
neoplasia (Loeb, 1991). An unstable, mutator phenotype would provide a continuing 
pool of mutants upon which selection could act to promote a tumour. It was o f great 
interest therefore, when a series o f seminal studies showed a link between heterozygous 
germ-line mutations in MMR genes, instability in tandem repeat sequences 
(microsatellites) and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch 
Syndrome) (Leach et al, 1993; Fischel et al, 1993; Bronner et al, 1994; Nicolaides et al, 
1994; Papadopoulos et al, 1994; Tannergard et al, 1995).
HNPCC is a common autosomal dominant disorder characterised by an inherited 
predisposition to early onset o f colorectal cancer (mean age, approximately 40-45) and 
accounts for 1-6% of all colorectal cancers (Lynch et al, 1993). It is also associated 
with an increased incidence o f carcinomas o f the endometrium, ovary, small intestine, 
stomach, ureter and renal pelvis, termed Lynch Syndrome (LS) (Lynch et al, 1996; 
Kinzler and Vogelstein, 1996).
Mutations in MLH1 and MSH2 are seen in >90% of HNPCC kindreds, whereas 
mutations in PMS2, PMS1 and MSH6 are considerably less frequent. These are 
heterozygous mutations, so individuals retain a functional allele and are apparently 
competent in MMR. Subsequent somatic mutation in the wild-type allele leads to the 
mutator cancer phenotype (Parsons et al, 1993). In individuals with homozygous 
deletions of MLH1, haematological malignancies (leukaemias and/or lymphomas) and 
neurofibromatosis Type 1 also present at a very early age (Ricciardone et al, 1999;
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Wang et al, 1999). HNPCC has also been associated with a mutant allele for MLH1 in 
breast cancer patients (Risinger et al, 1996).
A closely related disorder is Muir-Torre syndrome (MTS). MTS is a rare autosomal- 
dominant condition characterised by the occurrence of sebaceous skin lesions and 
visceral tumours. It has been demonstrated that microsatellite instability (MI) and 
mutations in MMR genes occurs in at least a subset of cases and that unrelated cases of 
MTS have been associated with germline mutations in MSH2 (Kruse et al, 1996).
1.1.5.2. Sporadic cancers
Outside o f HNPCC/LS/MTS, the properties o f many established colorectal 
adenocarcinoma cell lines are consistent with MMR defects. MI (Shibata et al, 1994), 
defects in MMR function in cell extracts (Umar et al, 1994) and mutator phenotypes 
(Bhattacharya et al, 1994) have been observed. Specific loss of MMR genes have also 
been documented. The MMR-defective LoVo cell line is homozygous for a partial 
deletion o f the MSH2 gene (Umar et al, 1994) and the MI+, mutator cell line HCT116 
has a mutation in the MLH1 gene (Parsons et al, 1993).
Other sporadic and familial cancers have been shown to contain unstable 
microsatellites. MI has been associated with 67% of familial gastric cancers sampled, 
although only 1/6 showed a somatic mutation in MSH2 (Akiyama et al, 1996). MI has 
been seen in 20% of melanoma cases (Peris et al, 1995), 41% of acute/lymphomatous 
adult T-cell leukaemia cases (ATL) (Hatta et al, 1998), all six tumours from a Turcot 
syndrome patient (a disorder associated with brain and colon cancers in early adult life) 
with a germline PMS2 mutant allele (Miyaki et al, 1997) and 25% of uterine sarcomas, 
with a subset showing mutations in MSH2 (Umar et al, 1994; Risinger et al, 1995). 
Furthermore, MI has also been strongly linked to the susceptibility o f previously 
operated cancer patients to develop multiple primary cancers (Horii et al, 1994).
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Finally, it has been seen that MI is highly frequent (86%) in hepatitis B positive livers 
o f cirrhotic patients compared to HBV-negative cirrhotic samples (35%) and that this is 
reflected in the propensity for HBV to induce hepatocellular carcinoma (Salvucci et al,
1996). Similarly, MI is found to be more prevalent in Kaposi’s sarcoma and aggressive 
lymphomas obtained from HIV-infected patients compared to tumours o f the same 
histological type from HIV-negative patients (Bedi et al, 1995). Although MMR status 
was not studied in the context o f viral carcinogenesis, it seems more likely that 
similarities in replication cycles o f HBV and retroviruses (Tiollais et al, 1985) may play 
a role in inducing the high instabilities observed (Salvucci et al, 1996).
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1.1.6. Mechanisms of oncogenesis induced by loss of 
MMR
Before the multistage cascade o f tumour progression in a MMR-defective pathway 
initiates, mechanisms other than inherited defects or spontaneous mutations that 
compromise MMR can take place. Epigenetic silencing of MMR by DNA methylation 
is one such mechanism. Organisms like vertebrates and others that methylate their 
genomes for essential processes such as embryonic development, contain regions of 
CpG dinuleotides which are the predominant sites o f methylation. Regions where they 
are more common, termed CpG islands, often reside in gene promoter sequences 
(Jones, 1996). CpG islands remain free of methylation but when methylated, gene 
expression becomes inactivated. Several studies provide evidence that aberrant 
hypermethylation o f the human MLH1 promoter correlates with lack o f expression of 
Mlhl in MMR-defective sporadic colon tumours and other MMR-defective tumour cell 
lines (Kane et al, 1997; Herman et al, 1998; Strathdee et al, 1999).
Colorectal cancers with MI have also been shown to contain hypermethylation of 
tumour suppresser genes themselves. The cell cycle regulator p i6, the angiogenesis 
inhibitor thrombospondin-1 (TSP-1) and insulin growth factor II (IGF2) genes were all 
found to be hypermethylated in MI+ compared to MI' colorectal cancers (Ahuja et al,
1997).
It has been suggested that two separate pathways leading to tumourigenesis can operate, 
one by p53 malfunction and one associated with MI, although this is disputed. It has 
been shown that MI+ cancers often show lower frequencies of mutations in p53 and in 
some activating oncogenes than do MT cancers (Aaltonen et al, 1993; Ionov et al, 1993, 
Kim et al, 1994, Cottu et al, 1996). However, in contrast, a positive correlation between 
p53 mutations and MI was seen in therapy-related paediatric secondary malignant
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neoplasms (Gafanovich et al, 1999) and no correlation was seen at all between p53 
mutation and MI in sporadic colorectal cancers (Ilyas et al, 1996).
More stringent and facilitated controls o f genetic background and manipulation make 
animal models attractive to the study of MMR-deficient-induced neoplasia. Mutant 
strains o f mice deficient for the murine homologues of the human genes MLH1, PMS1, 
PMS2 (Prolla et al, 1998) and MSH2 (Reitmair et al, 1996; de Wind et al, 1998) have 
been generated in order to investigate the tumourigenic phenotypes induced by each 
mutant. By comparing the tumour distribution o f mice with humans, surprisingly 
different tumours arose. By one year o f age, homozygous mlhP1' and msh2~l~ mice 
usually succumbed to T-cell lymphomas and autopsies revealed the development of 
intestinal adenomas and adenocarcinomas, and to a lesser extent, skin tumours and 
sarcomas (Prolla et al, 1998; Reitmair et al, 1996). However, msh2 hemizygous 
(Msh2+/~) disruptions did not affect survival and did not induce lymphomas.
Because o f the difference in tumour distribution and spectra, it was proposed that 
dietary intake might effect the development o f cancers particularly in the gut o f HNPCC 
patients. A study which treated mice with ethylnitrosourea (ENU) synergistically 
enhanced lymphomagenesis in completely ms/z2-deficient mice. However, by crossing 
the msh2 mutant strain with an immunocompromised tapP1' mutant (a gene that 
controls antigen presentation) lymphomas were not induced by ethylnitrosourea, with 
mice generally succumbing to HNPCC-like tumours. This suggests the HNPCC tumour 
spectrum is determined by exposure o f MMR-deficient cells to exogenous mutagens, 
rather than by tissue specific loss o f the wild-type MMR allele or by immune 
surveillance (de Wind et al, 1998).
However, evasion from immune surveillance has been suggested to occur in MMR- 
defective colorectal carcinoma cells. P 2-microglobulin, responsible for presenting 
antigen to cytotoxic T-lymphocytes (CTL’s), has been shown to be mutated to the point 
of loss o f expression in mutator cells (Bicknell et al, 1996).
Additionally, intestinal tumours of MLH1 -null mice express little or no adenomatous 
polyposis coli (Ape) tumour suppresser protein, similar to that seen in HNPCC
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(Edelmann et al, 1999) and the frequency of intestinal tumours rose by 40-100 fold 
when an Ape gene mutation was bred into the mlhl mutant mice (Edelmann et al, 
1999). Interestingly, when one allele of Ape was disrupted, it was seen that loss of the 
wild type MSH2 allele occurred in a significant fraction o f Apc+I'lmsh2+I~ mice (de Wind 
et al, 1998). A complementary loss o f Msh2 and Ape function may be a mechanism for 
the development of the HNPCC tumour spectrum.
It was discussed earlier that MI+ tumours often displayed less frequent mutations in 
tumour Supressor genes such as p53 than Mi-negative tumours. However, other 
oncogenic transformations have been linked to MI and MMR-deficiency. Inactivation 
of transforming growth factor-p type II receptor (Type II TGF-p R) by a single­
nucleotide frameshift in a polyadenosine tract of exonic sequence correlated highly with 
MI colon cancer cell lines compared to Mi-negative cell lines (Markowitz et al, 1995). 
TGF-P is a potent inhibitor of multiple epithelial cell types and loss of this negative 
regulation is thought to contribute to neoplasia (Markowitz et al, 1995).
Similar somatic frameshift mutations have been reported in the pro-apoptotic BAX 
(Rampino et al, 1997) and caspase-5 (Schwartz et al, 1999) genes and in insulin-like 
growth factor II receptor gene (Souza et al, 1996) of MI+ colon and endometrial cancer 
cell lines. Ikeda and colleagues (1998) have also found a close correlation between 
repeat CAG mutations of the transcriptional activator E2F4 gene (a member of the E2F 
family that is regulated by pl07 and pl30, close relatives o f retinoblastoma suppresser) 
and MI+ colorectal cancer cells with frameshift mutations in MSH3.
Finally, increased activity o f the anti-senescence enzyme telomerase is a common 
phenotype in the majority o f tumour specimens from most cancer types (Kim et al, 
1994); and it has been seen that normal and carcinoma samples from HNPCC patients 
show higher levels of activity of telomerase compared to normal and polyps tissue from 
non-HNPCC individuals (Cheng et al, 1998). It has been suggested that MMR- 
deficiency may indirectly activate the telomerase enzyme by loss o f regulation (Cheng 
etal, 1998).
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1.2. Cellular Responses to DNA Damage and 
Mechanisms of Drug Resistance
All organisms are exposed constantly and unavoidably to foreign chemicals 
(xenobiotics), toxic metabolites, free radicals and radiation, all o f which can react with 
DNA. The response a cell makes to these nucleophiles determines its sensitivity or 
resistance to them. A cell may manifest resistance to genotoxic agents such as 
chemotherapeutic drugs, which may be primary (present when the drug is first given) or 
acquired (developing during treatment with the drug). Acquired resistance may be due 
to adaptation or to mutation, with the emergence o f cells which are less/unaffected by 
the agent, thus conferring a selective advantage over sensitive cells. A cell may respond 
in several distinct ways to the presence o f the agent itself or to the effects it has upon 
DNA. The effect of a DNA-targeting genotoxic drug is determined by responses such 
as:
1) Reducing the physical interaction with DNA. This involves upregulating 
processes that a) decrease that amount of drug taken up by the cell; b) increase 
the physical efflux o f an agent out of the cell; c) bind toxicants to intracellular 
proteins and d) detoxify agents by enzymatic biotransformation.
2) Increasing the activity o f DNA repair pathways
3) Allowing SOS translesion bypass of a DNA adduct
4) Arresting the cell cycle
5) Activating programmed cell death
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1.2.1. Reducing import into the cell
Down-regulation of specialised membrane receptors and transport processes are 
adaptive mechanisms for reducing the delivery o f drugs to target molecules. 
Endocytosis o f some toxicant-protein complexes, such as Cd-metallothionein or 
lipoprotein receptor-mediated endocytosis o f lipoprotein-bound toxicants can be 
regulated as well as the internalisation of cationic aminoglycosides and heavy metals 
associated with anionic phospholipids (Laurent et al, 1990; Casarett and Doull, 1996).
1.2.2. Increasing export from the cell
Intracellular toxicants may be transported out o f cells containing the ATP-dependent 
membrane transporter known as the multidrug-resistance (MDR) protein, or P- 
glycoprotein. This protein extrudes many types o f chemicals e.g. the neurotoxic 
pesticide ivermectin, that are substrates for this efflux pump and the MDR gene may 
up-regulated to increase this activity (Elbling et al, 1993; Schinkel et al, 1994). Studies 
that have analysed relationships between sensitivity of cancer cell lines to 
chemotherapeutic drugs and P-glycoprotein expression have shown that drugs that 
induce MDR activity include doxorubicin, mitoxantrone and vincristine; where as non- 
MDR drugs include cisplatin, ifosfamide and bleomycin (Hoffmann et al, 1999).
However, enhanced expression o f the cMOAT protein, another efflux transporter pump, 
has been shown to increase the extrusion of the cisplatin-GSH conjugate (see Section 
1.2.4) from AH66 tumour cells (Minamino et al, 1999).
1.2.3. Association with intracellular binding proteins
An increase in the pool o f nontarget intracellular binding proteins can also reduce the 
concentration o f toxicants at the target site, at least temporarily. As mentioned above, 
Metalothionein, a cysteine-rich cytoplasmic protein sequesters cadmium during acute 
cadmium intoxication (Goering et al, 1995). The heat shock response is another
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mechanism that can protect a cell from physical injury and the toxic effects o f many 
chemicals. Heat shock proteins (Hsp) have been classified into different families based 
on molecular mass, are highly conserved in eukaryotes, and are induced by a number of 
pathophysiological states e.g. heat shock, anoxia, oxidative stress, toxicants, heavy 
metal exposure and tissue trauma (Jaatela and Wissing, 1992; Hightower, 1991). These 
proteins play an important housekeeping role in the maintenance of normal protein 
structure and the degradation of damaged proteins. Several studies looking at DNA 
damaging agents have shown that cisplatin toxicity correlates with Hsp expression. 
Continuous cisplatin incubation increased HSP27 levels and induced HSP27 
phosphorylation in GLC4 (human small-cell lung carcinoma) cells. However, no 
correlation was seen in the cisplatin resistant subline (Hettinga et al, 1996). Testis 
tumour cells in vitro retain their sensitivity to chemotherapeutic drugs, radiation and 
heat shock and having shown that this was associated with low constitutive levels of 
heat shock protein (HSP) 27, overexpressing cells were shown to be more resistant to 
heat shock, cisplatin, and doxorubicin (Richards et al, 1996).
1.2.4. Detoxication
Upregulating biotransformation enzymes in the cytoplasm is an important detoxication 
mechanism. These proteins can convert a lypophyllic absorbent agent to a hydrophyllic 
form which is more easily eliminated from the body by excretion (Casarett and Doull, 
1996). However, this process can also be responsible for the biotransformation o f a 
chemical into an active metabolite (e.g. the formation o f glutathione conjugates with 
nitrosoguanides). Phase I enzymes (e.g. cytochrome P450 and carboxylesterases) are 
involved in initial hydrolysis, reduction and oxidation reactions which expose or 
introduce an electrophyllic group (-OH, -NH2, -SH2, or -COOH). They usually result in 
only a small increase in the hydrophylicity of an agent whereas Phase II reactions (i.e. 
glutathione and amino acid conjugation, glucuronidation, acetylation, methylation and 
sulfonation) occur at the functional groups present or introduced/exposed by phase I 
enzymes (with the exception o f methylation/acetylation) and result in a large increase in
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hydrophilicity. Therefore, they greatly promote the excretion of xenobiotics (Casarett 
and Doull, 1996).
The conjugation o f xenobiotics with the phase II detoxicant glutathione is catalysed by 
a family of glutathione S-transferases (GST) and is a mechanism of resistance acquired 
during cisplatin therapy. This is because substrates for GST are hydrophobic and 
contain an electrophilic atom. Good substrates are those which contain leaving groups 
such as a nitro group and the displacement reaction which leads to conjugation is 
increased by the presence o f other electron-withdrawing groups (e.g. -Cl). Both o f these 
groups exist on agents such as l,2-Dich!oro-4-nitrobenzene and on cisplatin (cis- 
diaminedichloroplatinum) (see Fig.4).
Resistance to toxic compounds is often associated with an over-expression of GST (e.g. 
resistance o f insects to DDT or com to atrazine). Recent studies have shown that 
cisplatin stimulates GST activity in blood platelets after incubation with the drug. 
Levels o f glutathione were shown to be decreased because the complex of cisplatin with 
glutathione was formed (Olas and Zbikowska, 1999). Glutathione has been used 
effectively in cisplatin treatment regimens for the management of the toxic side-effects 
prevalent during cisplatin chemotherapy of advanced ovarian cancer (Bohm et al, 
1999). However, it is noteworthy that in this study, and in another which studied 
neurotoxicity during ovarian cancer treatment, glutathione cotreatment did not impair 
cisplatin antineoplastic effectiveness (Bogliun et al, 1996).
1.2.5. DNA Repair
Mechanisms involved in the repair of genetic lesions caused by DNA damaging agents 
may be upregulated in response to the presence o f DNA damage. The removal o f alkyl 
groups from bases is carried out by the alkyltransferases which are regulated by the 
presence o f alkylating agent-induced DNA damage. This is a major mechanism of 
resistance to DNA alkylating drugs e.g. MGMT expression during MNNG treatment 
(See Section 1.3.1). Base excision repair (BER) involves the complete removal o f a 
damaged base followed by insertion of a new complementary base. Oxidative damage
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can cause this kind o f lesion. BER involves the actions of N-glycosylase, 
apurinic/apyrimidinic endonuclease, exonulease, polymerase and ligase enzymes.
Nucleotide excision repair (NER) excises the damaged base, sugar and phosphate and is 
triggered in response to UV-induced damage and other agents that cause bulky lesions. 
Recombinational repair acts upon single or double strand breaks and responds to agents 
such as ionising radiation and chemicals that induce DNA strand breaks e.g. bleomycin 
(See Section 1.1.3).
In addition to efficient pre-replicative excision repair mechanisms, cells have also 
evolved SOS-like damage tolerance pathways enabling them to replicate lesion- 
containing DNA molecules either by directly replicating through the damaged base 
(translesion synthesis, TLS) or by employing the locally undamaged complementary 
strand thus avoiding the lesion (damage avoidance pathways, DA). During the SOS 
response the error-prone TLS pathway is strongly stimulated (approximately 20-fold) at 
the expense o f the error-free DA pathways (Becheral and Fuchs, 1999).
The enzymes involved in all o f these repair pathways can be regulated with varying 
degrees depending on cell/tissue type. In these cases, upregulation leads to resistance. 
However, as will be seen in the next Section, MMR defects or lack o f MMR protein 
expression leads to resistance to a wide variety of DNA damaging agents.
1.2.6. Cell cycle arrest
A cell can respond to DNA damage by arresting the cell cycle. This limits the chances 
of DNA replication occurring passed potentially mutagenic lesions and presumably 
allows time for correctable damage to be repaired. Any variance in this capability 
(mutations/polymorphisms in genes controlling this response) will affect the sensitivity 
a cell has to DNA damaging agents. The cell cycle has specific checkpoints at which 
arrest can occur, either before DNA synthesis (Gi arrest) or after DNA synthesis (G2 
arrest). In mammalian cells, the products of the p53 and p21 genes have a key role in
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response (See Section 1.3.5). Cisplatin, an agent that crosslinks DNA, is known to 
induce predominantly a G2 arrest in mammalian cells (Eastman, 1990) although the 
drug also induces p53 and p21 expression (Anthoney et al, 1996).
1.2.7. Cell death
The chemotherapeutic agent cisplatin exerts its cytotoxic effects by forming covalent 
adducts on DNA, blocking polymerases, and preventing replication, transcription and 
cell division (Bruhn et al, 1990). Consequently, mammalian cells characteristically die 
by apoptosis, or programmed cell death, in which nuclear condensation, blebbing and 
cellular shrinkage results. In unicellular organisms such as yeast, this process is called 
autolysis and can also be induced by genotoxic agents (Megan et al, 1996).
As well as being crucial during the development o f multicellular organisms, this 
response may function to ensure the elimination o f cells (unicellular or somatic) that are 
too severely damaged for normal functioning. Any cell with malfunctioning cell death 
pathways or those with uncoupled signal transduction pathways which connect damage 
detection systems to the cell death mechanism will become tolerant to the damage 
sustained (See Section 1.3.6). Chemotherapeutic agents like cisplatin are known to 
trigger cell death in mammalian cells (Eastman, 1990) and in yeast (Megan et al, 1996).
In mammalian cells, the Bcl-2 family of genes are important regulators o f apoptosis and 
among these, Bcl-2 and Bax control cell death, thus contributing to both tumour growth 
and drug sensitivity. After treatment with cisplatin, paclitaxel and other 
chemotherapeutic agents, Bax expression was shown to change from negative to 
positive in TC901 cells. Bcl-2/Bax status was correlated with drug sensitivity and 
treatment with chemotherapeutic agents induced apoptosis in these cancer cells 
(Kawakami et al, 1999).
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1.3. The Role of MMR Deficiency in Drug 
Resistance
Bacterial and yeast strains as well as the more recently isolated mammalian cell lines 
that harbour defects in MMR demonstrate chemoresistance to a wide variety o f DNA 
damaging agents. Various theories have been constructed to explain how this 
phenomenon exists and the following sites the literature used to support these 
hypotheses.
1.3.1. MMR-deficiency and resistance to alkylating 
agents
The involvement of MMR in the processing of O-6-methylguanine DNA residues in E. 
coli has been known for quite some time (Karran and Marinus, 1982). After E. coli 
MMR mutants (Eadie et al, 1984) and human lymphoblastoid B-cell lines were shown 
to be tolerant to the DNA methylating agent N-methyl-N’-nitro-N-nitrosoguanidine 
(MNNG) (Goldmacher et al, 1986), Kat and colleagues (1993) reported that derivatives 
of these human cell lines were defective in strand-specific mismatch repair. Extracts 
from these cell lines also failed to form complexes with substrates containing 
methylated bases (Griffin et al, 1994; Karran and Bignami 1994) and from here on, 
human MMR became heavily implied in the recognition and sensitisation of cells to 
methylation damage.
Subsequently, the human colorectal adenocarcinoma cell line HCT116 known to be 
deficient in MLH1 due to a homozygous mutation in MLH1 resulting in a truncated non­
functional product, displayed a 200-fold increase in colony forming ability after 10 days 
exposure to MNNG compared to an HCT116+Ch.3 transformant (chromosome 3 
containing MLH1) (Koi et al, 1994). Moreover, the homozygous MSH2 deficient
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human endometrial adenocarcinoma cell line HEC59 was shown to be resistant to 
MNNG compared to a chromosome 2 transformant (HEC59) which re-introduced 
MSH2 (Umar et al, 1997). Similarly, the EMS2-deficient endometrial adenocarcinoma 
cell line HEC-l-A was shown to be more resistant to MNNG when compared to MMR- 
proficient KLE cells (Risinger et al, 1995).
The dominance o f the MMR-defective alkylation tolerant phenotype over the 
hypersensitive phenotype resulting from 0 6-alkylguanine-DNA alkyltransferase (AGT)- 
deficiency was revealed by Branch et al, (1995). MMR proficient cells that lack the 
DNA repair enzyme AGT (or 0 6-methylguanine-DNA methyltransferase, MGMT), 
(termed mex' cells for MGMT expression) cannot remove the alkyl group from the O6 
position o f guanine and become sensitive to the cytotoxic lesion (Branch et al, 1995; 
Liu et al, 1996). Even though the human colorectal adenocarcinoma cell line SW48 
was not shown to express detectable levels o f the enzyme MGMT, it was seen to be 
highly resistant to N-methyl-N-nitrosourea and also slightly to methyl 
methanosulphonate (Branch et al, 1995). This cell line displayed a spontaneous mutator 
phenotype, MI and lack of hMLHl mRNA (Liu et al, 1995), indicating that MMR- 
deficiency overrides the sensitivity conferred by loss o f methylation repair.
A study using yeast as an isogenic model for alkylation tolerance then demonstrated that 
deletion o f any o f the MMR genes, MLH1, MSH2, MSH3, MSH6 and PMS1 did not 
rescue mgtA O6 MeG DNA repair methyltransferase-deficient cells from killing by 
MNNG (Xiao et al, 1995; Bawa and Ziao, 1997). However, a strain (XS-14) carrying a 
mutated form of the MSH5 gene, but not an msh5A null mutant, was responsible for 
cellular tolerance to MNNG (Bawa and Ziao, 1997). These cells did not display a 
mutator phenotype but did have a meiotic defect (spore inviability) consistent with the 
role scMSH5 has in meiosis (Hollingsworth et al, 1995). It was suggested that some 
mutated forms of MSH5 and possibly of MutS homologues in mammalian cells may be 
involved in alkylation tolerance.
Another methylating agent, busulphan, has been reported to be, at least in part, 
dependent on MMR for cytotoxicity. A MMR-proficient human glioblastoma
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multiforme xenograft was more sensitive to busulphan than a procarbazine-selected 
MMR-deficient derivative (Freidman et al, 1997). However, the bifunctional 
methylator, 1,3-bis(2-chloroethyl)-l-nitrosourea that forms 0 5-chloroethylguanine DNA 
adducts, and the nitrogen mustards, melphalan and perfosfamide (an active form of 
cyclophosphamide) were not shown to be differentially cytotoxic to MMR-proficient or 
deficient cell lines (Rode et al, 1996).
1.3.1.1. The abortive MMR hypothesis
During these studies, theories attempting to resolve the precise mechanism of MMR 
deficient-mediated resistance have been constructed. A mechanism of MMR-dependent 
cytotoxicity exerted by methylation damage has been proposed. The methylating agents 
MNU, MNNG, and the clinically relevant monofunctional methylating drugs 
procarbazine and its activated form, temozolamide form a variety of DNA adducts of 
which 0 6-methylguanine is the most cytotoxic (Fink et al, 1998). In the case o f O6- 
methylguanine adducts, MMR only seems to recognise 0 6-methylguanine opposite a 
thymine mispair (Griffin et al, 1994; Duckett et al, 1996). Such mispaired errors occur 
after DNA replication and one hypothesis is that MMR, after recognising the mismatch, 
will continue to replace the thymine with another thymine opposite the unrepaired 
distorting lesion after each replication cycle. Such futile attempts at repair is 
envisioned to increase the chances o f a double-strand break being encountered at the 
time o f the next S-phase -  an event that triggers apoptosis (Karran et al, 1994).
However, the abortive MMR theory is not conclusive for several reasons. Support for 
the theory comes from the fact that MGMT-deficient (mex ) cells require MMR for 
sensitivity to MNNG which takes away the dominance of direct genotoxicity o f  
unrepaired O6 MeG. However, 1) the mammalian cell lines used were not mutant for 
MGMT. Some were transcriptionally down regulated (Ostrowiski et al, 1991) and 
others actually interconvertible (Caims-Smith and Karran, 1992); 2) alkylation 
tolerance was only achieved after several rounds of selection under mutagenic
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conditions (Goldmacher et al, 1986) so the phenotype could be the manifestation of 
several mutations, and 3) these cell lines were derived from tumours that possibly 
harboured other mutations that could effect alkylation tolerance.
Furthermore, the study using isogenic yeast MMR mutants does not provide strong 
concomitant evidence to support what is seen in human tumour cell lines (Bawa and 
Xiao, 1997). Finally, 6-thioguanine is an agent that can be incorporated into DNA, 
subsequently causing mispairing with thymine (see Section 1.2.3). Because correct 
pairing with 6-thioguanine adducts can occur, studies suggest that the miscoding 
frequency of this lesion is not high enough for the level o f toxicity observed (Rappaport, 
1993). However, despite these criticisms, the abortive theory has yet to be disproved.
1.3.2. MMR-deficiency and resistance to DNA 
platinating agents
Cis-Diaminedichloroplatinum(II), or cisplatin, is widely used in the treatment of 
ovarian, testicular and head and neck carcinomas (Loehrer and Einhom, 1984). The 
popularity o f this agent as an effective treatment for these tumours is marred by the 
emergence of drug resistance, representing a major factor in treatment failure (Kaye, 
1996). A substantial body o f evidence indicates that cisplatin exerts its cytotoxic effect 
by forming DNA platinum adducts, primarily in the form of intrastrand crosslinks at the 
N-7 positions between adjacent purines (mostly guanines) (Sherman and Lippard, 
1987). Of these, 1,2 intrastrand crosslinks comprise about 90% and 1,3 crosslinks 
account for a further 5% (Fichtinger-Schepman et al, 1985). The 1,3 crosslink is 
efficiently removed by nucleotide excision repair (Moggs et al, 1996) but the 
predominant 1,2 crosslink remains refractory to removal by this pathway (Szymkowski 
et al, 1992) (See Fig. 4).
Carboplatin is a structurally related molecule to cisplatin, the only difference being the 
addition of a 1,1-cyclobutanedicarboxylato-leaving group (Fig. 3). The types o f DNA 
adducts caused by cisplatin and Carboplatin are the same. Carboplatin has a slower
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reaction time with DNA, a shorter pharmacokinetic half-life and is generally less toxic 
than cisplatin (Cavalli et al, 1997). Oxaliplatin has recently been shown to be effective 
in colorectal cancer treatment (Links M, personal communication); the spectrum of 
DNA adducts being the same despite its larger molecular size. The inactive trans 
isomer, transplatin does not cause intrastrand crosslinks (citing evidence for the 
importance o f this lesion for cytotoxicity) (Calvert et al, 1993) and is not used 
clinically.
Figure 3 Structures of platinum drugs.
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Figure 4 Illustration of DNA adducts formed by cisplatin
(courtesy of Brown and Bissett, 1993)
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The first indication o f an involvement o f MMR in cellular sensitivity to platinum 
compounds came from Fram et al, (1985) who showed that cisplatin hypersensitive dam 
E.coli mutants became resistant by introduction of mutant MutS or MutL. It was not 
until studies using tumour cell lines with known defects in MMR that the same was 
shown to be true in mammalian cells. Anthoney et al, (1996) demonstrated that 
cisplatin resistant ovarian cell lines acquired MI and that this was associated with 
defects in strand-specific mismatch repair (Drummond et al, 1996). It was also seen in 
cisplatin-resistant human colon and endometrial cancer cell lines with deficiencies in 
hMLHl or hMSH2 function that sensitivity to cisplatin could be complemented by 
chromosome transfer (Aebi et al, 1996).
It was then reported that pure hMsh2 bound to platinated DNA in mobility shift assays 
(Mello et al, 1996). The hMutSa heterodimer o f MSH2 and MSH6 was then shown to
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bind to the 1,2 intrastrand crosslink (Duckett et al, 1996) and the highest affinity of 
binding to this lesion was when a thymine was mispaired with a 3’ guanine (Yamada et 
al, 1997).
Subsequently, it has been shown that 9/10 independent subclones of the A2780 ovarian 
carcinoma cell line, selected for resistance to cisplatin (and subsequently shown to be 
cross-resistant to MNU, 6-thioguanine and doxorubicin), lost protein expression of 
Mlhl and Pms2 as measured by immunoassay (Brown et al, 1997). mRNA levels for 
MLH1, but not PMS2, were markedly reduced, possibly indicating that Pms2 was 
unstable without its MutLa partner. Both the parental and resistant subclones retained 
both copies of the MLH1 gene. It was also reported from a small sample population 
that 10% of ovarian tumours from patients that had not undergone chemotherapy were 
negative for MLH1 expression as measured by immunoblot, compared to 36% of 
tumours samples taken at second look laparotomy from patients after cisplatin and 
cyclophosphamide chemotherapy (Brown et al, 1997). Although sample size was small 
(n=50), these data may indicate that tumour cells in vivo that lose expression o f Mlhl 
and become resistant to cisplatin, survive treatment.
Further support for this comes from a study which showed that a variety of drugs could 
enrich for MMR-deflcient cells. A 50:50 mixed population of MMR-proficient and - 
deficient cells were exposed to cisplatin, Carboplatin, doxorubicin, etoposide or 6- 
thioguanine. Each drug enriched for MMR deficient cells and these cells became 
clonogenically resistant to the drug used (Fink et al, 1998).
1.3.2.1. The replication stalling model
An alternative model to the abortive, futile cycles of repair hypothesis (Karran and 
Bignami, 1994), to explain MMR-deficient-induced resistance has been proposed by 
Brown et al, (1997). Here, it is proposed that cisplatin adducts cause replication 
stalling in MMR proficient cells which leads to cell death. Absence of MMR, or at 
least components o f MMR, allows replication bypass of the lesion and cell survival.
Chapter 1-49
Support comes from the fact that cellular proliferation and hence presumably DNA 
replication is required for induction of apoptosis by cisplatin (Evans et al, 1994). 
Indeed, it has been shown that cisplatin-resistant hMLHl and hMSH6 defective cell 
lines displayed 2.5-6 fold increases in replicative bypass o f cisplatin adducts (Vaisman 
et al, 1998). However, the authors interpret this as MMR-deficiency contributing to 
increased replicative bypass and therefore to drug resistance by preventing the lethality 
exerted by futile rounds o f translesion synthesis (abortive theory).
Studies have shown that DNA polymerase 5 and 8 are able to bypass 1,2 intrastrand 
crosslinks induced by cisplatin in structures that resemble replication forks (Hofmann et 
al, 1996). The antibiotic, aphidicolin, inhibits DNA polymerases a , 8 and 8 by binding 
to polymerase nucleotide binding sites (Wood and Shivji, 1997). Recently, it was 
shown that aphidicolin increases the sensitivity o f MMR-deficient ovarian carcinoma 
cell lines to cisplatin and MNU to a greater extent than their MMR-proficient 
counterparts (Moreland et al, 1999). It is proposed that by inhibiting the elevated levels 
o f lesion bypass in MMR-deficient cells, replication stalling at the lesion reduces drug 
tolerance and leads to cell death.
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1.3.3. MMR deficiency and resistance to other drugs
6-Thioguanine is not an alkylating agent in itself but after incorporation into DNA, it 
can be methylated by S-adenosylmethionine to form ^-methylthioguanine. This is 
prone to mispairing with thymine which is recognised by MutSa (Swann et al, 1996). 
Even its natural pairing with cytosine is recognised by MutSa (Griffin et al, 1994; 
Waters and Swann, 1997) and MMR-deficient cells have been shown to be 5- to 10-fold 
more resistant to 6-thioguanine (Aebi et al, 1997; Hawn et al, 1995). Adducts produced 
by 6-thioguanine are not good substrates for MGMT (Swann et al, 1996) and so would 
be expected to persist in DNA until encountered by MMR.
Loss o f mismatch repair has also been associated with resistance to the antibiotic, 
doxorubicin (adriamycin) (Drummond et al, 1996) and the topoisomerase II inhibitor, 
etoposide (Aebi et al, 1997). Doxorubicin forms a variety of adducts in DNA and so 
the substrates recognised by MMR induced by this drug are less clearly defined. Even 
less well understood is the mechanism of resistance conferred by MMR deficiency to 
etoposide. This agent is not known to interact directly with DNA so mechanisms of 
MMR-induced cytotoxicity are speculative. It could be that MMR recognises and 
signals the presence o f certain damaged structures caused by the inhibition o f DNA 
unwinding normally carried out by topoisomerase II.
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1.3.3.1. The mutator theory
The development o f cross-resistance to a variety o f drugs has led to the theory that 
MMR deficiency, which is associated with an elevated mutator phenotype, leads to 
global genomic mutations. These may include mutations in cytoplasmic resistance 
genes that encode for proteins responsible for actions such as detoxification and drug 
transport. A long established axiom has described tumourigenesis as a form of somatic 
evolution; a concept that places the selection of advantageous mutations as the 
underlying mechanism of the multistep process towards neoplasia {for review, see 
Tomlinson et al, 1996). This has been extended to explain the development of cross­
resistance to drugs in cells that have lost MMR. It has been suggested using 
mathematical models that MMR-defective cells that have an elevated mutation rate 
will, over repeated rounds of division, accumulate mutations in resistance genes 
(Tomlinson et al, 1996).
Recently, it was shown that exposing MMR-proficient and deficient cell lines to 
cisplatin led to cross resistance to topotecan, gemcitabine and possibly paclitaxel -  
drugs commonly combined with cisplatin in cancer treatment regimens (Lin and 
Howell, 1999). Indeed the folds of resistance observed with these drugs were greater 
than those obtained for cisplatin.
The mutator theory predicts that re-introducing MMR back into resistant cells will have 
no effect on drug resistance because the cell would have undergone the fixation of 
mutations involved in drug resistance. However, there are a number o f  
complementation studies examining the involvement o f MMR in engaging cell death 
that dispute this. Sensitivity to MNNG is restored in HCT116-36 chromosome 3 
transformants where the MLH1 gene was re-introduced (Koi et al, 1994) and the 
homozygous MSH2 deficient human endometrial adenocarcinoma cell line HEC59 was 
shown to be more resistant to MNNG compared to an MS//2-restored HEC59 
Chromosome 2 derivative (Umar et al, 1997). Sensitivity to cisplatin in human colon
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and endometrial cancer cell lines with deficiencies in Mlhl or Msh2 function could be 
complemented by chromosome transfer (Aebi et al, 1996). However, the mechanism(s) 
of resistance conferred by loss of MMR to drugs such as etoposide and doxorubicin 
remain elusive.
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1.3.4. The response of MMR-defective cell lines to 
ionising radiation
The evidence surrounding the involvement o f MMR in cytotoxic responses to ionising 
radiation is inconsistent. M LHl-defective mouse cells were shown to be slightly more 
resistant to y-irradiation than MMR competent controls (Fritzell et al, 1997) but 
hMLHl-deficient HCT116 colorectal cancer cells were shown to be slightly y- 
irradiation sensitive and showed defects in G2 cell cycle arrest (see Section 1.2.5) 
(Davis et al, 1998). No difference was seen between MSH2-proficient and deficient 
cells defective in NER in response to IR (O’Driscoll et al, 1999).
The role o f MMR in IR-induced DNA damage processing is unclear. IR is known to 
cause single and double-strand breaks in DNA (Hiom, 1999). It has not been shown 
that MMR proteins bind to double-stranded breaks, although single-stranded DNA is 
targeted by MMR in nick-directed repair and is a substrate for homologous 
recombination - a pathway known to be regulated by MMR (see Section 1.1.3).
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1.3.5. MMR and cell cycle arrest
There is substantial evidence supporting an active involvement of proteins o f mismatch 
repair in the G2 cell cycle arrest response to DNA damage. Although it has been shown 
that certain components o f MMR are themselves cell cycle regulated (Kramer et al, 
1996; Harris et al, 1997), evidence for a functional role o f MMR proteins in the 
induction of cell cycle arrest comes from several studies using human cell lines. MMR- 
deficient human colon carcinoma (HCT116) cells which lacked Mlhl expression were 
more resistant to 6-thioguanine and lacked a G2-M arrest response compared to the 6- 
thioguanine-treated MMR proficient (HCT116 3-6) derivative (Koi et al, 1994; Hawn et 
al, 1995). Incidentally, a study that re-introduced wild type hMLHl in HCT116 cells 
showed that cellular proliferation and rate o f DNA synthesis was markedly reduced 
(Shine? a/, 1998).
In a study that used seven MMR-deficient and proficient human cancer cell lines (with 
and without confirmed mutations in MLH1 or MSH2), G2 growth arrest in response to 
MNNG treatment was seen in the proficient cell lines. The MMR-deficient cells, 
however, escaped an initial G2 delay and resumed a normal growth pattern (Carethers et 
al, 1996). Radio-sensitive, MMR-deficient HCT116 cells also showed a reduced delay 
of re-entry into the cell cycle after G2 arrest in response to ionising radiation (Davis et 
al, 1998). Similar IR responses were also noted between murine mlhl knockout 
compared to wild-type primary embryonic fibroblasts (Davis et al, 1998).
Furthermore, in addition to its role in G! arrest induction, p53 is known to be required 
for sustained G2-M arrest after DNA damage (Bunz et al, 1998; Innocente et al, 1999) 
and it has been shown that the MMR-deficient ovarian carcinoma (A2780-cp70) cell 
line shows loss o f p53 function as measured by reduced \>2\CIP1 mRNA compared to the 
MMR-proficient (A2780) derivative in response to cisplatin (Anthoney et al, 1996).
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To explain the apparent involvement of MMR in G2-M arrest as opposed to Gj arrest, 
the following studies suggest that DNA replication is required for MMR-dependent 
DNA damage processing. The MutS complex is known to bind to the DNA 1,2 
intrastrand crosslink with much greater affinity if opposite a mismatched base, 
suggesting that DNA synthesis past the lesion is required for recognition (Duckett et al, 
1996; Brown et al, 1997). Also, MMR deficient ovarian carcinoma (A2780-cp70) cells 
that show resistance to cisplatin compared to proficient (A2780) cells have a 
significantly reduced MMR-dependent resistance phenotype when treated with 
aphidicolin - a DNA polymerase inhibitor (Moreland et al, 1999).
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1.3.6. MMR and the signal transduction pathway for 
cell death
Eukaryotic cells respond to the presence o f cisplatin adducts in DNA by activating 
signal transduction pathways that result in cell cycle arrest, an increase in the activity o f 
certain types of DNA repair, and apoptosis (Eastman, 1990). Although the signalling 
pathways activated as part o f the cisplatin-induced injury response are as yet poorly 
characterised, studies have demonstrated that the response involves activation o f the 
stress-activated protein kinase JNK and the nuclear c-Abl protein kinase (Kharbanda et 
al, 1995).
JNK phosphorylates the transcription factors c-Jun, activator of transcription factor 2, 
and Elk-1 and stimulates their transcriptional activities (Hibi et al, 1993; Gupta et al, 
1995; Cavigelli et al, 1995). c-Abl associates with the retinoblastoma (Rb) protein thus 
indicating a role in cell cycle control (Welch and Wang, 1993). c-Abl has also been 
shown to phosphorylate and stimulate the transcription o f RNA polymerase II (Welch 
and Wang, 1993).
Nehme and colleagues (1997) investigated the effect of loss o f MMR function on the 
ability o f cisplatin to activate the stress-activated protein kinase JNK and the protein 
tyrosine kinase c-Abl, as these were reported to be activated in response to a variety of 
DNA damaging agents (Kharbanda et al, 1995). They showed that cisplatin activated 
JNK 3.8-fold more efficiently in MMR-proficient that MMR-deficient cells and that c- 
Abl activation was completely absent in MMR-deficient cells (Nehme et al, 1997). 
This suggests that JNK and c-Abl may be targets for the detector proteins of MMR in 
coupling cisplatin-induced DNA damage to apoptosis.
In addition, it has recently been demonstrated that cells proficient in MMR increased 
the level o f the p53-related protein, p73 in response to cisplatin (by increasing its half- 
life) (Gong et al, 1999). p73 can activate p53- responsive promoters and induce
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apoptosis when overexpressed in certain p53-deficient tumor cells. p73 encodes several 
isoforms including p73 alpha and p73 beta, each o f which can induce permanent growth 
arrest with markers o f replicative senescence when overexpressed in a tetracycline- 
regulatable manner in human cancer cells lacking functional p53 (Jost et al, 1997; Fang 
et al, 1999).
Gong et al, (1999) recently showed that the p73 half-life in MMR-deficient HCT116 
cells lacking the MLH1 gene was not increased in response to cisplatin compared to 
levels in MMR proficient cells. Furthermore, c-Abl enhanced the function o f p73 in 
cisplatin-treated MMR proficient cells by stabilising the protein. These proteins have 
indeed been shown to associate with each other (Agami et al, 1999; Yuan et al, 1999). 
c-Abl was found to be inactivated in MMR-deficient cells in response to cisplatin 
(Gong et al, 1999). It was also demonstrated that cisplatin could induce two parallel 
death-response pathways, one dependent on p53 and the other on p73. p53 was
induced by cisplatin in M lhl- and c-Abl-deficient murine embryonic fibroblasts 
indicating the lack o f requirement for these proteins in the p53 response. p73 was 
induced in p53-deficient cells in response to cisplatin but not in the absence o f Mlhl or 
c-Abl (Gong et al, 1999). These results indicate that c-Abl and p73 are components o f a 
MMR-dependent apoptosis pathway which contributes to the cytotoxic effect of 
cisplatin.
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1.4. Objectives of Thesis
From the existing evidence, it seems that the mechanisms underlying MMR-dependent 
cytotoxicity are multifactorial. The generation o f the lethal signal is still under debate 
and the spectrum of different types of DNA lesions caused by varying agents is still 
unclear. In addition, a large amount o f eukaryotic MMR homologues have been 
identified, many o f which have no known function. To this end, this thesis aims to 
investigate what genes and mechanisms are involved in eukaryotic MMR-dependent 
responses to DNA damage.
1.4.1. Cisplatin as a model DNA damaging agent
The following observations explain why the cytotoxic DNA damaging agent cisplatin 
was chosen for the study o f MMR-dependent cellular responses.
a) the recognition proteins, MutS homologues, o f MMR bind with strong affinity to the 
1,2 intrastrand crosslink,
b) this adduct is poorly repaired by NER. Transplatin, which does not induce this 
adduct, is not active which suggests that this is a cytotoxic lesion.
c) previous studies using human cell lines have reported MMR deficiency in response 
to cisplatin exposure and that this selection process lead to resistance to other DNA 
damaging drugs.
1.4.2. S. cerevisiae as a model organism
Particularly in the field o f DNA repair, the use of microbiological systems to study 
human mechanisms has proven invaluable because o f the homologous systems that 
have persisted through evolution. The yeast S. cerevisiae has gained popularity as a 
model for pre-screening new drugs, elucidating their mode o f action and understanding
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the mechanisms that regulate their effects on biological systems (Hannan 1988; Nittis 
and Wang 1988; Delitheos et al, 1995; Hartwell et al, 1997). This has recently become 
important due to the completion of the S. cerevisiae genome sequence database. One 
major advantage of using S. cerevisiae over human cell lines is the guarantee of 
isogenicity when comparing phenotypes o f strains with known gene manipulations. To 
this end, this thesis takes advantage of the S. cerevisiae model in the study of eukaryotic 
MMR.
1.4.3. Aims
1) To find out if  S. cerevisiae strains defective in certain MMR genes have altered 
cytotoxic responses to cisplatin. This will be carried out by setting up a standard 
clonogenic assay for specific isogenic strains of S. cerevisiae defective in individual 
genes involved in MMR.
2) To explore specifically which MMR genes in S. cerevisiae are involved in cisplatin 
cytotoxicity
3) To set up a complementary gene re-introduction system to investigate if restoring 
MMR function in MMR-defective S. cerevisiae strains also directly restores responses 
to cisplatin
4) To identify if other DNA repair genes i.e. RAD52 and RADI involved in 
recombination and excision repair, are involved in MMR-dependent responses to 
cisplatin
5) To examine if S. cerevisiae MMR genes are involved in cell cycle arrest in response 
to a variety of DNA damaging agents, i.e. cisplatin, transplatin (control), ultraviolet 
radiation and ionising radiation.
EQUIPMENT
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2. EQUIPMENT
Hybaid Touchdown PCR Thermal Cycler
Hybaid Omnigene PCR Thermal Cycler
Innova 4300 Incubator shaker - New Brunswick Scientific
Innova 4000 Incubator shaker - New Brunswick Scientific
Omega Prestige Medical autoclave
Flow laboratories C 02 incubator 220
Swan U170-80H -70°C refrigerator
Stratagene UV Stratalinker 2400
Voss eppendorf Rotator
MixiMatic shaker - Jencons Scientific Ltd
MSE Soniprep 150 sonicator
Hetovac speedivac DNA prep dryer
EEC Centra-7R refrigerated centrifuge
Sorvall Instruments - Dupont RC3C refrigerated centrifuge
Sorvall Instruments - Dupont RC5B refrigerated Superspeed centrifuge
EEC Micromax centrifuge
Luckham 4RT rocking table
Coming pH meter 240
Pharmacia Biotech Electrophoresis power pack supply EPS 600 
ABI373A DNA sequencer 
MPH Multipurpose gel electrophoresis chamber 
Bio-Rad gel doc 1000 UV box
Zeiss Axioskop fluorescent microscope connected with JVC lA INCH CCD digital 
videocamera
Applied Biosystems 392 DNA/RNA oligonucleotide synthesiser
Beckman DU 650 Spectrophotometer connected to IBM Personal system 2 colour display 
and Epson LX-800 dot matrix printer
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Techne Dri-Block DB2A and DB3D heating blocks 
Mettler AE100 and PM300 weighing balances 
Bigneat Ltd Captair fume hood
Becton Dickinson Facsan linked to Apple Macintosh Quadra 650 with CellQuest software 
Oce 3 107c digital colour printer 
Kodak ColourEase printer 
Pdi 420oe 1-D gel scanner
REAGENTS
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3. REAGENTS
Buffers, solutions and media
Yeast Peptone Dextrose Media
1 Og/500ml Difco Peptone
5g/500ml Yeast extract
Add 475ml H20, adjust pH to 5.8 and autoclave in pressure cooker.
Cool to ~50°C and add dextrose (glucose) to 2% by adding 25ml o f a 40% stock 
solution (filter sterilise) to each 500ml of medium.
Synthetic dropout media
Amino acids mg
adenine 800
arginine 800
aspartic acid 4000
histidine 800
leucine 800
lysine 1200
methionine 800
phenylalanine 2000
threonine 8000
tryptophan 800
tyrosine 1200
uracil 800
isoleucine 1200 (optional)
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valine 600 (optional)
Grind powders up together and store at RT. Leave out the amino acid that you are 
making dropout. Everything added for synthetic complete.
870 mg/L
6.7g yeast nitrogen base w/o amino acids 
20g glucose
1L dH20 then pH to 5.5 -6.0 using 1M NaOH. Autoclave.
9g/500ml Agar (if needed for plates)
DNA loading dye
0.25% Bromophenol blue
0.25% Xylene cyanol 
30% Glycerol
L-broth
1% Tiyptone
0.5% Yeast extract 
l%NaCl
Phosphate buffered saline (PBS)
0.8% NaCl
0.115%Na2HP04
0.02% KC1
0.02% KH2PO4
PLATE solution
90ml sterile 45% PEG 4000 (Sigma)
10ml 1M lithium acetate 
lml 1M Tris-HCl, pH 7.5
0.2ml 0.5MEDTA 
vortex mix.
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TBE (lx )
89mM Tris borate 
89mM Boric acid 
2.5mMEDTA
Q ia g e n ®  Plasmid Purification buffers:
Buffer composition
Buffer PI (Resuspension Buffer) 50mM Tris-Cl, pH 8.0;
lOmMEDTA; 
lOOpg/ml RNase A
Buffer P2 (Lysis Buffer) 200mM Na OH, 1% SDS
Buffer P3 (Neutralisation Buffer) 3.0M potassium acetate,
4°C
pH 5.0
Buffer QBT (Equilibration Buffer) 750mM NaCl;
50mM MOPS, pH 7.0 
15% isopropanol;
0.15% Triton® X-100
Buffer QC (Wash Buffer) 1.0M NaCl;
50mM MOPS, pH 7.0 
15% isopropanol
storage
4°C
room temperature 
room temperature or
room temperature
room temperature
Buffer QF (Elution Buffer) 1.25M NaCl; room temperature
50mM Tris, Tris-Cl, pH 8.5 
15% isopropanol
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Buffer QN (Elution Buffer) 1.6M NaCl;
50mM MOPS, pH 7.0; 
15% isopropanol
room temperature
STE lOOmMNaCl; 
lOmM Tris-Cl, pH 8.0 
ImMEDTA
room temperature
TE lOmM Tris-Cl, pH 8.0room temperature 
ImMEDTA
CDS (Chromatin denaturation solution):
Dissolve 2.5ml 4 NHC\, 0.5g Triton X-100 (Sigma), 1.75g NaCl in 97.5ml dH20 . Heat 
to dissolve Triton X-100 and cool on ice before using to treat fixed cells.
Formaldehyde solution (0.25% v/v):
Mix 0.156ml formaldehyde solution (16% ultrapure formaldehyde, EM Grade, 
Polyscience, Warrington, PA) in 10ml PBS.
Zymolyase solution (40U/ml):
Dissolve 20mg 20T zymolyase (20U/mg; ICN ImmunoBiochemicals, Lislie, EL) in 
10ml PBS; prepare solution right before use and store on ice.
FACS buffer:
211 mM Tris, 78mM NaCl, 75mM MgCl pH 7.8
METHODS
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4. METHODS
4.1. Saccharomyces cerevisiae mutant strains
Haploid isogenic S. cerevisiae strains were obtained in collaboration with Dr. Rhona 
Borts o f the Yeast Genetic department, Institute o f Molecular Medicine, John Radcliffe 
Hospital, Oxford, UK. All strains are derivatives o f RHB2096-lb (ura3-l lys2-d met 13- 
4 cyh2 Ieu2-R MAT a). (Hunter and Borts, 1997). Strains were generated by complete 
gene deletion using PCR-mediated recombinational insertion of the LEU2 or KANMX 
cassette (Wach et al, 1994; Hunter and Borts, 1997).
Description Strain
Wild type 2096-IB
Amsh2 RHB 2348
Amsh3 RHB2347
Amsh6 NHT 173
Amlhl RBT311
Amlh2 RBT 324
ApmsI RBT 289
Arad52 RHB 2692
Arad52/Amsh2 RHB 2700
Arad52/Amlhl RHB 2698
Arad52/Amlh2 RHB 2699
Aradl RBT 302
AradUAmsh2 RHB 2694
AradllAmlhl RHB 2693
Aradl! Amlh2 RHB 2695
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Upon arrival, strains are inoculated onto YPD agar plates, grown for 2-3 days in 30°C
and each lawn is scraped off and inoculated into 15% glycerol stocks and stored at
70°C.
4.2. Drug treatment of S. cerevisiae strains
1. Scrape off cells from frozen stock and grow to saturation in 10ml YPD medium by 
incubating universal for ~2 days in a 30°C shaking incubator.
2. Dilute cells to 2x l07 cells/ml, with a range of DMSO dissolved cisplatin 
concentrations e.g. 0, 0.5, 1, 1.5, 2mM cisplatin.
3. Incubate cells in a universal tube in 30°C shaking incubator for 24hrs.
4. (Take an aliquot for fixing with 70% ethanol for FACS analysis). Dilute and plate 
out cells on solid YPD at 400 cells per plate.
5. Incubate four plates per concentration o f cisplatin for ~2 days in a 30°C incubator.
6. Count colonies and calculate percent survival relative to controls.
4.3. Irradiation of S. cerevisiae
1. Scrape off cells from frozen (expanded) stock and grow to saturation in 10ml YPD 
medium by incubating universal for ~2 days in a 30°C shaking incubator.
2. Dilute cells to 2x107 cells/ml. Place universals under a source o f y-radiation emitter 
(Cobalt-60) and expose to lOOgy (dose equivalent at the time was: 58mins of  
1.43gy/min)
3. Immediately after irradiation take an aliquot for fixing with 70% ethanol for 
FACS analysis/Fluorescent microscopy - see section 5.8 & 5.9. Dilute and plate 
out cells on solid YPD at 400 cells per plate.
4. Incubate plates for ~2 days in a 30°C incubator. Count colonies and calculate 
percent survival relative to controls.
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4.4. S. cerevisiae MLH1 gene re-introduction
4.4.1. PCR of S. cerevisiae MLH1
cDNA from Saccharomyces cerevisiae (Sigma) was used for amplifying ScMLHl. 
Polymerase chain reaction o f ScMLHl was carried out in-frame including the 5’ ATG 
start site and ending at 3 ’ TAA stop codon. The following cycle was performed:
94°C 5 mins
94°C
Annealing temp. 
72°C
1 min 
1 min 
1 min _
x 30 cycles
72°C 5 min
Hold at 15°C
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4.4.2. S. cerevisiae MLH1 oligonucleotide primers
F-BamHI:
5’- TCGCCG GGATCC ATG TCT CTC AGA ATA AAA GCA -3’
BamHI start ANNEALING TEMP: 48.2°C
R-Mlu:
5’- AGGAT ACGCGT TTA ACA CCT CTC AAA AAC TTT G -3’
Mlul stop ANNEALING TEMP: 48.6°C
Enzyme restriction sites BamHI and Mlul were inserted into the primers as non­
annealing sequences surrounded by 5’ random sequences (to enable digestion). These 
ends were then used to clone into pYX212 after digestion.
4.4.3. Coding sequence for S. cerevisiae MLH1 gene
See Appendix
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4.4.4. Cloning ScM L H l  into yeast expression vector
P o l y  A
MCSGAL
Col 61 on
pYX Vector
H1S3
'L B J 2
o r  2)1
T P  I
P r o m o t e r
pYX212
(8346bp)C o l  E 1o r i
A m p '
F ig u re  5 pYX212 yeast expression vector
(R&D Systems). 2p /URA / TPI promoter - 
This replicates autonomously in yeast and is 
usually stable being maintained at 25-100
copies per cell. Selective pressure recommended for maintenance.
1. Digest the plasmid and PCR products (flanked with restriction sites) using BamHI 
and Mlul. Always use lOx concentration of enzyme to DNA (i.e. equal volumes 
with lOU/pl enzyme. In small eppendorf, add in order:
7 j l i 1 dH20
1 pi appropriate buffer ( l Ox)
1 pi DNA: ~1 pg/pl of plasmid and ~1 pg/pl insert
lp l enzyme (lOx) - put first enzyme in with lower salt buffer. Incubate at 
37°C on heating block for 2-4hrs. Put on ice. Adjust salt concentration and add
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second enzyme for sequential digest. Incubate at 37°C on heating block for 2-4hrs. 
Put on ice.
Make sure that the glycerol in enzyme solution is diluted by at least 1/1 Oth final 
volume.
2. For ethanol precipitation of restriction enzyme-cut products:
-add 3M NaAc (pH8) to give final conc. of 0.3M. i.e. 1/1 Oth volume.
- add lp l glycogen (optional)
- add 2 volumes ice cold ethanol and mix well. Place at -20°C or on dry ice for 0.5- 
lhr to allow DNA to precipitate.
- spin at 490g (13,000rpm on Sorvall RC3C) for 15min at 4°C.
- remove supematent. Add 1ml 70% ethanol and put on dry ice (or -20°C) for 0.5hr. 
Respin at 490g for 15min at 4°C.
- remove supernatant, allow to air-dry and resuspend in TE/water (pH 7.6) (20pl).
Use 0.6 volumes isopropanol instead of ethanol to precipitate larger fragment 
(leaving unwanted small R.E product in supernatant).
4. Set up the following ligation reactions maintaining a final volume of not more than 
than 10 pi:
- transfer 50ng plasmid DNA to each tube (50ng/pl)
- add 20x (lpg), lOx (500ng) and 5x (250ng) concentration of insert DNA
- add 4pl 5x T4 DNA ligase buffer
- add 2 units T4 DNA ligase (4units/ml)
- add 2pl Bovine serum albumen (acetylated, from lOmg/ml stock)
Adjust to 20pl with dH20. Incubate at 16°C over night.
5. Purify DNA using Wizard™PCR Preps DNA Purification System. See Section 4.5
6. To detect successful ligation reaction in samples, set up electrophoresis gel by 
making up 100ml gel. Heat dissolve:
agarose 0.8g
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0.5x TBE 100ml
-While hot, add: 0.5pg/ml ethidium bromide lOOpl o f 0.5mg/ml
7. Set gel in chamber with comb and allow to cool for 20mins.
8. Emerse in tank filled with running buffer:
0.5x TBE 400ml
(optional) 0.5pg/ml ethidium bromide 400pl of 0.5mg/ml
9. Load samples to each well containing:
2pl DNA 
2 pi 6x loading dye 
8pl TE pH. 8.0
10. Run at 80V, lOOmAmps
11. Image gel under transilluminator.
4.4.5. E.coli DH5a transformation
Preparation o f agar plates with Ampicillin for selection
1. Add 7.5g bactoAgar to 500ml LB.
2. Autoclaved LB bottles.
3. Add lOOpg/ml Amp (final conc.) i.e. 1ml o f 50mg/ml stock by filter sterilisation.
4. Poor into bacteria-grade petri-dishes up to line and leave to set.
5. Wrap in Parafilm “M” and store at 4°C.
E.coli (DH5a - competent strain) transformation.
1. Transfer 20pl thawed cells into chilled eppendorf tubes.
2. Add IjliI o f plasmid DNA to separate tubes (l-10ng/pl), shake gently.
3. Put on ice for 30 mins.
4. Heat shock for 40 secs, in 42°C heat block, then place on ice.
5. Add 80pl LB medium and shake tubes at 225rpm for lhr at 37°C.
6. Pipette all cells on to ampicillin-containing agar plate and spread evenly, incubate 
overnight.
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4.4.6. Isolating DH5a colonies containing correctly sized 
vector inserts.
Vector Primers:
pYX112Fl (187) 5’ GTC TAG CTC CAG CTT TTG 3’ 
pYXl 12 R1 (6454) 5’ CCT TTG CAT TAG CAT GCG 3’
pYX212 FI (8154): 5’ TAT ACC TTT GGC TCG GCT 3’ 
pYX212 R1 (187): 5’ CAA AAG CTG GAG CTA GAC 3’
1. Prepare appropriate numbers o f universals containing 5ml LB and thin-walled 
eppendorfs containing master-mix for PCR.
2. After growing bacterial colonies, use pipette tips or tooth picks to scrape off 
individual colonies and emerse in a) warmed up 10ml LB containing lOOpg/ml 
Ampicillin (20pl o f 50mg/ml stock) (go to step 3) and b) mastermix tube (go to step
3. Shake in incubator at 37°C for 2-3hrs.
4. Pour 1 litre o f LB into each flask, add lOOpg/ml Amp (2ml of 50mg/ml) and warm in 
incubator.
5. Add 10ml o f cells into flasks and shake at 37°C overnight.
6. Freeze down stock by placing 150pl autoclaved glycerol into plastic tubes, add 850pl 
cells and store at -70°C
7. PCR the bacterial plasmid template using vector primers and screen for correct 
insert. Using 0.5ml thin-walled tubes.
Make up the following master mix for 50pl reaction:
lOx PCR buffer 5 pi 
3 pi 
lpl
25mM MgCl 
lOmM dNTPs
Expand High Fidelity Taq polymerase
Chapter 4-77
(2-5 units/pl) 0.5pl
autoclaved dH20  36.5pl
to appropriate reaction:
primer 1 (lOpM) lpl
primer 2(1 OpM) 1 pi
8. Mix gently and layer 2 drops (~100pl) o f mineral oil over the reaction.
9. PCR cycle (see 4.4.1)
10. Analyse 10 to 20pl o f amplified sample using agarose gel electrophoresis.
11. Discard unsuccessful cultures and remaining liquid cultures.
12. Make glycerol preps o f successful cultures (150pl pure glycerol to 850pl LB)
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4.4.7. Isolation of vectors 
Extracting Plasmid DNA from E.coli
(Quaigen Maxi Prep Plasmid System - for buffer constituents see 
Reagents)
1. Pre-chill buffer P3 (Neutralisation buffer)
2. Spin down cultures in large centrifuge beaker at 3000rpm for 5 mins.
3. Resuspend pellet in 10ml buffer PI (Resuspension buffer) containing RNaseA.
4. Add 10ml buffer P2 (Lysis buffer), mix gently and incubate at room temp for 5 mins.
5. Add 10ml chilled buffer P3 (Neutralisation buffer), mix immediately but gently and 
incubate on ice for 20 mins.
6. Make sure tubes are balanced (very viscous precipitate).
7. Spin down at 290g (10,000rpm on Sorvall RC3C) at 4°C for 30 mins and remove 
supernatant promptly.
8. Repeat Step 7.
9. Equilibrate a Qiagen-tip 500 by running through 10ml buffer QBT (Equilibration 
buffer) and allow column to empty by gravity flow. Collect in 50ml Falcon tubes.
10. Run supernatant through, then wash through with 60ml buffer QC (Wash buffer) 
(10ml at a time).
11. Elute the DNA with 15ml buffer QF (Elution buffer) and collect.
12. Precipitate DNA by adding 0.7 volumes o f isopropanol (10.5ml) and mix at room 
temperature.
13. Mark outside o f tube where pellet will appear and spin down immediately at 290g at 
4°C for 30 mins. Carefully remove supernatant.
14. Wash DNA with 15ml 70% ethanol, spin down again, air-dry pellet for 5 mins and 
redissolve in TE buffer / water (200pi approx.)
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4.5. Purification of PCR products
{Wizard™PCR Preps DNA Purification System)
1. Transfer the aqueous (lower) phase to a clean eppendorf. The presence o f too 
much mineral oil in the sample can lead to a decreased yield in the PCR product 
purification.
2. Aliquot lOOpl o f Direct Purification Buffer into a 1.5ml eppendorf. Add the PCR 
product (30-300pl) and vortex briefly to mix.
3. Add 1ml o f Resin and vortex briefly 3x over a one minute period.
4. Make up 80% isopropanol. For each PCR product, prepare one Wizard 
Minicolumn. Set aside the plunger from a 2.5ml syringe. Attach the syringe barrel 
provided in kit to the Minicolumn.
5. Pipette the resin/DNA mix into the syringe barrel, insert and push the plunger 
slowly through. Discard the elute.
6. Detach the syringe barrel from the Minicolumn and remove the plunger. Reattach 
the syringe barrel and pipette in 2ml o f 80% isopropanol. Insert the plunger and 
gently push through to wash the column. Discard the elute.
7. Remove the syringe and transfer the Minicolumn to a 1.5ml eppendorf. Centrifuge 
for 2min at 9300g (10,000rpm in microfuge) to dry the resin.
8. Pre-heat an eppendorf full o f TE to 60°C. Transfer the Minicolumn to a new 
eppendorf. Apply 50pl o f 60°C TE and wait lmin. Centrifuge the Minicolumn for 
20sec at 9300g to elute the bound DNA. Remove and discard the Minicolumn and 
store DNA at 4°C or -20°C according to use.
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4.5.1. Measuring DNA concentration by spectrophotometry
1. Dilute DNA 1:500 i.e. 2pl into 9 9 8 j l l1  TE.
2. Using Spectrophotometer, blank with TE and measure absorbance of nucleic acid 
samples (OD, optical density) at 260nm.
3. Calculate concentration: abs at 260nm x dilution factor x 50pg/ml
= pg/ml o f DNA
4.6. Li-acetate yeast transformation
1. Take 0.5ml o f culture and spin 10 seconds in a microcentrifuge. Decant supernatant 
by
inverting the tube and shaking it once
2. Add IO jl iI  of carrier DNA (lOOpg salmon sperm DNA - boiled for lOmins) and ljug 
transforming DNA, subject to vortex mixing.
3. Add 0.5ml PLATE solution (PEG/Li-acetate/TE, see Reagents), subject to vortex 
mixing.
4. Incubate overnight at room temperature on bench top
5. Spread mixture directly on selective plate. (Cells tend to settle overnight - plate
0.2ml from bottom as PEG solution slows growth)
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4.7. Sequencing of ScMLHl insert
Taq Terminator Sequencing (on ABI 373A)
Fragments o f approximately 200bp are suitable for sequencing. Six 5’ primers and six 
y  primers were designed along ScMLHl:
seqMLHl - FI: 5’-
seqMLHl - Rl: 5’-
seqMLHl - F2: 5’-
seqMLHl - R2: 5’-
seqMLHl - F3: 5’-
seqMLHl - R3: 5’-
seqMLHl - F4: 5’-
seqMLHl - R4: 5’-
seqMLHl - F5: 5’-
seqMLHl - R5: 5’-
seqMLHl - F6: 5’-
seqMLHl - R6: 5’-
1. Mix 0.5 - lpg DNA with 3.2pmoles primer and make volume to 6pl with ddH20 .
Oligo size ng equivalent of 3.2pmoles
16mer 16.90
18mer 19.00
20mer 21.12
22mer 23.23
24mer 25.34
2. Add 4pl reaction mix
3. PCR with following conditions:
with Perkin Elmer 9600: with Perkin Elmer 480:
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preheat to 96°C 
96°C x 15sec 
50°C x lmin
96°C x 30sec
60°C x 4mins
50°C x 15sec
60°C x 4mins
25 cycles
25 cycles 
4°C
4°C
4. Add 2jli1  of 3M Sodium Acetate pH4.5 and 50pl Ethanol to the final aqueous phase 
(Use 0.5ml tubes for this and future steps)
5. Mix and stand at -70°C for 15mins
6. Spin for 15mins at full speed in Eppendorf microfuge
7. Carefully take off supernatant
8. Wash pellet with 250pl 70% Ethanol
9. Spin 5mins
10. Again remove supernatant carefully
11. Speedivac for 5mins to dry off pellet.
Samples prepared to stage 11 were then given to In-house Sequencer service.
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4.8. Mutator phenotype testing
4.8.1. Forward mutation frequency
Since wild type CAN1 confers sensitivity to L-canavanine, any mutation results in 
recessive resistance:
1. Make up agar plates containing synthetic complete media with arginine dropped out 
(as arginine represses L-canavanine uptake) and 0.006% L-canavanine (3ml o f 2% 
solution per litre media).
2. Plate out 106 cells on YPD-arginine' + agar + 0.006% L-canavanine and 400 cells on 
YPD + agar control. Count colonies surviving.
3. Calculate forward mutation frequency:
No. Can colonies x 400 
No. Ctrl colonies x 106
4.8.2. Mutation Rate - fluctuation analysis
Work carried out on mutation rate determination was carried out by Dr Gill Hirst. 
Fluctuation analysis was determined by plating out strains to obtain individual colonies.
1) Make up SC-Arg media plates.
2) Pick 12 single colonies >3mm diameter and resuspend in sterile 0.5ml H20.
3) Dilute cells 1/10 and 1/100 and seed onto Sc-Arg to obtain numbers of viable cells 
and Sc-Arg/L-canavanine plates to determine mutant colony number.
4) Grow for 2-3 days at 30° C and count.
5) The method of Lea and Coulson (1949) is then used to analyse data.
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4.9. Yeast FACS Analysis
1. From an exponentially growing culture remove 5mls and sonicate for lOsec at a 
frequency of 2500 using an MSE Soniprep 150 sonicator. Spin down 5min lOOg 
(lOOOrpm bench top centrifuge).
2. Resuspend in 2ml 70% EtOH
3. Leave for lhr room temp.
4. Spin cells for 5 minutes, lOOg (lOOOrpm in microfuge) and resuspend in 0.5ml ice- 
cold CDS and incubate lOmins on ice.
5. Spin down cells for 1 minute, 350g (2000rpm in microfuge) and resuspend in 0,5ml 
formaldehyde solution for 30min room temp.
6. Spin down cells for 1 minute, 350g and wash once with 0.5ml PBS.
7. Resuspend in 800pl 50mM Tris and add 200ul 5mg/ml pre-boiled RNAse A (.Kramel 
Biotech) in 50mM Tris, pH7.8 (i.e. using stock o f 2mg/ml RNAse A). Incubate for 
lhr in 37C room.
8. Spin down cells for 1 minute, 350g and resuspend pellet in 0.5ml zymolyase solution 
(or, 0.5ml of 5mg/ml pepsin in 55mM HC1. for 30 minutes at 37C) and incubate at 
30C for lOmin.
9. Spin down cells for 1 minute, 350g and resuspend in 1ml Tris/NaCl/MgCl - 200mM 
Tris Ph7.5, 21 ImM NaCl, 78mM MgCl
10. Spin down for 1 minute, 350g and resuspend in 0.5ml Tris/NaCl/Mg/Cl. Add 55pi 
500pg/ml propidium iodide in water for final conc. o f 50pg/ml PI and soon after, 
read on FACS. Transfer 50ul cells to FACS tube and add 2mls 50mM Tris, pH 7.8
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4.10. Yeast fluorescent microscopy
1. Harvest 1ml o f cells. Sonicate for 10 secs, at a frequency o f 5000 (MSE Soniprep 
150 sonicator), transfer to plastic tube and spin down cells (10 secs at 18300g or 
14000 rpm in microfuge). Wash pellet in 50mM Tris 7.8. Resuspend in 1ml 70% 
ethanol and 50mM Tris 7.8 (50pl o f 1M Tris 7.8). Incubate O/N. (The cells can be 
stored for months at 4°C at this stage)
2. Spin cells down for 1 minute, 350g and wash pellet 2x with 50mM Tris 7.8. 
Resuspend in 1ml 50 mM tris 7.8 and add 20jul lOmg/ml RNase A (DNase free - boil 
for 5mins). Incubate O/N at RT on a rotator.
3. Spin cells down for 1 minute, 350g and wash pellet lx  with FACS buffer (200mM 
Tris 7.5, 211 mM NaCl, 78mM MgCl2). Resuspend in 0.5ml FACS buffer and add 
55pl o f 0.5mg/ml propidium iodide. The cells can be stored frozen for at least 2 
weeks at this stage.
4. Sonicate for 10 seconds at a frequency o f 5000 (MSE Soniprep 150 sonicator) and 
place under a fluorescent microscope. Place one drop of oil on a cover-slip and 
observe under the microscope.
RESULTS
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5. RESULTS
5.1. Isogenic MMR mutant S. cerevisiae strains
Previous studies have tested the relative difference between parental and MMR- 
defective tumour cell lines to the cytotoxic effects of cisplatin and other DNA 
damaging agents (Anthoney et al, 1996; Brown et al, 1997). Studies using yeast as an 
isogenic model have only tested for alkylation tolerance (Xiao et al, 1995; Bawa and 
Ziao, 1997) and not for cisplatin resistance. They demonstrated that deletion of any of 
the MMR genes, MLH1, MSH2, MSH3, MSH6 and PMS1 did not rescue mgtA O6 MeG 
DNA repair methyltransferase-deficient cells from killing by MNNG (Xiao et al, 1995; 
Bawa and Ziao, 1997). However, a strain (XS-14) carrying a mutated form of the 
MSH5 gene, but not an msh5A null mutant, was responsible for cellular tolerance to 
MNNG (Bawa and Ziao, 1997) and it was suggested that some mutated forms of MSH5 
and possibly o f MutS homologues in mammalian cells may be involved in alkylation 
tolerance.
This thesis has taken advantage of isogenic strains o f S. cerevisiae with specific 
disruptions in known MMR genes and tested the relative cytotoxicity of each mutant to 
cisplatin treatment. Certain fundamental differences between yeast and mammalian 
cells have to be taken into account when screening for cytotoxic phenotypes. First, the 
plasma membrane of yeast is made up of the polysaccharide chitin and p-1,3 glucan 
making up a densely interwoven fibrillar mesh (Pringle et al, 1997). This requires 
much higher concentrations of drug to achieve cytotoxicity and previous studies that 
have analysed the cytotoxicity o f cisplatin in yeast have used concentrations ranging up 
to 1.2mM in the medium (Megan et al, 1996). This is approximately one thousand 
times the concentration o f cisplatin used for tumour cell line studies (Anthoney et al, 
1996; Brown et al, 1997).
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An advantage of using yeast is the doubling time. Budding yeast doubling times are 
much quicker, typically 90-120 minutes, compared to mammalian cells in culture 
(Pringle et al, 1997). Therefore, assays can be carried out over a 2-3 day basis 
compared to those that span a week for mammalian studies.
Isogenic S. cerevisiae strains were generated in collaboration with Dr. Rhona Borts, 
EMM, John RadclifFe Hospital, Oxford, UK. Individual MMR genes were disrupted by 
recombination plasmids containing KANMX and LEU2 selection markers (Wach et al, 
1994). Before the strains were tested for cisplatin cytotoxicity, each strain was screened 
for the correct selectable marker (See Table 1) as determined by resistance to the 
aminoglycoside antibiotic, kanamycin, growth on leucine drop-out media and for ADE 
selection as determined by red colony formation. Approximately 400 cells were seeded 
per plate. Fig. 6 shows an example o f KANMX resistant and sensitive strains and Fig. 7 
shows strains able to grow without the presence of leucine in the media.
Description Strain Phenotypes
Wild type 2096-1B Mata, Ieu2, trp1,ade1
msh2 RHB 2348-9b Mata, Ieu2, trp1,ADE1
msh3 RHB 2347-4b Mata, LEU2, trp1,ADE1
msh6 NHT 173 Mata, KANMX, Ieu2, trp1,ade1
mlh1 RBT 311 Mata, LEU2, trp1,ade1
mlh2 RBT 324 Mata, KANMX, Ieu2, TRP.ADE1
pms1 RBT 289 Mata, LEU2, TRP,ade1
rad52 RHB 2692-1 c Mata, LEU2, trp1,ADE1
rad52/msh2 RHB 2700-1 b Mata, LEU2, trp1,ADE1
rad52/mlh1 RHB 2698-5C Mata, LEU2, trp1,ADE1
rad52/mlh2 RHB 2699-4C Mata, LEU2, KANMX, trp1,ADE1
rad1 RBT 302 Mata, LEU2, trp1,ADE1
rad1/msh2 RHB 2694-9C Mata, LEU2, trp1,ADE1
rad1/mlh1 RHB 2693-8a Mata, LEU2, trp1,ADE1
rad1/mlh2 RHB 2695-2b Mata, LEU2, KANMX, TRP.ADE1
Table 1 Phenotypes of S. c e rev is ia e  MMR mutant strains
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v
msh6
Figure 6 KANMX  resistance - 
phenotype test
The strains with KANMX  resistance gene 
inserted grow on KAN  selective media. 
This confirms the presence of the 
KANMX  cassette plasmid used for MMR 
gene disruption in the appropriate strains 
(See Table 1 for phenotypes).
Figure 7 LEU2 gene insertion - 
phenotype test
The strains with the LEU2 gene inserted 
grow on Leu drop-out selection media. 
This confirms the presence of LEU2 
plasmids used for MMR gene disruption in 
the appropriate strains (See Table 1 for 
phenotypes).
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5.2. Clonogenic responses of MMR mutants to cisplatin
n
Each strain was seeded at 2x10 cells in 1ml of liquid YPD media and exposed to 0- 
lmM cisplatin (dissolved in lOpl of DMSO) as previously described (Megan et al, 
1996). Cells were initially exposed to cisplatin for 1 hour, washed and plated out on 
YPD agar at 400 cells per plate. No cytotoxic response was seen in wild type or mutant 
strains as measured by colony forming ability after 2-3 days incubation. Therefore, the 
concentration range was increased from 0 to 2mM cisplatin and time of exposure was 
increased to 24 hours in separate experiments. Under these conditions, a standard kill 
curve was achieved for wild type cells exposed for 24 hours and to the higher 
concentration o f cisplatin. This enabled a comparison o f cisplatin sensitivity o f the 
isogenic MMR mutants. Fig. 8 shows photographs o f plates with colonies formed from 
wild type and mlhl mutants in response to a 24 hour exposure o f 0, 0.5, 1, 1.5 and 2mM 
cisplatin. Fig. 9 shows the clonogenic responses averaged from at least four separate, 
repeated experiments using wild type, mlhl, msh2, msh3, msh6, mlhl, pm sl and mlh2 
strains.
Table 2 shows the inhibitory constant at 90% inhibition o f colony formation for each 
mutant tested. The L.D. 90 value for the wild type strain under these conditions was 
ImM, whereas the L.D. 90 values for msh2, msh3, msh6, mlhl and mlh2 were 
significantly different (P<0.05), as tested by the student’s unpaired, two-tailed t-test at 
1.7, 1.8, 1.7, 1.5 and 2mM respectively. The L.D. 90 value o f l.lm M  for pm sl was not 
significantly different from wild type (P>0.05). The surviving fractions (SF) at ImM 
cisplatin treatment for each strain were: wild type (0.14), mlhl (0.39), msh6 (0.55), 
msh2 (0.61),/m?7 (0.29), msh3 (0.69) and mlh2 (0.82) (See Appendix).
These results demonstrate that all the MMR mutants tested, but not pm sl , were 1 .5 -2  
fold more resistant to ImM cisplatin than wild type cells at the L.D. 90 value. These 
folds o f resistance are slightly lower than those seen in mammalian cell lines deficient
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MMR which have typically shown 2-5 folds of resistance (Anthoney et al, 1996; Brown 
et al, 1997).
Figure 8 Photographs of colonies formed after cisplatin exposure.
A typical example of colonies grown on YPD agar. Approximately 400 cells were 
inoculated onto YPD agar plates after exposure to 0-2mM cisplatin for 24 hours in 
liquid culture. (A) shows wild type and (B) shows m lhl colonies grown after 2-3 days 
incubation at 30°C. mlhl colonies are seen to grow after 1.5 and 2mM whereas wild 
type cells do not form colonies at these concentrations.
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Figure 9 Clonogenic responses of wild type and MMR mutants to 24hr exposure of 
cisplatin.
All MMR mutants, but not pm sl , show a 2.6 - 5.6-fold significant increase (P<0.05, as 
measured by student’s unpaired two-tailed t-test) in resistance to ImM cisplatin 
compared to wild type. At L.D. 90 values, resistance values range from 1.4 - 2-fold. 
(See appendix for statistical analysis). Mutants listed in descending order o f resistance 
are mlh2, msh2, msh3, msh6 and mlhl. Regression lines were drawn to 2 orders and 
error bars represent 99% confidence limits.
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Description Strain L.D. 90
(cisplatin, mM)
Resistance Factor.
Wild type 2096-1B 1 1
msh2 RHB 2348-9b 1.7 1.7*
msh3 RHB 2347-4b 1.8 1.7*
msh6 NHT 173 1.7 1.6*
mlhl RBT 311 1.5 1.4*
mlh2 RBT 324 2.0 2*
pm sl RBT 289 1.1 1.1
Table 2 Lethal Doses at 90% cell death and resistance factors of MMR mutants.
Clonogenic survival showed that all MMR mutant strains tested for cisplatin toxicity, 
but not p m sl , showed significant resistance values (P<0.05, student’s unpaired two- 
tailed t-test). Asterix indicates significant difference determined by student’s unpaired 
two-tailed t-test.
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5.3. Mutator phenotypes
5.3.1. Forward mutation frequency
Loss o f MMR function is associated with a mutator phenotype. Therefore, to assess the 
MMR proficiency of these strains, forward mutation frequency was calculated. This is 
carried out by measuring the frequency o f colonies developing mutations in the gene 
controlling sensitivity to L-canavanine. 0.006% L-canavanine in YPD agar was made 
up and plates were inoculated with a concentration of cells that produced a countable 
number o f colonies after incubation. This was calibrated at 106 cells per plate. Forward 
mutation frequency was calculated as shown in Methods. Table 3 shows the mutation 
frequencies obtained from wild type, mlhl, msh2, pm sl and mlh2 mutants. The mutant 
frequencies tested place the mutator phenotype of each strain in descending order of 
mutant frequency: pm sl > mlhl > msh2 > mlh2. The mlh2 strain did not display an 
elevated mutation frequency compared to wild type.
5.3.2. Mutation rate
A more accurate determination o f mutagenicity is achieved by carrying out fluctuation 
analysis to measure mutation rate. Ten single colonies or more are isolated and cells 
from these colonies were assessed for L-canavanine resistance. Mutation rate was 
calculated using the formula shown in Methods and carried out by Dr. Gill Hirst.
Table 3 shows the comparison between frequencies and rates calculated. Again mlh2 
was shown not to have a significant difference from wild type and pm sl showed an high 
mutation rate, with an equivalent difference observed in mutation frequency.
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Table 3 Mutation frequencies and rates of MMR mutant strains
Strain Forward mutation 
frequency
Mutation rate
wild type 1.6 x lcr6 3.7 x 10’8
msh2 2.5 x 10'5 nd
mlhl 4.7 x 10'5 nd
pm sl 8 .7 x 1  O'5 8.7 x 10^
mlh2 9.6 x lO'7 6.7 x 10‘8
These results show that pm sl mutants have the highest mutation frequency and rate but 
do not confer a significant increase in resistance to cisplatin. Whereas mlh2 mutants do 
not show a significantly elevated (P>0.05) mutation frequency or rate but do confer the 
highest significant increase in resistance to cisplatin compared to the other mutants and 
wild type strain. This provides evidence to suggest that separate components o f MMR 
have separate roles in conferring drug resistance and elevated mutation 
frequencies/rates. Specific components o f MMR but not MMR activity per se are 
required for sensitivity to cisplatin.
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5.4. ScMLHl gene re-introduction
It has previously been shown that the majority o f human tumour cell lines that were 
selected for resistance to cisplatin did not express hMLHl as measured by mRNA 
levels. PMS1 and MSH2 mRNA levels in cells derived from the human ovarian cell 
line A2780 could be detected. Consequently, these cell lines showed cross resistance to 
MNU and doxorubicin (Brown et al, 1997). Of the MMR-specific genes identified, the 
MutL complex (Mlhl/Pms2 heterodimer in humans and the Mlhl /Pmsl heterodimer in 
yeast) is the most down stream known to date.
For these reasons, it was considered important to examine if there was something 
particular about ScMLHl that was important for sensitising cells to cisplatin. 
Consequently, ScMLHl was cloned and re-introduced back into the mlhl mutant. This 
could then be used as a complementary system to ascertain if  restoring wild type 
ScMLHl function could restore cisplatin sensitivity in yeast. This was carried out to 
exclude the possibility that the mutator hypothesis has a mechanistic role in the 
development of cisplatin resistance.
Furthermore, re-introducing the hMLHl gene alone by plasmid transfection into human 
cell lines has proven difficult in the past. Instead, previous studies using human cell 
lines have carried out chromosome 3 transfer, the chromosome containing hMLHl, to 
restore wild type protein in MLH1-defective cell lines. Therefore, transfecting the 
scMLHl gene into yeast using a yeast expression vector was performed in order to test 
for cisplatin toxicity without introducing any other possibly confounding chromosomal 
sequences.
Fig. 10 shows a screen for DH5-a E. coli transformants selected for growth on 
Ampicillin plates with the yeast expression vectors containing the Amp resistance gene. 
Bands were generated using the ScMLHl primers shown in Methods and annealing 
positions shown in Appendix. PCR fragments generated show the putative ScMLHl
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size (2.2kb) as measured by the lOOkb ladder. A larger ladder would have been more 
appropriate for size determination, however due to availability and convenience, the 
lOOkb ladder was used. Yeast expression vectors used were the low copy plasmid 
pYX112 and the high copy plasmid pYX212. Only from the high copy vectors were 
correctly-sized fragments generated. The reason for the lack of detection in the 
pYXl 12 vector has been identified. An error of design of pYXl 12 primers was made in 
that the 5’ forward primer and 3’ reverse primer were reversed. This therefore 
generated PCR products across the entire sequence o f the vector and not across the 
cloning site. Indeed it can be seen that low yields o f very large fragments exist towards 
the top of the gel. Therefore the selection for colonies containing the correct clones 
could not be made for this vector.
pYX212-transformed colonies containing the appropriately sized fragments were then 
grown up to isolate vector-plus-inserts ready for sequencing and transforming into 
yeast. Wild type and mlhl mutant strains were transformed using the Li-acetate method 
(see Section 7.1). Cells were incubated with vector + insert and vector alone using 
salmon sperm DNA as a carrier. Cells were then grown on SC-leucine and SC- 
tryptophan drop-out media depending on vector used for transformation. The few
n
colonies that grew (plating efficiency: <10 from a 1.5ml inoculation o f 10 cells) were 
then isolated.
Fig. 11 shows the result of a PCR reaction using ScMLHl primers and pYX112 / 
pYX212 vector primers shown in Methods to detect the correctly sized inserts within 
wild type and mlhl mutant strains of S. cerevisiae. Yeast cells were placed directly in 
the PCR reaction so that high temperature lysis o f cells allowed for direct template 
DNA for the reaction. Fig. 11 shows the presence o f ScMLHl-sized fragments in the 
mlhl mutant. Both vector and ScMLHl primers detected the 2.2kb-sized insert, the 
vector primers generating a slightly larger band due to the extra sequences flanking the 
insert region.
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Figure 10 A screen of 13 E.coli colonies for each plasmid transfection.
Correctly sized (2.2kb) ScMLHl PCR fragments using vector primers are indicated. 
Vector pYX112 does not show clear bands at the putative size for the MLHl gene. 
However, vector pYX212 primers yield two potential colonies that contain the correctly- 
sized fragments. Colony from pYX212 Lane 10 was selected due to size and yield.
I
2.2kb
1 OOkb ladder
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Figure 11 Agar gel electrophoresis for the detection of scM LHl in yeast strains.
The ScMLHl primers {M LHlpr) and vector primers (pYX112pr or pYX212pr) were 
used to detect the presence of ScMLHl in the yeast transformants. Cells were placed 
directly into the PCR reaction. Lanes 4 and 6 show the presence of correctly sized 
fragment using both M LH lpr and pYX212pr vectors (note the pYX212pr yields slightly 
larger fragment due to the inclusion of vector sequence).
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5.5. ScMLHl S equencing
In order to confirm the presence o f the correct sequence o f the insert, sequencing o f the 
ScMLHl insert in pYX212 was carried out on two separate occasions using the same 
cloned sequence as template. Forward and reverse primers were designed to generate 
PCR sequences that stretched across the entire scMLHl sequence. In the appendix, 
sequences generated by each primer are shown. Both FASTA and BESTFIT analysis 
using GCG software were carried out to align the PCR sequences generated with the 
known scMLHl gene sequence in the database (Saccharomyces Genome Database - 
Accession number: U07187).
The results show that 5 point mutations were detected.
Cys208Trp
Ile263Val
Ala712Thr
Ser717Asp
Leu770Pro
(Numbers indicate codon)
Sequencing was repeated using the same template sample. Therefore it cannot be ruled 
out that the template itself was correct in sequence but o f a quality insufficient for Taq 
terminator sequencing. The same primers were also used which may have influenced 
the fidelity of the PCR products especially at the ends o f long sequences (see 
Appendix).
The ScMlhl protein has 781 amino acids with the most highly conserved sequence 
residing in the amino-terminus. Here, the GFRGEAL MutL box is located, a region of  
high sequence homology between the MutL proteins in all eukaryotes studied. The 
majority of point mutations detected in this sequence lie nearer the carboxy-terminus
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where the greatest degree o f sequence variation exists (Peltomaki et al, 1997; 
Papadopoulos et al, 1994; Shimodaira et al, 1998). Most mutations occurring in human 
MLH1 in HNPCC patients are frameshift non-sense mutations. (Peltomaki et al, 1997; 
Papadopoulos et al, 1994).
5.6. Clonogenic response of ScMLHl -re-introduced transformant to
cisplatin
Fig. 12 shows the response obtained by treating isolated clones o f mlhl mutants 
transformed with pYX212 vector alone (legend: mlhl vec), pYX112 (unknown insert, 
legend: mlhl 112), and pYX212 containing the sequenced ScMLHl insert (legend: 
mlhl 212). The figure shows the hypersensitive response obtained by the scMLHl 
transformant compared to wild type and mlhl-vector alone controls. The L.D. 90 value 
for this transformant was 0.5mM, as shown in Table 2.
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Figure 12 Survival curves for S c M L H l  re-introduced strains.
The transformed ScMLHl mutant with the ScMLHl -inserted expression vector 
(pYX212) restores sensitivity to levels higher than wild type.
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5.7. Clonogenic response of MMR mutants in a Rad52-deficient 
background
The involvement o f MMR in recombinational repair is well documented and discussed 
in Section 1.1.3. However, previous studies have not addressed the issue o f the 
involvement o f MMR in recombinational repair with respect to DNA damage 
responses. Homologous recombination is used to repair double strand breaks in DNA 
by using homologous chromosomes as templates for repair. Mutations o f the genes in 
the Rad52-epistasis group (RAD50-RAD57) confer sensitivity to X-rays and to 
chemicals that cause strand breaks in DNA (Game et al, 1974; Friedberg 1988). Rad52 
is an essential component o f this repair pathway (Shinohara and Ogawa, 1998). 
Previous studies have indicated that Rad52-dependent recombinational repair is 
modulated by MMR (Paques and Haber, 1997; Sugawara et al, 1997). By studying any 
difference that might exist in response to cisplatin-induced DNA damage between S. 
cerevisiae MMR mutants and MMR mutants in a recombinational repair-deficient 
background, any dependence on the presence of Rad52 could be assessed.
Isogenic rad52 mutants were generated by LEU2 gene insertion and rad52fMMR 
double mutants were generated by isolating segregants o f crosses between the rad52 
with each of the MMR mutants: m lhl, msh2 and mlh2.
Fig. 13 shows the clonogenic responses o f the rad52 mutant compared to wild type. 
The hypersensitivity observed (L.D. 90 value o f 0.7mM) is significant (P<0.05) as 
determined by the student’s unpaired, two-tailed t-test. Fig. 13 also shows the relative 
sensitivities of MMRlrad52 double mutants. These are all as sensitive as the single 
rad52 mutant (for L.D. 90 values and resistance factor values see Table 3).
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5.8. Clonogenic response of MMR mutants in a Rad 1 -deficient 
background
The involvement of MMR in NER is discussed in Section 1.1.4. It has been shown in S. 
cerevisiae that repair o f 26-base loops involves both the NER protein Radi (human 
ERCC4) and Msh2 (Kirkpatrick and Petes, 1997). A mutation of mei-9, the Drosophila 
melanogaster homologue of scRadl (Sekelsky et al, 1995) increases PMS, and thus 
may be defective in meiotic mismatch repair (Carpenter 1982). Cisplatin-induced DNA 
interstrand crosslinks are known to be repaired by the nucleotide excision repair (NER) 
system. It was o f interest, therefore, to investigate the effects of disrupting individual 
components o f MMR in an NER-compromised background. Used as a control, the 
availability o f a radl mutant was taken advantage o f and used to assess the effect of 
knocking out the genes from a separate repair system (MMR). However, Radl, as 
discussed in Section 1.1.3, has also been shown to be involved in recombinational 
repair. Therefore the present data suggest an involvement of Radl in MMR and 
recombinational repair. To elucidate the role this protein has in MMR-dependent 
cisplatin cytotoxicity, isogenic radl mutants were generated, crossed with the MMR 
mutants and tested for clonogenic sensitivity to cisplatin.
Fig. 14 shows the response o f the radl strain to cisplatin treatment. As shown in Table 
4, the hypersensitive radl strain displayed an L.D. 90 value o f 0.6mM, a value 
significantly different from wild type (P<0.05). The kill curves obtained for the 
MMR/radl double mutants were indistinguishable from the single radl strain and 
displayed similar responses to those seen in the rad52 background. These results 
suggest that MMR-dependent cytotoxicity is also dependent on the presence o f Radl 
protein.
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Figure 13 Clonogenic responses of MMR mutants in a ra d 5 2  background.
M lhl, msh2 and mlh2 mutants show the same resistant phenotype as rad52 single 
mutant (not statistically different as determined by student’s unpaired two-tailed t-test), 
therefore losing the single MMR mutant resistant phenotype. Regression lines were 
drawn to 2 orders and error bars represent 99% confidence limits.
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Figure 14 Clonogenic response of MMR mutants in a radl background.
m lhl, msh2 and mlh2 mutants show the same resistant phenotype as radl single mutant 
(not statistically different as determined by student’s unpaired two-tailed t-test), 
therefore losing the resistant phenotype when RADI was present. Regression lines were 
drawn to 2 orders and error bars represent 99% confidence limits.
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Description Strain L.D. 90 
(cisplatin, mM)
Resistance Factor. Mutant Frequency
Wild type 2096-1B 1 1 1.6x1 O’6
msh2 RHB 2348-9b 1.7 1.7* 2.5x10*
msh3 RHB 2347-4b 1.8 1.7* n.d.
msh6 NHT 173 1.7 1.6* n.d.
mlhl RBT311 1.5 1.4* 4.7x10*
mlh2 RBT 324 2.0 2* 9.6x10’'
pms1 RBT 289 1.1 1.1 8.7x10*
m/M+vector RBT311:v 1.6 1.6* n.d.
mlh1+pMLH1 RBT311:MLH1 0.5 0.5 n.d.
rad52 RHB 2692-1 c 0.7 0.7* n.d.
rad52/msh2 RHB 2700-1 b 0.7 0.7 n.d.
rad52/mlh1 RHB 2698-5C 0.5 0.5 n.d.
rad52/mlh2 RHB 2699-4C 0.6 0.6 n.d.
radl RBT 302 0.6 0.6* n.d.
rad1/msh2 RHB 2694-9C 0.6 0.6 n.d.
rad1/mlh1 RHB 2693-8a 0.7 0.7 n.d.
rad1/mlh2 RHB 2695-2b 0.6 0.6 n.d.
Table 4 Sensitivities to cisplatin and mutator phenotypes of MMR mutants.
The table shows lethal doses taken at 90% reduction in colony forming ability (L.D. 90) 
compared to untreated controls. Resistance factors (asterixed) indicate significant 
increase (P<0.01) as determined by student’s unpaired, two-tailed t-test. Forward 
mutation frequency measured by number of resistant colonies arising on 0.006% L- 
Canavanine agar plates per 106 colonies grown without L-canavanine on agar.
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5.9. Effect of growth inhibition on sensitivity of MMR mutants to 
cisplatin
There are a number of studies which suggest that DNA replication is required for 
MMR-dependent sensitivity to cisplatin. It has been shown that the human MutS 
complex binds to the DNA 1,2 intrastrand crosslink with much greater affinity if  
opposite a mismatched base, suggesting that base misincorporation and DNA synthesis 
past the lesion is required for recognition (Duckett et al, 1996; Brown et al, 1997). 
Also, it has been shown that MMR deficient ovarian carcinoma (A2780-cp70) cells 
which show resistance to cisplatin compared to proficient (A2780) cells have a 
significantly reduced MMR-dependent resistance phenotype when treated with 
aphidicolin - a DNA polymerase inhibitor (Moreland et al, 1999).
Therefore to address whether or not DNA replication is required in yeast for MMR- 
dependent cisplatin cytotoxicity, growth inhibitory conditions were put on the strains. 
Strains were grown to confluence and reached a stationary phase at a concentration of < 
1.5 x 108 cells/ml (see Fig. 15).
After this was determined, wild type and msh2 strains (chosen because they showed 
greater resistance to cisplatin than mlhl cells) were grown logarithmically and seeded at 
concentrations that reached confluence. Cells were then exposed to cisplatin. Fig. 16 
and 17 show the cytotoxic responses o f each strain. Fig. 16 shows that for wild type 
cells, the effect of growth inhibition significantly increased the resistance to cisplatin at 
2mM. However, Fig. 17 shows that growth inhibition had no significant effect on the 
sensitivity of msh2 mutants to cisplatin.
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Figure 15 Growth curves for wild type and m lhl mutant strains.
The curves show that both strains of 1ml o f 2 x 107 cells grown in closed-capped
Q
universals in shaking incubator reached a plateau in growth concentration of 1.4 x 10 
/ml as measured by haemocytometer after 12 hours incubation.
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Figure 16 Clonogenic response for growth suppressed and exponentially growing 
wild type cells exposed to cisplatin.
Cells grown to confluence (>1.6x10 /ml) show significantly increased resistance 
(P<0.05) as determined by student’s unpaired two-tailed t-test, to 2mM cisplatin 
compared to logarithmically growing cells (seeded at 2x l07/ml). Original log 
curves are included from the previous toxicity data and show that the results are 
repeatable in this assay. Error bars represent standard deviation from the mean.
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Figure 17 Clonogenic response for growth suppressed and exponentially growing 
msh2 mutants exposed to cisplatin
Cells grown to confluence do not show a significant difference (as determined by 
student’s unpaired two-tailed t-test), in sensitivity to 2mM cisplatin (P>0.05) compared 
to logarithmically growing cells. Error bars represent standard deviation from the mean.
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5.10. Cell cycle analysis
Cell cycle analysis was carried out for the following reasons: i) The DNA replication 
inhibition experiments here show that MMR-dependent cytotoxicity is, at least in part, 
dependent on DNA replication and thus progression through S-phase of the cell cycle;
ii) previous studies have shown that MLH1 transfection induced growth suppression in 
an MLH1-defective cell line (Shin et al, 1998) and MMR-proficient cells were able to 
enter G2 arrest while MMR-defective cells continued cycling in response to certain 
types o f DNA damage (Koi et al, 1994; Hawn et al, 1995; Carethers et al, 1996), and
iii) the cell cycle o f S. cerevisiae MMR mutants has not previously been analysed in 
response to cisplatin-induced DNA damage.
5.10.1. FACS analysis
After cells were treated with cisplatin, stained with PI and analysed by FACS, G2 peaks 
were observed as shown in Fig. 18. To span the 24 hour period o f drug treatment cells 
were synchronised to allow accurate peak histogram study of cell cycle responses. 
Mating Type a (Mata) cells were studied due to the availability of the cell cycle arrest 
pheromone, a-Factor. Mating Type a  (Mata) cells, which were the strains used in the 
cytotoxicity assays, could not be used due to the commercial unavailability o f the highly 
lipophilic A-Factor. Cells were treated with 15pg/ml a-Factor (Peira et al, 1998) and 
samples were taken every hour during synchronisation. Cells were sonicated, 
enzymatically treated to partially digest the cell membrane, fixed in 70% ethanol, 
stained with propidium iodide and analysed by FACS. Fig. 18 shows that in row 1 cells 
show G1 and G2 peaks for at least 6 hours of pheromone treatment. After 24 hours, 
cells became asynchronous. Yeast begin to ignore a-Factor after approximately 4 hours 
due to down regulation o f a-Factor receptor (E. Scheibel, personal communication). 
Therefore cell synchronisation was carried out for 2 hours and FACS analysis was
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carried out after cells started cycling again. Row 2 shows the G1 and G2 peaks during 
the initial pheromone treatment and row 3 shows the response of cells after being 
washed from pheromone. Surprisingly a large G2 peak is seen initially, followed by 
cells becoming asynchronous after approximately 3 hours. Cycling yeast cells become 
asynchronous after one cell cycle because mother and daughter cells are of different 
sizes (Pringle et al, 1997). This has made the synchronisation of yeast difficult for 
longer periods of time and FACS analysis difficult to interpret.
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Figure 18 FACS analysis of wild type cells in response to a-Factor.
To synchronise cells for FACS analysis, cells were exposed to 15pg/ml a-Factor and 
analysed. Gi and G2 peaks are evident during the first 6hrs exposure. After 24hrs, cells 
come out of arrest and become asynchronous. When cells were exposed for 2hrs and 
washed off the pheromone cells displayed a large G2 peak followed by cells becoming 
out of phase after three hours. The reason for this G2 peak is unclear. It may be 
artefactual as this was not repeated.
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5.10.2. FACS analysis after cisplatin treatment
Wild type, mlhl and msh2 cells were then treated with ImM cisplatin to investigate cell 
cycle responses after synchronisation. Fig. 19 shows that exposure to ImM cisplatin 
after 4 hours with 4 hours treatment with pheromone resulted in wild type cells entering 
predominantly a Gi arrest. Pheromone alone caused a Gj and G2 peak. Again after 24 
hours, cells became asynchronous and difficult to interpret. Cisplatin however did show 
signs of sustaining a G] arrest in cells that otherwise became asynchronous to a 24 hour 
exposure to a-Factor. This cell cycle response was also seen in the MMR mutants 
although no G2 peak was seen in response to a-Factor alone. This may indicate a defect 
in MMR-defective yeast cells in inducing G2 arrest. The figure shows the difficulty in 
distinguishing between Gj, S, G2 and M phases. Background noise, which was reduced 
by slowing the rate o f flow cytometry, remains high, making analysis difficult to 
interpret.
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Figure 19 FACS analysis of wild type (WT), m lhl and msh2 mutants exposed to a- 
Factor and cisplatin.
Graphs show Gi peak and G2 peaks in wild type cells in response to a-Factor and 
predominantly a Gi peak in response to a-Factor with ImM cisplatin. MMR mutant 
strains displayed this response also but possibly showed a defect in G2 arrest in response 
to pheromone alone.
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5.11. Fluorescent Microscopy
Due to the problems encountered by FACS analysis of yeast, a more rapid method for 
measuring cell cycle arrest in budding yeast which does not require the synchronisation 
of cells for analysis was therefore adopted. Budding yeast arrest in G2-M by forming 
enlarged, equally sized buds with a 2N nucleus at the bridge between the unseparated 
buds (resembling a dumb-bell structure) (Lowndes N, personal communication; Pringle 
etal, 1997).
At the time of carrying out these experiments, it was considered important that cells 
should not be exposed to cisplatin for such a long period as cell cycle responses may be 
affected by prolonged exposure. Cisplatin exposure was therefore reduced to a 1 hour 
treatment but at a higher concentration o f 4mM instead of ImM. The PI stained 
samples were scored under a fluorescent microscope and Fig. 20 shows an example of 
the micrographs used to score for G2 buds. Wild type and ScMLHl transformant cells 
did not visually start exiting from G2 arrest until 12-16 hours after the initial exposure to 
cisplatin, therefore, samples were taken over a 24 hour period until background levels 
were reached (See Figs. 20). Fig. 21 shows a magnified example o f a G2 budded 
structure and also an example of cell exposed to cisplatin indicating signs o f nuclear 
fragmentation typical o f mammalian programmed cell death. Fig. 22 shows the G2 
arrest response pattern o f wild type, m lhl, msh2 and the mlhl transformants after a 1 
hour exposure to 4mM cisplatin.
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Figure 20 Micrographs of WT and m lhl responses to a 1 hour exposure of 4mM 
cisplatin.
Random field-of-view pictures were taken o f cells fixed, RNAse digested and 
propidium iodide stained at various time points after initial exposure to cisplatin. 
Pictures show on left wild type (WT) cells prolonged in G2-associated enlarged, equal­
sized budded structures compared to mlhl mutants on the right. White arrows indicate 
G2-buds, blue arrows indicate cells progressed through mitosis with separated nuclei.
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Figure 21 Magnified pictures of Pi-stained S. cerevisiae cells.
PI stain shows (A) a wild type cell exposed to 12 hours with cisplatin showing equal­
sized buds typical o f cells in G2 and (B) a wild type cell exposed to cisplatin for 24 
hours showing signs o f DNA fragmentation.
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Figure 22 Percentage of cells of each strain in G2-M arrest in response to cisplatin.
Cells in logarithmic growth phase were exposed to 4mM cisplatin in liquid YPD media 
for 1 hour. After exposure, cells were resuspended in YPD, placed in shaking incubator 
and taken off every 2 hours for sampling. G2 buds were scored out of 200 cells counted 
under a fluorescent microscope. Experiments were repeated three times, mlhl and 
msh2 mutants show an early release from G2 arrest after 6 hours compared to a 
sustained 10 hour peak for WT. Re-introducing ScMLHl back into the mlhl mutant 
restores the prolongation o f G2-M arrest (error bars represent standard error of the 
mean).
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5.12. Clonogenic response to 1 hour exposure of 4mM cisplatin
In order to ascertain the cytotoxicity o f this cisplatin exposure, clonogenic assays were 
performed on samples before fixation and staining for cell cycle analysis. 200 cells 
were seeded out onto YPD agar plates and incubated at 30°C for 2-3 days. Colonies 
were counted and surviving fractions calculated from no treatment controls (Table 5).
Number of colonies Wild type mlhl msh2
10pl DMSO control 1. 277 152 180
2. 210 194 116
3. 220 143 195
mean 233.91 161.56 159.68
S.F 1 1 1
4mM cisplatin dissolved in 10pl DMSO, 1 hr 1. 270 168 145
2. 128 125 158
3. 219 159 121
mean 196.34 149.46 140.48
S.F 0.84 0.93 0.88
students’ t test compared to no treatment, t= 0.57 0.58 0.47
Table 5 Clonogenic response to a 1 hour exposure of 4mM cisplatin
Figures show that a 1 hour exposure to 4mM cisplatin was not significantly cytotoxic to 
any o f the strains tested as measured by colony forming ability on YPD agar.
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5.13. Cell cycle responses to ionising radiation
The literature concerning cell cycle responses made by tumour cell lines defective in 
MMR to ionising radiation (IR) is inconsistent. Some studies have observed an 
attenuated G2 arrest and others have observed no difference at all (See Section 1.2.4). 
Therefore, isogenic yeast strains defective in specific components of MMR was carried 
out to investigate the responses made in S. cerevisiae. The experiment was also carried 
out as a control, since it has not been shown that MMR proteins bind to DNA damaged 
by ionising radiation.
Exponentially growing yeast were exposed in liquid culture in universal tubes to lOOgy 
y-irradiation (Weinert and Hartwell, 1988) to induce cell cycle arrest. Cells were then 
sampled every two hours as before, fixed, PI stained and scored for G2 buds under 
fluorescent microscopy. Fig. 23 shows the responses made by wild type, m lhl, msh2, 
rad I and rad52 strains.
radl and rad52 mutants show a significantly elevated G2-M arrest response (P<0.05) 
compared to wild type at 0 and 2 hours after IR exposure. The mlhl and msh2 strains 
show similar responses to that of wild type. However, a significant difference (P<0.05) 
is observed between mlhl and wild type at 2 and 4 hours after IR exposure and between 
msh2 and wild type at 2 hours after IR exposure. No difference was seen after this 
initial response.
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Figure 23 Percentage of cells of each S. c e rev is ia e  strain in G2-M arrest in 
response to IR.
Exponentially growing strains were exposed to lOOgy y-IR and samples were taken at 2 
hourly intervals after exposure. G2-M - associated equally sized buds were scored by 
propidium iodide-staining followed by fluorescent microscopy. Error bars indicate 
standard deviation from the mean.
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5.14. Clonogenic response to ionising radiation
The clonogenic responses o f these strains were also tested to ascertain if  lOOgy IR was 
cytotoxic to the cells. This dose was chosen to induce G2 arrest and not to kill the cells 
outright (Weinert and Hartwell, 1988). If the dose used was cytotoxic to the cells, then 
cell cycle analysis would be confounded by the presence o f severe DNA damage and 
the activation o f cell death signals.
Table 6 shows the surviving fraction obtained from cells taken after IR exposure before 
the fixation and staining procedures for cell cycle analysis. 200 hundred cells were 
plated out on YPD agar and colonies counted after 2-3 days incubation. The table 
shows that colony forming ability was reduced, especially for the radl mutants. rad52 
mutants showed no difference in cytotoxicity compared to wild type. This is surprising 
due to the fact that Rad52 is involved in double strand break repair by recombination. 
rad mutants should be IR-sensitive. This is seen in radl mutants but not rad52. The 
reason for this is unclear. Statistical analysis was not possible due to the single 
experiment carried out for the no treatment control.
WT mlhl msh2 radl rad52
ogy 238 113 290 309 175
100gy 69 44 99 56 92
64 49 118 76 44
102 185 45 55
S.F 0.33 0.41 0.46 0.19 0.36
Table 6 Number of colonies formed after ionising radiation exposure
The surviving fraction (S.F) values show that colony forming ability was reduced in 
response y-ray IR exposure. The T-test could not be calculated due to the single assay 
carried for the no treatment control.
These results suggest that the dose of IR used was partially cytotoxic to all the strains 
exposed. Caution must therefore be taken in the analysis of cell cycle phenotypes when 
considering the amount of DNA damage induced. The relative number o f replication
Chapter 5-128
forks encountering IR-induced DNA lesions must be taken into account when assessing 
the differences between strains in ability to undergo cell cycle arrest. However, it is 
difficult not to induce cell death in a proportion of cells exposed to cell cycle arresting 
doses o f IR and the majority of stained cells scored for G2 arrest in the cell cycle 
analysis would probably have been viable considering that cells subjected to lethal 
doses o f IR would not cycle at all.
DISCUSSION
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6. DISCUSSION
6.1. Cytotoxic response of MMR mutants to cisplatin
Strains o f S. cerevisiae with specific MMR gene disruptions were used to test the 
relative clonogenic responses to cisplatin exposure compared to wild type. Each strain, 
exposed for 24 hours to 0-2mM cisplatin in liquid culture, was assessed for colony 
forming ability on agar. Fig. 9 shows the relative sensitivities o f wild type, msh2, msh3, 
msh6, mlhl, pm sl and mlh3 mutants. The graph shows that all of the mutants, except 
for pm sl, displayed a 1.4- to 2-fold significant (P < 0.05) increase in resistance to lmM  
cisplatin. Table 2 shows the L.D. 90 (mM) and the resistance factor (RF) for each 
strain. The RF’s for each strain are in the descending order o f resistance: mlh2 > msh2 
= msh3 > msh6 > m lhl>pm sl.
Since not all o f the genes knocked out for MMR produced the resistance phenotype (i.e. 
pm sl), these results suggest that MMR activity per se, or at least MMR involving 
PMS1, need not be required for cisplatin-induced cytotoxicity. In support of this, it has 
been noted in patients with HNPCC a surprisingly low frequency o f germ-line PMS2 
(PMS1 in yeast) mutations exists compared to MLH1 mutations especially given that 
mutations in both of these genes cause the same type o f MMR defect (Boyer et al,
1995). Additionally, Mlhl in S. cerevisiae has been shown to be unique among MMR 
proteins in its involvement in recombinational processes (Hunter and Borts, 1997). In 
this context, it has been suggested that eukaryotic Mlhl and Pmsl/2 do not play
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equivalent roles in the cell even though they are subunits o f the same complex, or that 
like Msh3 and Msh6, there is a function that is redundant with ScPmsl/hPms2 
(Kolodner, 1996).
Disrupting ScMLH2 lead to the strongest resistant phenotype of all the MMR mutants. 
No known function for scMLH2 has yet been ascribed although it was suggested that 
the gene might be involved in homeologous recombination (Prolla et al, 1994a). 
Interestingly, scMLH2 is more closely related in sequence to the human PMS genes than 
to hMLHl (Kolodner, 1996) which is surprising considering the differences observed 
here in cytotoxic responses o f the two mutants. However, to date no human MLH2 gene 
has been identified and the percentage sequence similarity observed between scMLH2 
and hPMS2 was only 39.87% (Mcllwrath et al, 1998).
These strains were also exposed to carboplatin, doxorubicin and UV irradiation (Durant 
et al, 1999). Resistance to carboplatin was also seen and each strain displayed similar 
orders o f resistance (mlh2 > mlhl > msh2 = msh6 > msh2 > pm sl). This is consistent 
with the fact that Carboplatin is a structurally related compound to cisplatin known to 
induce the same spectrum of DNA adducts. Even higher folds o f resistance to 
doxorubicin was observed, but no difference was seen between wild type and mutants 
exposed to UV irradiation. Doxorubicin induces a range o f adducts in DNA including 
double strand breaks and redox cycling-induced DNA crosslinks (Sladanowski and 
Konopa, 1994). Therefore it may be the case that more than one doxorubicin-induced 
substrate is recognised by MMR, increasing the chance o f a lethal signal being 
generated.
Mismatched bases damaged by UV irradiation (inducing cyclobutane pyrimidine 
dimers) have also been reported to be substrates for bacterial MutS (Feng et al, 1991; 
Wang et al, 1997) and human MutSa (Wang et al, 1999). However, the major 
cytotoxic lesion induced by UV is removed efficiently by NER and is therefore not 
expected to persist (Sweder et al, 1996).
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The cytotoxic responses to these DNA damaging agents and the low level of resistance 
obtained are in concordance with what is seen in cisplatin-resistant tumour cell lines 
(Fink et al, 1996), lending credence to the extrapolation of the yeast model to human 
cells. The low level o f resistance (< 2-fold) observed in vitro is regarded as clinically 
relevant to the acquisition or enrichment of chemotherapeutically resistant tumour cells 
during treatment and is therefore sufficient to account for treatment failure (Andrews et 
al, 1990).
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6.2. ScMLHl gene re-introduction
Previously, it has proven difficult to re-introduce hMLHl into M LHl-deficient tumour 
cell lines. Instead, chromosome 3 transfer which carries the MLH1 gene has been 
carried out (Koi et al, 1994; Aebi et al, 1996; de la Alas, 1997). The obvious 
disadvantage of this is that many other genes are re-introduced which might confound 
the phenotypic effect under study. To test if  ScMLHl had a direct role in conferring 
sensitivity to cisplatin, ScMLHl alone was re-introduced back into the mlhl mutant 
using a yeast expression vector. The cisplatin toxicity assay was then carried out on the 
yeast transformants with the wild type ScMLHl gene detected and sequenced. As there 
is no commercially available antibody for scMlhl protein, PCR and sequencing were 
the principle methods used for the detection o f the cloned ScMLHl gene in yeast.
6.2.1. Detection of ScMLHl in pYX vectors
Fig. 10 shows the absence of an ScMLHl-sized band in E. coli colonies transformed 
with the cloned pYX112 (low copy yeast expression vector). However, a correctly 
sized band is shown in colonies transformed with the cloned pYX212 (high copy yeast 
expression vector). During the preparation o f this thesis, the reason for the lack of 
detection in the pYXl 12 vector was identified. During the design o f the vector primers 
that flank the cloning sites of the two vectors, an error of design of pYX112 primers 
was made in that the 5’ forward primer and 3’ reverse primer were reversed. This 
therefore generated PCR products across the entire sequence of the vector and not 
across the cloning site. Therefore the selection for colonies containing the correct 
clones could not be made for this vector.
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6.2.2. ScMLHl cloned into yeast
Fig. 11 shows the PCR products produced using ScMLHl primers and vector primers 
from individual yeast colonies isolated on selective media. This confirms the re- 
introduction of an ScMLHl-sized product with the pYX212 transformed yeast clone 
isolated. The slightly larger fragment seen using the vector primers is consistent with 
the extra vector sequences flanking the insert region.
6.2.3. ScMLHl sequencing
Following two separate sequencing tests (using the same forward and reverse primers in 
each) on the same ScMLHl insert cloned into yeast, the same five point mutations were 
detected (See Appendix). The following lists the missense mutations detected.
Cys208Trp
Ile263Val
Ala712Thr
Ser717Asp
Leu770Pro
scMlhl: 781 amino acids (see Appendix)
Note that none of these are nonsense frameshift mutations. According to the ICG- 
HNPCC database, 90% of hMSH2 mutations and 69% of hMLHl mutations are 
nonsense, frameshift and splice site mutations (Peltomaki et al, 1997; Papadopoulos et 
al, 1994; Shimodaira et al, 1998), indicating that pathological mutations, for the 
majority, represent gene disruptions that completely knock out their function. 
Furthermore, the majority o f the point mutations detected here lie in the C-Terminus of 
scMlhl. The region o f high sequence homology between the MutL proteins lies within
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the N-Terminus, where the so called MutL box: GFRGEAL resides. Results presented 
here show that the cytotoxic function of ScMLHl was not affected sufficiently by these 
mutations/polymorphisms. It would have been interesting to see if  these point 
mutations had any effect on MMR function as measured by mutation frequency/rate. 
This was not carried out due to time constraints.
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6.3. Mutator phenotypes
6.3.1. Mutation frequency & rate
After testing the forward mutation frequencies and rates of the MMR mutants as 
determined by L-canavanine resistance, Table 3 shows the values established for each 
strain. Both methods revealed that pm sl mutants were the highest mutators, followed 
by mlhl and msh2 mutants. mlh2 mutants did not show a significantly different mutator 
phenotype as measured by frequency or rate, compared to wild type. These data agree 
with previous reports that showed that MLH2, originally identified and cloned as a 
homologue of the yeast MutL genes, is not a mutator when knocked out (Prolla et al, 
1994a; Borts R, personal communication).
These mutator phenotypes provide additional evidence to support a separation o f roles 
of MMR proteins involved in the cytotoxic response to DNA damage. The mlh2 mutant 
did not display a mutator phenotype but conferred the highest level o f resistance to 
cisplatin and the pm sl mutant displayed the highest mutator phenotype but did not 
confer resistance to cisplatin. This indicates again that not all components o f MMR 
may be involved in the cytotoxic response and that mismatch repair per se, or at least 
MMR requiring Pmsl, need not be required.
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6.4. Cytotoxic response of MMRJradS2/radl mutants to 
cisplatin
Fig. 13 & 14 show the clonogenic responses of the rad52 and radl mutants compared to 
wild type. The hypersensitivity observed in both mutants was significant (P<0.05) 
indicating that RAD52 and RADI are involved in the repair of cisplatin-induced DNA 
damage. The figures also show responses made by MMRIrad52- and M M R/radl-double 
mutants. Without the presence of either Rad52 or Radl, the resistance phenotype 
originally conferred by the absence of msh2, mlhl or mlh2, is lost (no significant 
difference seen between rad52- or radl-MMR  double mutants and the hypersensitive 
radl or rad52 mutants alone, P>0.05). This indicates that the presence o f Rad52 and 
Radl are required for MMR-dependent cytotoxicity in response to cisplatin and 
implicates a recombinational-dependent process in damage tolerance (Durant et al, 
1999).
Rad52 is an essential component of homologous recombination. It has been proposed 
that bypass o f lesions during DNA replication is carried out by recombinational repair 
(Zou and Rothstein, 1997). Here, rad52 mutation in mitotically growing yeast were 
shown to greatly reduce the level of Holliday junctions, S-phase specific structures of 
recombination stimulated to repair replication-related lesions.
Radl is a component o f NER but has also been implicated in recombination repair. 
RADI was shown to be required for removal of nonhomologous DNA from the 3' ends 
of recombining DNA, a process analogous to the excision of photodimers during repair 
of ultraviolet-damaged DNA (Fishman-Lobell and Haber, 1992). In a similar role to 
Rad52, Radl has been suggested to act to resolve Holliday junctions (Habraken et al, 
1994) explaining the recombination defect observed in radl mutants. It has also been 
shown that purified ScRadl and ScRadlO interacted with a synthetic bubble structure 
and incised the DNA at the 5'-side o f the centrally unpaired region, resembling the dual
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incision step in nucleotide excision repair in vivo (Fishman-Lobell and Haber, 1992; 
Davies et al, 1995).
6.5. Recombination bypass and DNA replication
A model to explain the dependence on the presence of Rad52/Radl proteins for MMR- 
dependent cytotoxicity is shown in Fig. 24.
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Figure 24 Model of recombination-dependent bypass
Mismatch repair proteins inhibit a RAD52/1 -dependent cisplatin adduct bypass 
mechanism either by blocking the bypass apparatus at the adduct or by direct functional 
inhibition.
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The bypass model predicts that loss o f MMR proteins will reduce the probability o f 
lethal signals being generated during replication by allowing adduct bypass to proceed. 
Studies which support such a model have shown that MMR-defective ovarian 
carcinoma cell lines display enhanced replicative bypass of platinum adducts compared 
to MMR-proficient derivatives (Mamenta et al, 1994; Vaisman et al, 1998). Indeed it 
has been shown, without inducing any DNA damage, that re-introducing human MLH1 
into HCT116 MLH1-deficient cells decreased cellular proliferation and rate o f DNA 
synthesis (Shin et al, 1998). This suggests that MMR, or at least M lhl, has a function 
in inhibiting DNA replication and possibly in inhibiting recombination-dependent DNA 
replication passed specific lesions.
To test if  DNA replication was indeed necessary for MMR-dependent drug sensitivity, 
the cytotoxic responses of the wild type and msh2 mutant strain to cisplatin under 
growth inhibitory (and therefore reduced DNA replication) conditions were analysed. 
Cells were grown exponentially and at stationary phase by seeding at growth-promoting 
(2xl07/ml) and confluent (>1.5xl08) concentrations, respectively. Fig. 16 shows a 
significantly increased resistance o f wild type cells exposed to cisplatin during 
stationary phase o f growth (L.D. 90 o f 1.8mM) compared with logarithmically growing 
cells (L.D. 90 o f l.OmM). However, Fig. 17 shows that the cisplatin-sensitivity o f the 
msh2 strain is not affected by growth phase. These results suggest that DNA replication 
is required for MMR-dependent cytotoxicity.
One must lend caution to this observation. RAD52/RAD1-dependent recombinational 
bypass o f genetic lesions occurs during DNA replication as a system to restore 
collapsed replication forks (Zou and Rothstein, 1997). It has been shown that the 
recombination intermediate, the Holliday Junction, reaches its highest level during S 
phase (Zou and Rothstein, 1997). Inhibiting DNA replication may therefore also inhibit 
the bypass mechanism and thus have no net effect on drug sensitivity. One 
interpretation o f the results is that recombination is not as dependent on S-phase as the 
lethal signal generated by MMR. Another is simply that more DNA damage is 
generated and/or are channelled into the recombinational repair pathway during 
replication, with recombination not being directly dependent on replication.
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6.6. Cell cycle analysis
Cell cycle analysis was carried out for the following reasons, i) The DNA replication 
inhibition experiments here show that MMR-dependent cytotoxicity is, at least in part, 
dependent on DNA replication and thus progression through S-phase o f the cell cycle; 
ii) previous studies have shown that MLH1 transfection induced growth suppression in 
an M LHl-defective cell line (Shin et al, 1998) and DNA damage sensitive MMR- 
proficient cells were able to enter G2 arrest while DNA damage resistant MMR- 
defective cells continued cycling (Koi et al, 1994; Hawn et al, 1995; Carethers et al,
1996), and iii) the cell cycle o f S. cerevisiae MMR mutants has not previously been 
analysed in response to cisplatin-induced DNA damage.
6.6.1. FACS analysis
After cells were treated with cisplatin, stained with PI and ran through the FACS 
machine, G2 peaks were analysed as shown in Fig. 18. Cells were synchronised to 
allow accurate peak histogram study o f cell cycle responses. Mating Type A (MatA) 
cells were studied due to the availability o f the cell cycle arrest pheromone, a-Factor. 
Mating Type a  (Mata) cells, which were the strains used in the cytotoxicity assays, 
could not be used due to the commercial unavailability o f the highly lipophilic A- 
Factor. The analysis showed that MatA wild type cells became synchronised by 
treatment with the yeast pheromone a-Factor. This induced a Gi and a G2 arrest in 
preparation for meiosis. However, this response lasted only for some time after 6 hours, 
after which cells began cycling out o f phase (due to the initial difference between 
mother and daughter cell size and physiology). Yeast begin to ignore external 
pheromonal influences after approximately 3-4 hours by down regulating receptor 
levels (Schiebal E., personal communication), therefore synchronisation can only be 
maintained for this period of time.
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Cells were therefore washed off the pheromone after a 2 hour treatment (Pereira et al, 
1998) and the analysis shows that cells became asynchronous after 2-3 hours. Fig. 19 
shows the analysis o f wild type, mlhl and msh2 cells treated with a-Factor and ImM 
cisplatin. The peaks show that wild type cells entered a G! and G2 arrest after 4hrs 
exposure to drug and a-factor. After this period, the distinction between cell cycle 
stages became difficult to interpret. The mlhl and msh2 mutants responded by 
displaying a Gi peak with little or no G2 peak. This may indicate a defect in G2 arrest 
induction in response to a-Factor. FACS analysis in response to cisplatin was 
confounded by a lack o f clear distinction between peaks and background noise.
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6.6.2. Fluorescent microscopy
A simpler and quicker method for measuring cell cycle arrest in budding yeast exists 
which does not require synchronisation o f cells for analysis. Using a fluorescent 
microscope, budding yeast can be scored by counting G2-M structures that form 
enlarged, equally sized buds with a 2N nucleus at the bridge between the unseparated 
buds. This resembles a dum-bell-like structure (Goldstone et al, 1997; Lowndes N, 
personal communication).
At this juncture, it was taken into consideration that cells exposed to cisplatin for such a 
prolonged period o f time (24 hours) might affect cell cycle responses. Other factors 
such as repair activities and prolonged replication stalling times might confound the 
arrest response. Cisplatin exposure was therefore reduced to a 1 hour treatment but at a 
higher concentration o f 4mM, compared to ImM. The PI stained samples were scored 
under a fluorescent microscope and Fig. 20 shows an example o f the micrographs used 
to score for G2 buds for wild type and mlhl strains and Fig. 21 shows more clearly an 
example o f a G2 bud structure and a cell undergoing DNA fragmentation.
Fig. 22 shows the data for G2 arrest responses for wild type, mlhl, msh2, mlhl vector 
alone and ScMLHl transformants, from three separate experiments. Although FACS 
analysis could have been used under these conditions, scoring for G2 buds under the 
microscope proved to be effective. Fig. 22 shows the percentage o f cells in G2-M arrest 
in response to a 1 hour exposure to 4mM cisplatin. The mlhl and msh2 strains show an 
early (approximately 4 hour) release from G2-M arrest compared to wild type. In fact, 
msh2 cells only reached a 40% peak G2-M arrest before release compared to a near 60% 
G2-M peak observed for wild type, mlhl G2-M arrest responses are significantly 
different (P<0.05) compared to wild type at 10, 14, 16 and 18 hours after cisplatin 
treatment. msh2 G2-M arrest responses are significantly different (P<0.05) at 8, 10, 12, 
14 and 18 hours after cisplatin treatment. The m//z/+vector alone transformant control 
showed no difference compared to mlhl mutant and the mlhl+MLHl transformant
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showed a prolonged G2-M arrest possibly even greater than wild type (significantly 
greater than wild type at 16 and 20 hours, P<0.05 1-tailed T-test).
The cytotoxicity o f  a 1 hour exposure o f 4mM cisplatin was assessed by plating 
approximately 400 cells before the fixing and staining procedures. Table 5 shows that 
this exposure was not significantly cytotoxic to any o f the strains tested. Surviving 
fractions reached 0.84, 0.93 and 0.88 for wild type, mlhl and msh2 strains respectively. 
Therefore, this indicates cells maintained viability after release from G2 arrest.
These results strongly suggest that the S. cerevisiae MMR genes MLH1 and MSH2 are 
involved in prolonging G2-M cell cycle arrest in response to cisplatin. This may have 
implications for a role o f MMR proteins in the inhibition o f cells entering mitosis in 
response to cisplatin-induced DNA damage (See Section 6.6.3).
6.6.3. Cisplatin-induced cell cycle arrest pathways involving 
MMR
Studies using S. cerevisiae and S. pombe have shed some light on the possible 
mechanisms at fault in human disease. The M ecls7Rad3sp (human Atr) protein 
pathway is central to the cell cycle checkpoint response in yeast, with the closely related 
protein, Atm, being mutated in individuals with the rare disease ataxia telangiecstasia 
(Sanchez et al, 1996). Studies exploiting the yeast S. pombe and S. cerevisiae have 
defined many proteins involved in checkpoint control (Carr and Hoekstra, 1995). 
M eclsc is a protein essential for viability and is required for all known DNA structure 
checkpoints by inhibiting G2-M progression via Pdslsc/Chklsp kinase (Carr 1997). 
Pdslsc/Chklsp in turn phosphorylates and inhibits W eelsp, a p34cdc2 tyrosine kinase. 
Two checkpoint signals during S-phase exist in yeast - one generated by DNA 
replication inhibition (in which DNA-protein complexes e.g. Rad proteins, formed 
during different stages o f S-phase, repair and recombination could be structures 
monitored by this checkpoint pathway) (Carr 1997) and the other by DNA damage.
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Both require activation o f a protein kinase cascade dependent on M ecl. In the DNA 
damage checkpoint, Mecl is required for phosphorylation of Rad53, a protein activated 
by Rad9 binding which is in turn phosphorylated in response to DNA damage (Sun et 
al, 1998). Rad53 disruption in S. cerevisiae and inhibition o f Rad9-Rad53 binding 
abolishes G2/M cell cycle arrest in response to DNA but does not affect replication 
inhibition-induced arrest (Sun et al, 1998).
The results presented here may provide evidence to suggest that MMR proteins act up­
stream in either o f these cell cycle arrest pathways in response to cisplatin-induced 
DNA damage. A model to explain the early release from G2 arrest in MMR mutants in 
response to cisplatin damage could be that MMR proteins, upon binding to poorly 
repaired cisplatin intrastrand crosslinks, either prevent DNA replication/lesion bypass 
or signal the presence o f a damaged site (see Fig. 25). This then provides an additional 
persistent signal that prolongs the phosphorylation events and leads to a sustained cell 
cycle arrest.
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Figure 25 Model of yeast cell cycle arrest involving MMR
MMR proteins bound to unrepaired cisplatin-induced DNA adducts (i.e. 1,2 intrastrand 
crosslinks) cause replication stalling and bypass inhibition - which then activates the 
Mecl/Rad3-dependent pathway of cell cycle arrest. Or, MMR proteins signal a DNA 
damage response pathway dependent on Rad9 and Rad53 which also leads to cell cycle 
arrest. Either way, the persistent lesion which is not bypassed, leads to a prolonged cell 
cycle arrest.
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6.6.4. S. cerevisiae responses to IR
MMR and rad  mutant S. cerevisiae strains were also exposed to lOOgy y-irradiation 
under a 60Co source. Fig. 23 shows the G2-M arrest responses of each strain, radl and 
rad52 mutants showed a significantly elevated G2-M arrest response (P<0.05) compared 
to wild type at 0 and 2 hours after IR exposure. This indicates that radl and rad52 cells 
enter G2-M arrest quicker than wild type, possibly as a result of unrepaired IR-induced 
lesions triggering cell cycle arrest responses. The mlhl and msh2 strains show very 
similar responses to that o f wild type, however, a significant difference (P<0.05) was 
observed between mlhl and wild type at 2 and 4 hours after IR exposure and between 
msh2 and wild type at 2 hours after IR exposure. This may suggest that mlhl and msh2 
mutants arrest in G2-M earlier in response to IR. The reason for this is unclear. The 
lack o f these DNA binding proteins may cause a transient reduction in IR shielding and 
increase the exposure o f DNA to direct damage by IR. However, y-IR mainly causes 
indirect chemical damage to DNA, such as the formation o f hydroxyl free radicals from 
reactions with water, as opposed to the direct physical damage caused by a-emitters. 
No difference was seen after this initial phase.
In comparison with inconsistent studies using murine and human MMR-defective cell 
lines, these cell cycle results contradict with the majority finding. It was shown that 
radio-sensitive HCT116 cells show deficiency in G2-M checkpoint arrest in response to 
ionising radiation (Davis et al, 1998) and similar IR responses were also noted between 
murine MLH1 knockout compared to wild-type primary embryonic fibroblasts (Davis 
et al, 1998). However, O’Driscoll et al, (1999) showed that NER-defective cells were 
no different in sensitivity to y-irradiation compared to an MS7/2-/NER-defective 
derivative; cell cycle analysis was not carried out in this study. In the study using 
HCT116 cells, X-rays were used as a source o f IR. Work presented here is based on y- 
irradiation. X-rays have slightly less energy than y-rays but the spectrum of adducts 
caused by both are generally considered to be the same (Hall, 1994). It is possible that 
MLH1-deficient HCT116 cells and embryonic fibroblasts have other mutations that 
might effect responses to IR. The results obtained here using isogenic MMR defective
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yeast strains argues against the finding that MMR deficiency leads to an abrogation of 
G2 arrest.
Clonogenic assessment on the IR-treated strains suggested that the exposure was 
partially cytotoxic to the strains (see Table 6) with surviving fractions o f 0.33, 0.41, 
0.46, 0.19 and 0.36 for wt, m lhl, msh2, radl and rad52 strains respectively. The degree 
o f lethality must therefore be considered when studying cell cycle phenotypes. The 
proportion o f replication forks encountering IR-induced DNA damage, the severity of 
the lesions themselves and the temporal persistence o f unrepaired adducts will all play a 
role in determining the outcome of the cellular response. However, inviable cells 
receiving lethal doses o f IR should not have cycled at all, would appear 
morphologically different and would represent a small proportion of the cells scored for 
G2 arrest. Rad52, which is responsible for repairing double strand breaks, did not show 
sensitivity to this dose o f IR, indicating either that double strand breaks were not the 
main adducts induced or the lesions induced were repaired by other pathways (non- 
homologous recombination). The former suggestion is consistent with the fact that oc- 
particles and not y-rays are responsible for causing DNA double strand breaks (Hall et 
al, 1994). The sensitivity observed in the radl mutants suggests that IR resulted in 
chemical modifications to DNA that represent substrates for Radl-dependent repair.
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6.7. Future experiments
Due to time constraints several questions remain unaddressed. With regard to the 
ScMLHl re-introduced transformant strain generated, it is not known if  re-introducing 
wild type ScMLHl restores MMR function as measured by mutation frequency or rate. 
These are experiments that could be repeated on the transformants isolated. Mutation 
frequency and rate was also not determined for the remaining MMR mutants.
Secondly, these transformants were not exposed to ionising radiation, since no 
significant difference in cell cycle response or cytotoxicity was seen between wild type 
and mlhl mutants. However, it would be interesting to see if  the transformants, which 
under the pYX212 vector highly express ScMLHl, respond differently to ER, especially 
since the transformants demonstrated hypersensitivity to cisplatin. On the subject o f IR, 
increasing the number o f repeats for both the cytotoxicity and cell cycle experiments 
would statistically clarify/nullify the results obtained here.
Repeating the cloning o f  the ScMLHl gene into the low expression vector would be 
useful to explore any difference observed between low and high protein levels in cell 
cycle and cytotoxic responses. The point mutations detected in the ScMLHl gene insert, 
according to the phenotypes observed, may be gain-of-function mutations or artefactual 
mutations responsible for some other MMR-independent effect. Therefore, repeating 
the cloning in the high copy vector and sequencing o f the insert in an attempt to reduce 
the number o f point mutations obtained could be carried out.
Cloning o f the human MLH1 gene into the yeast vectors could be carried out, with the 
ultimate aim in cancer therapy to re-introduce sequences that restore cisplatin
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sensitivity. Cell cycle and cytotoxic responses would then confirm or negate the use of 
these MMR mutant strains for higher eukaryotic extrapolation.
In testing for dependence on RADI and RAD52 for MMR-dependent cytotoxicity, it was 
shown that both defects abolished the MMR deficiency-induced resistant phenotype. 
Therefore, a suitable negative control is needed to confirm that only specific DNA 
proteins are necessary for MMR-dependent cytotoxicity. Therefore, strains with 
proteins from other rad epistasis groups would be useful to disrupt. Radl4 is a protein 
known to be exclusive to NER. A radl 4 background could then be used to test the 
MMR deficient strains.
Cell cycle analysis using FACS could not be carried out effectively. Yeast FACS 
analysis is notoriously difficult and a number o f technical factors could be addressed to 
improve the method. Prolonged enzyme digestion o f the cell wall (although partially 
carried out here), slowing the rate o f flow cytometry, prolonged sonication o f cells to 
reduce clumping and more sophisticated cell cycle synchronisation protocols could all 
be tested.
6.7.1. Longer term plans
The models constructed to explain the observations o f RADI and RAD52 dependence 
on MMR-dependent cytotoxicity and G2-cell cycle arrest attenuation in response to 
cisplatin treatment, both provide a platform for further work. At present there are no 
biochemical studies that link recombination repair pathways and G2 checkpoint 
pathways to MMR. The yeast two-hybrid screen, immunoprecipitation and gel retard 
experiments could be used to pull out various proteins associated with these pathways.
In the follow up o f the cell cycle story that has emerged, exploring the activation of 
specific cyclin-dependent kinases and/or checkpoint proteins with and without the 
presence o f specific MMR genes in yeast would also provide information on the
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pathways operating in cell cycle control. Phosphorylation, protein binding and local 
distribution o f these proteins would be important studies to undertake.
The use o f genetic suppresser elements to identify important functional sequences 
within MMR genes in yeast could be exploited. These studies may provide specific 
sequences that are possible to re-introduce into human cell lines with the aim of 
restoring drug sensitivity in MMR-defective resistant cells. More ambitious still, 
restoring MMR function in MMR-defective cells may protect against further 
mutagenesis and the multistep progression towards neoplasia.
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9.1. Statistics
Sheetl
MutS m utan ts.....
•  mlh2:msh3
RHB 2347- 
4b (msh3) 
NHT 173 
(msh6) 
RHB 2348- 
9b (msh2)
-  1 2096-1B
 (wild-type)
1
CDDP (mM)
•2096-1B 
(wild-type) 
■RBT 324 
(mlh2) 
com.mlhl
MutL m u tan ts
1
CDDP (mM)
RHB2695-2b 
(rad1 :mlh2)
"3K® ”” ,RHB2693-8a 
(rad1:mlh1) 
RHB2694-9C 
(rad1 :msh2) 
RBT302 
(rad 1)
2096-1B 
(wild-type)
Rad1:MMR doub le  m u tan ts
1
CDDP (mM)
Page 1
Sheetl
1 0 0
1 0
0 . 1
♦  RHB2692-1C
(rad52) 
RHB2699-4C 
(rad52:mlh2) 
RHB2700-1 b 
(rad52:msh2) 
**##™»r HB2698-5c 
(rad52:mlh1) 
C8a!^ E“ com.mlh1
“ ♦ “ 2096-1B 
 (wildtype Mat@)
Rad52:MMR double  m utants
1
CDDP (mM)
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Sheet 1
i survival of yeast mutants exposed for 24hr with cisplatin - 
ingle mutant strains:
iplatin (mM) 0 0.5 1 1.5 2
96-1A 1 100 114 143 16.9
2 100 89.2 116.6 16.8
3 100 116.6 72.2 9.3
4
5
96-1B 1
2 100 64 38.2 1.1
3 100 59.8 8 1
4 100 21.6 6.3 0.003
5 100 112.5 14 0.29 0.29
6 100 73.4 9.2 0.43 0.0025
7 100 83 12.7 0.72 0.97
8 100 72.6 0.68 0.96 0.0025
9 100 73.9 13.6 2.1 0.07
10 100 27 2 0.007
11 100 126 15.1 1.6 0.5
.7.97 12 100 38.8 4.8 0.5 0.3
13 100 33.1 7.2 1.2 0.2
14 100 48.4 14.7 1.1 0.3
IT 311 1 100 62.8 17.7 7.1
hi 2 100 50.4 47.8 1.1
3 100 23.5 2.7 2
4 100 67 30.2 8.2 0.03
5 100 78.8 52 11 2.9
6 100 83.1 33.1 11.8 4.3
7 100 72.7 54.7 13.1 3.4
.7.97 8 100 87.1 56.2 16.6 2.8
IT 173 1 100 109 74.3 7.1
>h6 2 100 50.4 27.6 33.2
3 100 55.2 18.9 4.1 1.7
4 100 64.4 107.6 3.8 2.4
5 100 75.3 36.8 13.2 4.6
6 100 81.4 48.4 11.8 3.6
IT 289 1
is 2 100 63.9 13.2 2.5 0.004
3 100 55.3 17.7 2.8 0.01
4 100 71.8 15.1 1.6 0.008
5 100 84.7 71.6 0.03 0.01
IB 2348-9b 1 100 159.8 160.1 52.2
;h2 2 100 32.2 13.6 3.7
3 100 158.3 78.3 36.2 7.7
4 100 100.8 36 10.2 3.7
5 100 49.1 72.1 9.3 3.8
6 100 147.7 85.2 17.7 6.6
IB 2347-4b 1
;h3 2 100 40.2 23.9 4
3 100 115.4 96 21.4 7.8
4 100 98.2 76.8 29.3 7.3
5 100 93.8 39.8 14.3 4.3
6 100 141.8 92 19.1 7.1
IT 324 1 100 56.5 107 14.7
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Ih2 2
3 100 85.2 59.2 26.3 9.5
4 100 90.7 55.8 26.7 8
5 100 116.6 116.6 31.7 13.2
6 100 104.3 69 18.8 13
3T341
Ih1 1 100 103.2 45 15.6 4.1
id disruption 2 100 88.1 65.5 16.1 6.6
3 100 88.4 70.5 38.8 6.3
4 100 53.4 55.9 25.1 2.2
Ih2:msh3 1 100 65.9 54.3 37.5 9
2 100 86 95.4 39.3 19.7
3 100 74.2 43.5 22.6
4 100 145.6 114 59.7 22.5
EAN
jplatin (mM) 0 0.5 1 1.5 2
h2:msh3 100 92.925 87.9 45 18.45
HB 2347-4b (msh3) 100 102.0564 58.6051 21.51562 5.594181
HT 173 (msh6) 100 75.01259 48.83499 9.229677 5.015946
HB 2348-9b (msh2) 100 113.0827 66.852 15.25671 7.188673
196-1B (wild-type) 100 71.40909 14.36769 1.563636 0.365
3T 324 (mlh2) 100 84.46922 80.12343 28.13037 11.01986
m.mlhl 100 74.0975 37.4645 10.87917 4.494415
3T 289 (pms) 100 68.0861 22.41864 0.761351 0.007521
tandard deviation
jplatin (mM) 0 0.5 1 1.5 2
196-1B 0 28.39822 9.922764 1.684472 0.406001
47-4B 0 21.76327 27.39029 5.571355 1.801388
3T324 0 24.6515 31.62462 3.008876 3.124633
3T311 0 12.73787 15.08869 4.733146 2.142221
HT173 0 20.49532 31.08567 9.675226 12.11853
3T289 0 12.4901 28.19373 1.244277 0.002828
48-9B 0 47.86536 46.22984 11.01612 19.30438
Ih2:msh3 0 36.07209 30.54849 10.11731 6.441791
■TEST (student unpaired, two-tailed)_____________________________
jplatin (mM) 0| 0.5 1 1.5 2
196-1 B:2347-4b 0 0.073573 0.010405 0.000857 0.001749
196-1 B:RBT324 0 0.79245 0.005207 0.001873 0.000765
196-1 B:RBT311 0 0.25972 0.002908 0.004731 0.01154
196-1 B:NHT173 0 0.634271 0.023933 0.07529 0.151425
196-1 B:RBT289 0 0.202783 0.417084 0.943542 0.027056
196-1 B:2348-9b 0 0.139563 0.022048 0.033186 0.172029
h2:msh3-mlh2 0 0.917227 0.783208 0.023635 0.12335
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id1 :MMR double mutant strains -
32695-2b 100 62.5 6.3 0.0025 0.0025
1 :mlh2 100 75 9.1 0.0025 0.0025
100 67.2 7.5 0.0025 0.0025
100 59.3 8.9 0.29 0.0025
100 47 0.75 0.0025 0.0025
32693-8a 100 114.7 40 5.9 0.5
1:mlh1 100 53.8 17.7 2.6 2.3
100 74.7 24.8 4.9 0.2
100 79.6 31.3 1.7 0.2
B2694-9C 100 101.3 25.7 3.8 1.9
1 :msh2 100 93.6 18.4 6.6 0.3
100 74.3 10.4 0.6 0.02
100 72.7 8.8 1.1 0.3
r302 100 20.3 1.1 0.0025 0.0025
1 100 12.8 0.0025 0.0025 0.0025
100 20.8 0.0025 0.0025 0.0025
100 19 0.9 0.0025 0.0025
an
>latin 0 0.5 1 1.5 2
B2695-2b (rad1:mlh2) 100 62.2 6.51 0.06 0.0025
B2693-8a (rad1:mlh1) 100 80.7 28.45 3.775 0.8
B2694-9c (rad1:msh2) 100 85.475 15.825 3.025 0.63
T302 (rad1) 100 18.225 0.50125 0.0025 0.0025
16-1B (wild-type) 100 71.40909 14.36769 1.563636 0.365
indard dev.
)latin 0 0.5 1 1.5 2
B2695-2b (rad1:mlh2) 0 10.34867 3.414015 0.128574 0
B2693-8a (rad1:mlh1) 0 21.5432 8.386517 1.902367 0.944458
B2694-9c (rad1:msh2) 0 14.19539 7.808702 2.766918 0.856894
T302 (rad1) 0 3.69538 0.581666 0 0
)6-1B 0 28.39822 9.922764 1.684472 0.406001
Bst (between wt & m utants)
Dlatin 0 0.5 1 1.5 2
B2695-2b (rad1 :mlh2) 0.360386 0.023846 0.014372 0.007365
B2693-8a (rad1:mlh1) 0.565079 0.048377 0.10417 0.456984
B2694-9c (rad1:msh2) 0.231971 0.770088 0.379659 0.586988
T302 (radl) 8.46E-05 0.000284 0.011765 0.007365
sst (between Rad-1 single and RAD-1 double m utants)
Dlatin LOoo 1 1.5 2
1B2695-2b (rad1:mlh2) 0.000254 0.015834 0.373901 #DIV/0!
1B2693-8a (rad1:mlh1) 0.014817 0.009627 0.030752 0.212391
1B2694-9c (rad1:msh2) 0.001621 0.029057 0.116828 0.239257
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RAD52:MMR double mutant strains -
sisplatin (mM)
RHB2692-1C
BHB2699-4C
BHB2700-1 b
BHB2698-5C
BBT341
^BT340
0 0.5 1 1.5 2
100 39.1 0.0025 0.0025 0.0025
100 49.3 0.0025 0.0025 0.0025
100 31.4 1.4 0.0025 0.0025
100 27.5 2.7 0.0025 0.0025
100 21.9 1.7 0.3 0.0025
100 10.7 1.2 0.6 0.0025
100 24.9 1.6 0.4 0.0025
100 16.5 0.9 0.0025 0.2
100 29.3 7 0.0025 0.0025
100 22.1 1.7 0.7 0.0025
100 6.6 0.5 0.5 0.0025
100 16.8 6.3 0.0025 0.0025
100 10.7 0.0025 0.0025 0.0025
100 9.9 0.0025 0.0025 0.0025
100 8.7 4.8 0.0025 0.0025
100 1.4 0.0025 0.0025 0.0025
100 2 0.5 0.0025 0.0025
100 3.1 0.0025 0.0025 0.0025
100 68 56.5 32.2 2.3
100 81.7 34 4.1 1.1
100 70.9 39.8 6.9 8.5
100 70.4 40.3 8.9 2.4
100 103.2 45 15.6 4.1
100 88.1 65.1 16.1 6.6
100 88.4 70.5 38.8 6.3
100 53.4 55.9 25.1 2.2
100 92.9 48.7 12.1 1
100 58.1 15.1 0.7 0.0025
100 26.8 4.9 1 0.2
100 18.1 2.5 0.5 0.0025
100 73.1 12 0.0025 0.0025
100 22.5 8 1.2 0.0025
Vlean
:isplatin (mM) 0 0.5 1 1.5 2
^HB2692-1c (rad52) 100 29.25714 1.229286 0.0025 0.0025
1HB2699-4C (rad52:mlh2) 100 18.625 2.525 0.30125 0.051875
}HB2700-1 b (rad52:msh2) 100 7.514286 1.658571 2.50E-03 2.50E-03
1HB2698-5C (rad52:mlh1) 100 72.75 42.65 13.025 3.575
:om.mlh1 100 74.0975 37.4645 10.87917 4.494415
!096-1 B (wildtype Mat@) 100 72.2 17.42 1.65 0.445376
».d
:isplatin (mM) 0 0.5 1 1.5 2
1HB2692-1C 0 12.40804 0.963867 0.18572 0.718131
*HB2699-4c 0 9.576838 3.024759 0.355897 0.099995
*HB2700-1b 0 5.638389 2.700527 5.35E-06 5.35E-06
*HB2698-5c 0 6.099454 9.66592 3.336041
*BT341 0 18.79614 10.74653 10.77697 2.464346
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IBT340 
096-1B
12.93403
r-test
isplatin (mM) 0 0.5 1 1.5 2
)iff between:
Vildtype:Rad52 0.000637 0.000443 0.022493 0.025441
Vildtype:Rad52/mlh2 0.000125 0.001868 0.036944 0.022465
Vildtype: Rad52/msh2 1.5E-05 0.000598 0.011765 0.007365
Vildtype:Rad52/mlh1 0.885156 0.003556 0.174302 0.149796
■test (diff between rad52 single nutant and doubles)
ad52:rad52/mlh2
ad52:rad52/msh2
ad52:rad52/mlh1
0.355668
0.002627
2.87E-05
0.46007
0.548209
0.003224
0.594921
0.094889
0.141341
0.391002
#DIV/0!
0.121651
0 25.89895 5.907834 0.420313 0.099995 
0 22.49171 14.98318 2.302347 0.491082
Surviving Fraction (com pared to wt)
:isplatin (mM) 0 0.5 1 1.5 2
!096-1 B (wild-type) 
^BT 324 (mlh2) 1 1.182892 5.576639 17.99035 30.19141
iom.mlhl 1 1.037648 2.607552 6.957607 12.31347
}BT 289 (pms) 1 0.953465 1.560351 0.48691 0.020606
nih2:msh3 1 1.301305 6.117893 28.77907 50.54795
1HB 2347-4b (msh3) 1 1.429179 4.07895 13.75999 15.32652
4HT173 (msh6) 1 1.050463 3.398945 5.9027 13.74232
*HB 2348-9b (msh2) 1 1.583589 4.652939 9.757196 19.69499
Surviving Fraction (SF) (compared
:isplatin (mM) 0
lHB2695-2b (rad1:mlh2) 1
=lHB2693-8a (rad1:mlh1) 1
=11462694-90 (rad1:msh2) 1
3BT302 (rad1)
0.5 1 1.5 2
3.412894 12.98753 24 1
4.427984 56.7581 1510 320
4.689986 31.57107 1210 252
Surviving Fraction (com pared to rad52 mutant)
jisplatin (mM) 0 0.5 1 1.5 2
4HB2692-1C (rad52)
4HB2699-4C (rad52:mlh2) 1 0.636597 2.054038 120.5 20.75
4HB2700-1b(rad52:msh2) 1 0.256836 1.349216 1 1
4HB2698-5C (rad52:mlh1) 1 2.486572 34.69494 5210 1430
4BT341 (mlh1) 1 #REF! #REF! #REF! #REF!
>096-1 B (wildtype Mat@) 1 2.467773 14.17083 660 178.1506
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Chapter 9-192
9.2. scMLHl gene sequence and cloning primers
F - B a m H I  P r i m e r
1 ATGTCTCTCA GAATAAAAGC ACTTGATGCA TCAGTGGTTA ACAAAATTGC
5 1  TGCAGGTGAG ATCATAATAT CCCCCGTAAA TGCTCTCAAA GAAATGATGG
1 0 1  AGAATTCCAT CGATGCGAAT GCTACAATGA TTGATATTCT AGTCAAGGAA
1 5 1  GGAGGAATTA AGGTACTTGA AATAACAGAT AACGGATCTG GAATTAATAA
2 0 1  AGCAGACCTG CCAATCTTAT GTGAGCGATT CACGACGTCC AAATTACAAA
2 5 1  AATTCGAAGA TTTGAGTCAG ATTCAAACGT ATGGATTCCG AGGAGAAGCT
3 0 1  TTAGCCAGTA TCTGACATGT GGCAAGAGTC ACAGTAACGA CAAAAGTTAA
3 5 1  AGAAGACAGA TGTGCATGGA GAGTTTCATA TGCAGAAGGT AAGATGTTGG
4 0 1  AAAGCCCCAA ACCTGTTGCT GGAAAAGACG GTACCACGAT CCTAGTTGAA
4 5 1  GACCTTTTTT TCAATATTCC TTCTAGATTA AGGGCCTTGA GGTCCCATAA
5 0 1  TGATGAATAC TCTAAAATAT TAGATGTTGT CGGGCGATAC GCCATTCATT
5 5 1  CCAAGGACAT TGGCTTTTCT TGTAAAAAGT TCGGAGACTC TAATTATTCT
6 0 1  TTATCAGTTA AACCTTCATA TACCGTCCAG GATAGGATTA GGACTGTGTT
6 5 1  CAATAAATCT GTGGCTTCGA ATTTAATTAC TTTTCATATC AGCAAAGTAG 
7 0 1  AAGATTTAAA CCTGGAAAGC GTTGATGGAA AGGTGTGTAA TTTGAATTTC
7 5 1  ATATCCAAAA AGTCCATTTC ACCAATTTTT TTCATTAATA ATAGACTAGT
8 0 1  GACATGTGAT CTTCTAAGAA GAGCTTTGAA CAGCGTTTAC TCCAATTATC
8 5 1  TGCCAAAGGG CAACAGACCT TTTATTTATT TGGGAATTGT TATAGATCCG
9 0 1  GCGGCTGTTG ATGTTAACGT TCACCCGACA AAGAGAGAGG TTCGTTTCCT
9 5 1  GAGCCAAGAT GAGATCATAG AGAAAATCGC CAATCAATTG CACGCCGAAT
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1 0 0 1  TATCTGCCAT TGATACTTCA CGTACTTTCA AGGCTTCTTC AATTTCAACA
1 0 5 1  AACAAGCCAG AGTCATTGAT ACCATTTAAT GACACCATAG AAAGTGATAG
1 1 0 1  GAATAGGAAG AGTCTCCGAC AAGCCCAAGT GGTAGAGAAT TCATATACGA
1 1 5 1  CAGCCAATAG TCAACTAAGG AAAGCGAAAA GACAAGAGAA TAAACTAGTC
1 2 0 1  AGAATAGATG CTTCACAAGC TAAAATTACG TCATTTTTAT CCTCAAGTCA
1 2 5 1  ACAGTTCAAC TTTGAAGGAT CGTCTACAAA GCGACAACTG AGTGAACCCA
1 3 0 1  AGGTAACAAA TGTAAGCCAC TCCCAAGAGG CAGAAAAGCT GACACTAAAT
1 3 5 1  GAAAGCGAAC AACCGCGTGA TGC CAATAC A ATCAATGATA ATGACTTGAA
1 4 0 1  GGATCAACCT AAGAAGAAAC AAAAGTTGGG GGATTATAAA GTTCCAAGCA
1 4 5 1  TTGCCGATGA CGAAAAGAAT GCACTCCCGA TTTCAAAAGA CGGGTATATT
1 5 0 1  AGAGTACCTA AGGAGCGAGT TAATGTTAAT CTTACGAGTA TCAAGAAATT
1 5 5 1  GCGTGAAAAA GTAGATGATT CGATACATCG AGAACTAACA GACATTTTTG
1 6 0 1  CAAATTTGAA TTACGTTGGG GTTGTAGATG AGGAAAGAAG ATTAGCCGCT
1 6 5 1  ATTCAGCATG ACTTAAAGCT TTTTTTAATA GATTACGGAT CTGTGTGCTA
1 7 0 1  TGAGC TATTC TATCAGATTG GTTTGACAGA CTTCGCAAAC TTTGGTAAGA
1 7 5 1  TAAACCTACA GAGTACAAAT GTGTCAGATG ATATAGTTTT GTATAATCTC
1 8 0 1  CTATCAGAAT TTGACGAGTT AAATGACGAT GCTTCCAAAG AAAAAATAAT
1 8 5 1  TAGTAAAATA TGGGACATGA GCAGTATGCT AAATGAGTAC TATTCCATAG
1 9 0 1  AATTGGTGAA TGATGGTCTA GATAATGACT TAAAGTCTGT GAAGCTAAAA
1 9 5 1  TCTCTACCAC TACTTTTAAA AGGCTACATT CCATCTCTGG TCAAGTTACC
2 0 0 1  ATTTTTTATA TATCGCCTGG GTAAAGAAGT TGATTGGGAG GATGAACAAG
2 0 5 1  AGTGTCTAGA TGGTATTTTA AGAGAGATTG CATTACTCTA TATACCTGAT
2 1 0 1  ATGGTTCCGA AAGTCGATAC ATCTGATGCA TCGTTGTCAG AAGACGAAAA
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2 1 5 1  AGCCCAGTTT ATAAATAGAA AGGAACACAT ATCCTCATTA CTAGAACACG
2 2 0 1  TTCTCTTCCC TTGTATCAAA CGAAGGTTCC TGGCCCCTAG ACACATTCTC
R - M l u l  P r i m e r
2 2 5 1  AAGGATGTCG TGGAAATAGC CAACCTTCCA GATCTATACA AAGTTTTTGA 
2 3 0 1  GAGGTGTTAA
(sequence num ber U 07187_l.cds from Saccharomyces Genome Database). Underlined 
sequences show annealing prim er sites.
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U 07187 L e n g th :  3 2 1 8  F e b r u a r y  3 , 1998  1 2 :2 0  T y p e : N C h e c k : 690 . .
1 AAATAGGAAT GTGATACCTT CTATTGCATG CAAAGATAGT GTAGGAGGCG
. 51 CTGCTATTGC CAAAGACTTT TGAGACCGCT TGCTGTTTCA TTATAGTTGA
1 0 1 GGAGTTCTCG AAGACGAGAA ATTAGCAGTT TTCGGTGTTT AGTAATCGCG
151 CTAGCATGCT AGGACAATTT AACTGCAAAA TTTTGATACG ATAGTGATAG
201 TAAATGGAAG GTAAAAATAA CATAGACCTA TCAATAAGCA [ATGTCTCTCA
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GAATAAAAGC ACTTGATGCA TCAGTGGTTA ACAAAATTGC TGCAGGTGAG 
ATCATAATAT CCCCCGTAAA TGCTCTCAAA GAAATGATGG AGAATTCCAT 
CGATGCGAAT GCTACAATGA TTGATATTCT AGTCAAGGAA GGAGGAATTA 
AGGTACTTCA AATAACAGAT AACGGATCTG GAATTAATAA AGCAGACCTG 
CCAATCTTAT GTGAGCGATT CACGACGTCC AAATTACAAA AATTCGAAGA 
TTTGAGTCAG ATTCAAACGT ATGGATTCCG AGGAGAAGCT TTAGCCAGTA 
TCTCACATGT GGCAAGAGTC ACAGTAACGA CAAAAGTTAA AGAAGACAGA 
TGTGCATGGA GAGTTTCATA TGCAGAAGGT AAGATGTTGG AAAGCCCCAA 
ACCTGTTGCT GGAAAAGACG GTACCACGAT CCTAGTTGAA GACCTTTTTT 
TCAATATTCC TTCTAGATTA AGGGCCTTGA GGTCCCATAA TGATGAATAC 
TCTAAAATAT TAGATGTTGT CGGGCGATAC GCCATTCATT CCAAGGACAT 
TGGCTTTTCT TGTAAAAAGT TCGGAGACTC TAATTATTCT TTATCAGTTA 
AACCTTCATA TACAGTCCAG GATAGGATTA GGACTGTGTT CAATAAATCT 
GTGGCTTCGA ATTTAATTAC TTTTCATATC AGCAAAGTAG AAGATTTAAA 
CCTGGAAAGC GTTGATGGAA AGGTGTGTAA TTTGAATTTC ATATCCAAAA 
AGTCCATTTC ATTAATTTTT TTCATTAATA ATAGACTAGT GACATGTGAT 
CTTCTAAGAA GAGCTTTGAA CAGCGTTTAC TCCAATTATC TGCCAAAGGG 
CTTCAGACCT TTTATTTATT TGGGAATTGT TATAGATCCG GCGGCTGTTG 
ATGTTAACGT TCACCCGACA AAGAGAGAGG TTCGTTTCCT GAGCCAAGAT 
GAGATCATAG AGAAAATCGC CAATCAATTG CACGCCGAAT TATCTGCCAT 
TGATACTTCA CGTACTTTCA AGGCTTCTTC AATTTCAACA AACAAGCCAG 
AGTCATTGAT ACCATTTAAT GACACCATAG AAAGTGATAG GAATAGGAAG 
AGTCTCCGAC AAGCCCAAGT GGTAGAGAAT TCATATACGA CAGCCAATAG 
TCAACTAAGG AAAGCGAAAA GACAAGAGAA TAAACTAGTC AGAATAGATG 
CTTCACAAGC TAAAATTACG TCATTTTTAT CCTCAAGTCA ACAGTTCAAC 
TTTGAAGGAT CGTCTACAAA GCGACAACTG AGTGAACCCA AGGTAACAAA 
TGTAAGCCAC TCCCAAGAGG CAGAAAAGCT GACACTAAAT GAAAGCGAAC 
AACCGCGTGA TGCCAATACA ATCAATGATA ATGACTTGAA GGATCAACCT 
AAGAAGAAAC AAAAGTTGGG GGATTATAAA GTTCCAAGCA TTGCCGATGA 
CGAAAAGAAT GCACTCCCGA TTTCAAAAGA CGGGTATATT AGAGTACCTA 
AGGAGCGAGT TAATGTTAAT CTTACGAGTA TCAAGAAATT GCGTGAAAAA 
GTAGATGATT CGATACATCG AGAACTAACA GACATTTTTG CAAATTTGAA 
TTACGTTGGG GTTGTAGATG AGGAAAGAAG ATTAGCCGCT ATTCAGCATG
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ACTTAAAGCT
TATCAGATTG
GAGTACAAAT
TTGACGAGTT
TGGGACATGA
TGATGGTCTA
TACTTTTAAA
TATCGCCTGG
TGGTATTTTA
AAGTCGATAC
ATAAATAGAA
TTGTATCAAA
TGGAAATAGC
CTTTAAAACG
GTGATTGTGT
CGCGAGATTT
AGAAATGTAT
GTTCCGTATT
TTATTCAACG
ATCATTTTTC
CAGGATGGTA
AAAAGTTTTA
TTTTGAACCG
CTAAAAGTTG
ATGAAAGAGA
GAAAAACTCA
CCTTAGAATA
TTTTTTAATA
GTTTGACAGA
GTGTCAGATG
AAATGACGAT
GCAGTATGCT
GATAATGACT
AGGCTACATT
GTAAAGAAGT
AGAGAGATTG
ACTCGATGCA
AGGAACACAT
CGAAGGTTCC
CAACCTTCCA
TTTTGGCTGT
TTCATTTGAA
CAAAGGATAT
ATTCGGATTG
GTTTTCGTCC
GTACCAAAGA
AACTCAATTA
AAACGAATCA
ATTTACTGAG
AATATTGTGG
TTTGACAGCA
CCTCGCGCGT
CTTTTTGCAT
ATGTATAA
GATTACGGAT
CTTCGCAAAC
ATATAGTTTT
GCTTCCAAAG
AAATGAGTAC
TAAAGTCTGT
CCATCTCTGG
TGATTGGGAG
CATTACTCTA
TCGTTGTCAG
ATCCTCATTA
TGGCCCCTAG
GATCTATACA
AATACCAAAG
AGTGTATGCC
GAAATATGGT
AAACTCTTCT
TCTTCCTCAA
CCCGAGTCCT
TCTTAATATC
CCTGAATCTA
CCTTTCGGTC
GCAGATTTGC
GCCGATTCCA
AATGGTTTGC
GGAAGTTATT
CTGTGTGCTA
TTTGGTAAGA
GTATAATCTC
AAAAAATAAT
TATTCCATAG
GAAGCTAAAA
TCAAGTTACC
GATGAACAAG
TATACCTGAT
AAGACGAAAA
CTAGAACACG
ACACATTCTC
AAGTTTTTGA
TTTTTGTTTA
CTTTCCTTTA
TGCAGTTAGG
AATAGTTCTG
GCAACGATTC
TTTATGAGAG
ATTTTGTAGT
GAAGCTGTAC
AAGTAAACTA
AGTAAGTTCA
CAAAAATTTG
ATCACCATCG
AACAATAAGA
TGAGCTATTC
TAAACCTACA
CTATCAGAAT
TAGTAAAATA
AATTGGTGAA
TCTCTACCAC
ATTTTTTATA
AGTGTCTAGA
ATGGTTCCGA
AGCCCAGTTT
TTCTCTTCCC
AAGGATGTCG
g a g g t g t t a a ]
TTTCCTGAGT
ACGATTCATC
AAAGTATGTC
AAGTCACTTG
TTGTCTAAGC
AAAACATTTC
ATTTTGAAAA
CTTGTCCCAT
GTTTATCTAG
GTTAGATCTA
GTAAAAGGAG
GATGTCTGTT
CTAATGATTA
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U07187_l.cds begins at 21
ASSEMBLE J u n e  1 6 , 1997 0 6 :1 6
S y m b o ls : 1 t o :  2 3 5 0  f ro m : s c m lh i  c k :  690 , 221  t o :  2570
LOCUS SCMLHI 3 2 1 8  b p  DNA PLN 17-M A R-1994
DEFINITION S a c c h a ro m y c e s  c e r e v i s i a e  DNA m is m a tc h  r e p a i r  (MLH1) g e n e ,  c o m p le te  
c d s .
ACCESSION U 07187
NID g 4 6 0 6 2 6
KEYWORDS . . . .
g c g o u t . tm p .3 1 5 0 4  L e n g th :  2 3 5 0  J u n e  1 6 , 1997  0 6 :1 6  T y p e : N C h e c k : 1685
r -ifr
LAI'CATAGACCTA TCAATAAGCA l TGTCTCTCA GAATAAAAGC XCTTGATGCA
51 TCAGTGGTTA ACAAAKTTGC ifccAGGTGAG ATCATAATAT CCCCCGTAAA
V' W  U f& t
101 TGCTCTCAAA GAAATGATGG AGAATTCCAT CGATGCGAAT GCTACAATGA
151 TTGATATTCT AGTCAAGGAA GGAGGAATTA AGGTACTTCA AATAACAGAT
201 AACGGATCTG GAATTAATAA AGCAGACCTG CCAATCTTAT GTGAGCGATT
251 CACGACGTCC AAATTACAAA AATTCGAAGA TTTGAGTCAG ATTCAAACGT
301 ATGGATTCCG AGGAGAAGCT TTAGCCAGTA TCTCACATGT GGCAAGAGTC
351 ACAGTAACGA CAAAAGTTAA AGAAGACAGA TGTGCATGGA GAGTTTCATA
r -  ~ >  ^
401 TGCAGAAGGT AAGATGTTGG AAAGgCCQAA ACCTGTTGCT GGAAAAGACfi
451 GTACCACGAT CCTAGTTGAA GACCTTTTTT TCAATATTCC TTCTAGATTA/ L  ----------- -----------------
501 AGGGCCTTGA GGTCCCATAA TGATGAATAC TCTAAAATAT TAGATGTTGT
551 CGGGCGATAC GCCATTCATT CCAAGGACAT TGGCTTTTCT TGTAAAAAGT
601 TCGGAGACTC TAATTATTCT TTATCAGTTA AACCTTCATA TACAGTCCAG
651 GATAGGATTA GGACTGTGTT CAATAAATCT GTGGCTTCGA ATTTAATTAC
701 TTTTCATATC AGCAAAGTAG AAGATTTAAA CCTGGAAAGC GTTGATGGAA
16/06/97 1-
for a region of U07187_ 1 .cds http://genome-www2.stanford.edu/cgi-bin/SGD/get
7 51 AGGTGTGTAA TTTGAATTTC AT AT C C AAAA AGTCCATTTC ATTAATTTTTSfv
801 TTCATTAATA ATAGACTaIgT GACATGTGAT CTTCTAAGAA GAGCTTTGAA t— -------->------- —   |f (L^
851 CAGCGTTTAC TCCAATTATC TGCCAAAGGG CTTCAGACCT TTTATTTATT t  ^ ----. - ■ ' •   i
901 TGGGAATTGT TATAGATCCG GCGGCTGTTG ATGTTAACGT TCACCCGACA
951 AAGAG AG AG G TTCGTTTCCT GAGCCAAGAT GAGATCATAG AGAAAAT C GC
1001 CAATCAATTG CACGCCGAAT TATCTGCCAT TGATACTTCA CGTACTTTCA
1051 AGGCTTCTTC AATTTCAACA AACAAGCCAG AGTCATTGAT ACCATTTAAT
1101 GACACCATAG AAAGTGATAG GAATAGGAAG AGTCTCCGAC AAGCCCAAGT
1151 GGTAGAGAAT TCATATACGA CAGCCAATAG TCAACTAAGG AjAAGCGAAAA
1201 GACAAGAGAA TAAACTAGTC AGAATAGATG CTTCACAAGC TAAAATTACG
 — ------------ 1 £*+ x  yy*
1251 TCATTjTTTAT CCTCAAGTCA ACAGTTCAAC TTTGAAGGAT CGTCTACAAA 
1301 GCGACAACTG AGTGAACCCA AGGTAACAAA TGTAAGCCAC TCCCAAGAGG 
1351 CAGAAAAGCT GACACTAAAT GAAAGCGAAC AACCGCGTGA TGCCAATACA 
1401 ATCAATGATA ATGACTTGAA GGATCAACCT AAGAAGAAAC AAAAGTTGGG 
1451 GGAT TAT AAA GTTCCAAGCA TTGCCGATGA CGAAAAGAAT GCACTCCCGA 
1501 TTTCAAAAGA CGGGTATATT AGAGTACCTA AGGAGCGAGT TAATGTTAAT 
1551 CTTACGAGTA T CAAGAAATT GCGTGAAAAA GT AGAT GATT CGATACAT CG
1601 AGAACTAACA GACATTTTTG CftAATTTGAA TTACGTTGGG GTtTGTAGATG   ~i— ■— it J
1651 AGGAAAGAAG ATTAGCCGCT ATTCAGCATG ACTTAAAGCT TTTTTTAATA■ \ —  —    1 ^
1701 GATTACGGAT CTGTGTGCTA TGAGCTATTC TATCAGATTG GTTTGACAGA 
1751 CTTCGCAAAC TTTGGTAAGA TAAACCTACA GAGTACAAAT GTGTCAGATG 
1801 ATATAGTTTT GTATAATCTC CTATCAGAAT TTGACGAGTT AAATGACGAT 
1851 GCTTCCAAAG AAAAAATAAT TAGTAAAATA TGGGACATGA GCAGTATGCT 
1901  AAATGAGTAC TATTCCATAG AATTGGTGAA TGATGGTCTA GATAATGACT
f t  i
1951 1AAAGTCTJGT GjAAGCTAAAA TCTCTACCAC TACTT^TAAA AGGCTAjCATT < 2 ^ -------- L----------------- :------------    1 ---
200 1  CCATCTCTGG TCAAGTTACC ATJTTTTTATA TATCGCCTGG GTAAAGAAGT 
ts" '7 ’ '
205 1  TGATTGGGAG GATGAACAAG AGTGTCTAGA TGGTATTTTA AGAGAGATTG
2101  CATTACTCTA TATACCTGAT ATGGTTCCGA AAGT C GAT AC ACTCGATGCA
215 1  TCGTTGTCAG AAGACGAAAA AGCCCAGTTT ATAAATAGAA AGGAACACAT
220 1  ATCCTCATTA CTAGAACACG TTCTCTTCCC TTGTATCAAA CGAAGGTTCC
2 2 5 1  TGGCCCCTAG ACACATTCTC A^GGATGTjCG TGGAAATAGC CAACCTTCCA
23 0 1  GATCTATACA AAGTTTTTGA GAGGTGTTAa I CTTTAAAACG TTTTGGCTGT 
f ‘  U -i— I
16/06/97 14
BESTFIT of: 212R1.consensus check: 155 from: 1 to: 2622
t o :  u 0 7 1 8 7  c h e c k :  690 f ro m : 1 t o :  3218
pOCUS SCMLHI 321 8  b p  DNA PLN 17-M A R-1994
EFIN IT IO N  S a c c h a r o m y c e s  c e r e v i s i a e  DNA m is m a tc h  r e p a i r  (MLH1) g e n e ,  c o m p le te  
c d s .
•CCESSION U 07187
flD g 4 6 0 6 2 6
EYWORDS . . . .
S ym bol c o m p a r i s o n  t a b l e :  / s o f t w a r e / g c g 9 / g c g c o r e / d a t a / r u n d a t a / s w g a p d n a . cmp 
C om pC heck: 2 3 3 5
Gap W e i g h t : 50 A v e ra g e  M a tc h : 1 0 . 0 0 0
L e n g th  W e i g h t : 3 A v e r a g e  M is m a tc h : - 9 .0 0 0
Q u a l i t y : 2 1 5 0 3 L e n g t h : 2369
R a t i o : 9 .1 9 7 G a p s : 25
P e r c e n t  S i m i l a r i t y : 9 8 .8 8 6 P e r c e n t  I d e n t i t y : 9 8 .7 5 7
M a tc h  d i s p l a y  t h r e s h o l d s  f o r  t h e  a l i g n m e n t ( s ) : 
I = IDENTITY 
: = 5
. = 1
2 1 2 R 1 . c o n s e n s u s  x u 0 7 1 8 7  F e b r u a r y  3 , 1998  1 4 :0 3
61 a a a a a a c a c a t a c a g g x ia t t c a c c a t g g a t c c E t g t c t c t c a g a a t a a a a  1 1 0  
I I I I I I I I I I I : I I II I I I I  I I I I I I I I I I I I I I I I
213 AAAAATAACATAGACCTAT CAATAAGCJ^T^TC^CT^AG^ATiy^Aiy 258
111 GCACTTGATGCATCAGTGGTTAACAAAATTGCTGCAGGTGAGATCATA.A 159 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
259  GC^CT'^GA^GCiyrCApTCjGT^AA^AAA^TT/SC^GayGG^GAqATCAT^.A 307
160 TATCCCCCGTAAATGCTCTCAAAGAaATGATGGAGAATTCCATCGATGCG 209 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
308 ^ATC/CCC;CG,^ yyyrGC^rC^CAi^G^^AA,93A'^GG^GAiyrTC/CA^CGiyTGg3 357
210 AATGCTACAATGATTGATATTCTAGTCAAGGAAGGAGGAATTAAGGTACT 259  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
358 A2yTGC/TA£AArpGA']^G2yrA^TC^GT£A^PGA^G§AG(£AA£TAiy3G'pVC,]J. 407
260 TCAAATAACAGATAACGGATCTGGAATTAATAAAGCAGACCTGCCAATCT 309 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
408 TC^AA^AAgAGATA^CGGATCTGGAA^TAA^Ai^AGgAGA^CC^GCgAATpT 457
310 TATGTGAGCGATTCACGACGTCCAAATTACAAAAATTCGAAGATTTGAGT 359 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
458 T^ATGl’GAGCCJAT^CACGAgGTCCA^ATTACAAAA^TTjCGAAGAJT'^GAgT 507
360 CAGATTCAAACGTATGGATTCCGAGGAGAAGCTTTAGCCAGTATCTC.AC 408 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
508 CApA^TC^AAgGTi^TGgATTCCCjAGgAG^AGgTT^AGgCAG^A^CT^.A£ 556
409 ATGTGGCAAGAGTCACAGTAACGACaAAAGTTAAAGAAGACAGATGTGCA 458 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
557 ATG£G(^CAiySAGTCApAGJTAiyZGACAiy^AGTTiyVAgAAgAC^GA^GTG,CA 606
459 TGGAGAGTTTCATATGCAGAAGGTAAGATGTT. GGAAAGCCCCAaACCTG 507 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
607 TGGApAG/TTI)CA'^ATgCAgAAgGT^AG^TGTT. gGA^AGCCCgAAACC^G 655
508  TTGCTGGAaaAGACGGTACCACGATCCT. AgTTG. AAgACC. . TTTTTTT 553 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
65 6  T^GC^GGAAA^GACGGgACCACGATgCT .^AG^TG ./A^ACC,. . ^TT^TTT, 701
554
702
CAATATT. CCTTCTAG. ATTAA. GGGCCTTG. AGGTCCCaTAATG. ATGA 598 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CAA^A^T . qCTTCTA£A v . TTAAG/SGCCTT/S. ApGTpCC^Ti^ATG,. A^GA 746
648
$4* Ay
59 9  ATACTCTAAAATATTAGATGTTGTCgGGcGATACGCCaTTCATTCTAAGG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I l ? l  I I I 
747 ^ACTCTAAAATATTAGATGTTGTCGGGCGATACGCCATTCA^TCgAAC^G 7 96
649 ACATTGGCTTTTCTTGTAAAAAGTTCGGAGACTCTAATTATTCTTTATCA 698
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
797 A^AT^GGgTTT/TCT/TG,^ A2VAAGTTCGGAGACTCTAATTATTCTTTATC^ 846
699 GTTAAACCTTCATATACCGTCCAGGATAGGATTAGGACTGTGTTCAATAA 748 
I I I I I I I I I I I I I I I I l?l I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
847 GT'pAA^CCTJTCiyrA^ACi^GTqCAqGAgAGqAT^AGQAC^GTQTTgAA^AA 896  ^  CDJ
74 9  ATCTGTGGCTTCGAATTTAATTACTTTTCATATCAGC. AAAGTAGAAGAT 7 97 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
897 ATCTGTGGCTTCGAATTTAATTACTTTTCATATCAGC. AAAGTAGAAGAT 945
798 TTAAACCTGGaAAGCGTTGATGGAAAGGTGTGTAATTTGAATTTCATATC 847 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
946 TTAAACCTGGAAAGCGTTGATGGAAAGGTGTGTAATTTGAATTTCATATg 995
v il
848 CAAAAAG. TCCATTTCaCCAATTTTTTTCATT. AATaATAG. ACTAGTGA 894
I I I I I I I I I I I I I I I I I?? I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
996 CA^AA^C. TpCA^T^CA^TAA^T^TT^TCiyrT .^ ^ A A ^ A G  ./AC,JAG^GA 1042  k e
895 CATGTGATCCTCTAAGAAGAGCTttGAAcAGCG. TtTACTCCAATTATCT 943 
I I I I I I I I I? I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
104 3  CATGTGATCTTCTAAGAAGAGCTTTGAACAGCG. TTTACTCCAATTATCT 1091
944 G . CCAaAGGGCAACAGACCTTTTATTTATTTGGGAATTGTTATAGATCCG 992 
I I I I I I I I I I ?? I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1092  G vCCAAACGG9.TT9AGACCCTT,p\TCTACTTCGGAATCGT,yATAGATJCCC 1140
993 GCGGCTGTTGATGTTAACGTTCACCCGACAAAGAGAGAGGTTCGTTTCCT 1042 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1 14 1  GCGGCTGTTGATGTTAACGTTCACCCGACAAAGAGAGAGGTTCGTTTCCT 1190
1 04 3  GAGCCAAGATGAGATCATAGAGAAAATCGCCAATCAATTGCACGCCGAAT 1092 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I II I I I I I I I I I 
1 19 1  GAGCCAAGATGAGATCATAGAGAAAATCGCCAATCAATTGCACGCCGAAT 1240
1 09 3  TATCTGCCATTGATACTTCACGTACTTTCAAGGCTTCTTCAATTTCAACA 1142 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
124 1  TATCTGCCATTGATACTTCACGTACTTTCAAGGCTTCTTCAATTTCAACA 1290
A** J
1143  AACAAGCCAGAGTCATTGATACCATTTAATGACACCATAGAAAGTGATAG 1192 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
AACAAGCCAGAGTCATTGATACCATTTAATGACACCATAGAAAGTGACAG 13401291
1193  GAATAGGAAGAGTCTCCGACAAGCCCAAGTGGTAGAGAATTCATATACGA 1242 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
134 1  GAATAGGAAGAGTCTCCGACAAGCCCAAGTGGTAGAGAATTCATATAC<CA 1390
124 3  CAGCCAATAGTCAAcT. arGGAAAGCGaaaaGA. CaaGAGaATAAACTAG 1290  
I I I I I I I I I I I I I I I I I I : I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
139 1  CAGCCAATAGTCAACT. AAGGAAAGCGAAAAGA. CAAGAGAATAAACTAG 1438
1291  TCAGAATAGATGCTTCACAAGCTAAAATTACGTCaTTTTTATCCTCAAGT 1340
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1 4 3 9 TCAGAATAGATGCTTCACAAGCTAAAATTACGTCATTTTTATCCTCAA13T 1488
1 3 4 1 CAACAGTTCAACTTTGAAGGATCGTCTACAAAGCGACAACTGAGTGAACC
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 II 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 
CAACAGTTCAACTTTGAAGGATCGTCTACAAAGCGACAACTGAGTGAACJC
1390
1 4 8 9 153 8
139 1 CAAGGTAACAAATGTaAGCCACTCCCAAGAGGCAGAAAAGCTGACACTAA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CAAGGTAACAAATGTAAGCCACTCCCAAGAGGCAGAAAAGCTGACACTA^
144 0
1 5 3 9 1588
1 44 1 ATGAAAGCGAACAACCGCGTGATGCCAATACAATCAATGATAATGACTTG 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ATGAAAGCGAACAACCGCGTGATGCCAATACAATCAATGATAATGAC^TG
149 0
1 5 8 9 1638
1 4 9 1 AAGGATCAACCTAAGAAGAAACAAAAGTTGGGGGATTATAAAGTTCCAaG 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
AAGGATCAACCTAAGAAGAAACAAAAGTTGGGGGATTATAAAGTTCCA^G
154 0
1 6 3 9 168 8
1 5 4 1 CATTGCCGATGACGAAAAGaATGCACTCCCGATTTCAAAAGACGGGTATA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CATTGCCGATGACGAAAAGAATGCACTCCCGATTTCAAAAGACGGGTAT^
159 0
1 6 8 9 173 8
1 5 9 1 TTAGAGTACC. TAA. GGAGCGAGTTAATGTTAaTCTTACGAGTATCaAGA 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TTAGAGTACCT. . AAGGAGCGAGTTAATGTTAATCTTACGAGTATCA^GA
1638
1 7 3 9 1 7 8 6
1 6 3 9 AATTGCGTGAAAAAGTAGATGATTCGATACATCGAGAACTAACAGACATT
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 ! 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
AATTGCGTGAAAAAGTAGATGATTCGATACATCGAGAACTAACAGACA^T
168 8
1787 1 8 3 6
1 6 8 9 TTTGCAAATTTGAATTACGTTGGGGTTGTAGATGaGGAGAGAAGATTAGC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TTTGCAAATTTGAATTACGTTGGGGTTGTAGATGAGGAAAGAAGATTAG9
1738
1837 1 8 8 6
1 7 3 9 CGCTATTCAGCATGACTTAAAGCTTTTTTTAATAGATTACGGATCTGTGT 
1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CGCTATTCAGCATGACTTAAAGCTTTTTTTAATAGATTACGGATCTG^GT
178 8
1887 1 93 6
1 78 9 GCTATGAGCTATTCTATCAGATTGGTTTGACAGACTTCGCAAACTTTGGT
1 1 I I I I I I I 1 I I 1 I I I I I I 1 1 1 I I I i I I I I 1 I I I I I 1 1 1 I 1 I 1 1 1 1 1 1 i i
1 8 3 8
1937
1 II 1 1 II II II  II  1 1 1 II II II 1 1 1 1 1 II 1 1 1 1 II 1 II II 1 II 1 1 1 1 1 II 
GCTATGAGCTATTCTATCAGATTGGTTTGACAGACTTCGCAAACTTTG^T 1 9 8 6
1 8 3 9 AAGATAAACCTACAGAGtACaAATGTGTCAGatGAtATAGTTTtGtATAa 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
AAGATAAACCTACAGAGTACAAATGTGTCAGATGATATAGTTTTGTATA^
1 88 8
1987 2 0 3 6
1 8 8 9 TcTCCTATCAGAATTkGACGAGTTAAATGACGATGCTTCCAAAGaAAAAA 
1 1 1  1 1 1 1 1 1 1 1 1 1 1 1 : 1 1 1 1  1 1 1 1 1 1 1  1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TCTCCTATCAGAATTTGACGAGTTAAATGACGATGCTTCCAAAGAAAi^AA
193 8
2 03 7 2 0 8 6
193 9 t  TAATTAGTAAAATATGGGA. CATGAGCAGCATGCTAAATGAGTACTATT
1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 l ? l  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
.TAiyTTA^TAAAiyrA^GG^A. (^AT^AG^AG^ATC^CT^AA^GAGyTAC^A^T
1987 S er
2 08 7 2 1 3 4 Ser '
198 8 CC. ATAGAATTGGTGAATGATGgTCTAGATAATGACtTAAAGT. CTGTgA 2 0 3 5  
i i i i m  i m  i i i i i  i i i i i i i i m  i i i i i i i i i i i i i i i i i i i i i i i i i i
2 1 3 5
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
CC. ATAGAATTGGTGAATGATGGTCTAGATAATGACTTAAAGT. CTGTG^, 2 1 8 2
2 0 3 6 AGCTAAAATCTCTACCACTACTTTTAAAAGGCTACATTCCATCTcTGGTC 
I 1 1 1 1 1 1 1 I i i I i i i i I I i I I I i i i i i  i i i i i i i i i i i i i i i i  i i  i i i i i
2 0 8 5
2 1 8 3
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 
AGCTAAAATCTCTACCACTACTTTTAAAAGGCTACATTCCATCTCTG^TC 2 2 3 2
2 0 8 6 AAGTTACCATTTTTTATATATCGCCTGGGTAAAGAAGTTAATTGGGAGGA
1 I I I I l l l l l l l l l l l l l I l l l l I l I i l I l l l l I I i i l  l7 l I l l I I i i i i
2 1 3 5 f&x Asrt
2 2 3 3
I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 . 1 1 1 1 1 1 1 1 1 1
A^GTyTA^CA^TT^TT^TA^AT^GCCTG^GTiyAA^AACyrT^AT^GG^AG^A 2 2 8 2 fa n
2 1 3 6  TGAACAAGAGTGTCTAGATGGTATTTTAAGAGAGATTGCATTACTCTATA 2 1 8 5  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 2 8 3  TGAACAAGAGTGTCTAGATGGTATTTTAAGAGAGATTGCATTACTCTATA, 233 2
2 1 8 6  TACCTGATATGGTTCTGAAAGTCGATACATCTGATGCATCGTTGTCAGAA 2 2 3 5  5
I I I I I I I I I I I I I I I ? I I I I I I I I I I I I I??? I I I I I I I I I I I I I I I I I I 
2 3 3 3  TACCT^ATAyCGG^TCpG^AAG^C^ATiyCACyrC^AT^CA^G^TG^CA^AA 2 3 8 2
2 2 3 6  GACGAAAAAGCCCAGTTTATAAATAGAAAGGAACACATATCCTCATTACT 2 2 8 5
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 3 8 3  GACGAAAAAGCCCAGTTTATAAATAGAAAGGAACACATATCCTCATTA^T 2 4 3 2  
2 2 8 6  AGAACACGTTCTCTTCCCTTGTATCAAACGAAGGTTCCTGGCCCCTAGAC 2 3 3 5
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2 4 3 3  AGAACACGTTCTCTTCCCTTGTATCAAACGAAGGTTCCTGGCCCCTAGA9  2 4 8 2
2 3 3 6  ACATTCT. CAAGGATGTCGTGGAAATAGCCAACCTTCCAGGTCTATACAA 2 3 8 4  Qt*
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I l?l I I I I
2 4 8 3  ACATTCT.CAAGGATGTCGTGGAAATAGCCAACCTTCCiyGAT/CTiyrA9AA 2 5 3 1  A if Lu*
2 3 8 5  AGTTTTTGAGAGGTGTTAAj 2 4 0 3  
I I I I I I I I I I I I I I I I I I I 
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